,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,192,1,1,,442487,3016,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
1,248,1,1,,118340,3016,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
2,248,1,1,,442487,3016,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
3,256,1,1,,118340,3016,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
4,485,1,8,,26719642,3016,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
5,631,1,4,,26719642,3016,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
6,631,1,4,,26719642,3016,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
7,731,1,5,,26719642,3016,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
8,731,1,5,,26719642,3016,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
9,781,1,1,,26719642,3016,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
10,782,1,2,,26719642,3016,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
11,782,1,2,,26719642,3016,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
12,880,2,1,,26719642,3016,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
13,880,2,1,,26719642,3016,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
14,950,1,1,,26719642,3016,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
15,951,1,1,,26719642,3016,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
16,952,1,1,,26719642,3016,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
17,1001,2,2,,26719642,3016,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
18,1006,1,6,,26719642,3016,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
19,1007,1,1,,26719642,3016,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
20,1008,1,2,,26719642,3016,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
21,1009,1,2,,26719642,3016,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
22,1012,1,4,,26719642,3016,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
23,1016,1,4,,26719642,3016,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
24,1018,2,5,,26719642,3016,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
25,1019,1,4,,26719642,3016,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
26,1020,1,5,,26719642,3016,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
27,1021,1,1,,26719642,3016,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
28,1022,1,1,,26719642,3016,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
29,1027,1,3,,26719642,3016,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
30,1032,1,2,,26719642,3016,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
31,1032,1,2,,26719642,3016,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
32,1040,1,2,,26719642,3016,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
33,1048,1,1,,26719642,3016,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
34,1048,1,1,,26719642,3016,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
35,1049,1,1,,26719642,3016,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
36,1049,1,1,,26719642,3016,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
37,1051,1,1,,26719642,3016,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
38,1051,1,1,,26719642,3016,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
39,1066,1,2,,26719642,3016,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
40,1085,1,1,,26719642,3016,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
41,1135,1,3,,26719642,3016,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
42,1136,1,3,,26719642,3016,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
43,1189,1,5,,48413548,3016,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
44,1194,1,3,,48413548,3016,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
45,1195,1,2,,48415873,3016,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
46,1199,1,3,,48413548,3016,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
47,1203,1,3,,26719642,3016,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
48,1205,1,4,,48413548,3016,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
49,1208,1,3,,48413548,3016,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
50,1209,2,2,,26719642,3016,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
51,1214,1,4,,26719642,3016,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
52,1216,1,5,,26719642,3016,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
53,1217,1,4,,26719642,3016,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
54,1220,2,2,,26719642,3016,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
55,1222,1,6,,26719642,3016,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
56,1229,1,3,,26719642,3016,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
57,1236,1,1,,26719642,3016,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
58,1251,1,1,,26719642,3016,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
59,1274,1,2,,26719642,3016,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
60,1304,1,2,,26719642,3016,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
61,1321,1,2,,26719642,3016,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
62,1325,1,2,,26719642,3016,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
63,1359,1,4,,26719642,3016,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
64,1362,1,2,,26719642,3016,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
65,1415,1,2,,26719642,3016,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
66,1415,1,2,,26719642,3016,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
67,1416,1,2,,26719642,3016,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
68,1423,1,2,,26719642,3016,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
69,1423,1,2,,26719642,3016,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
70,1424,1,1,,26719642,3016,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
71,1434,2,3,,26719642,3016,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
72,1434,2,3,,26719642,3016,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
73,1439,1,1,,26719642,3016,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
74,1439,1,1,,26719642,3016,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
75,1440,1,1,,26719642,3016,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
76,1440,1,1,,26719642,3016,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
77,1441,1,1,,26719642,3016,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
78,1441,1,1,,26719642,3016,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
79,1443,1,3,,26719642,3016,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
80,1445,1,1,,26719642,3016,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
81,1446,1,3,,26719642,3016,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
82,1448,1,3,,26719642,3016,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
83,1454,1,1,,26719642,3016,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
84,1456,1,1,,26719642,3016,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
85,1460,1,3,,26719642,3016,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
86,1461,1,2,,26719642,3016,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
87,1463,1,1,,26719642,3016,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
88,1466,1,2,,26719642,3016,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
89,1467,1,3,,26719642,3016,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
90,1468,1,1,,26719642,3016,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
91,1469,1,1,,26719642,3016,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
92,1477,1,1,,26719642,3016,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
93,1479,1,2,,26719642,3016,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
94,1481,1,2,,26719642,3016,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
95,1486,1,3,,26719642,3016,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
96,1490,2,1,,26719642,3016,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
97,1496,1,4,,26719642,3016,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
98,1496,1,4,,26719642,3016,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
99,1509,1,2,,26719642,3016,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
100,1510,1,3,,26719642,3016,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
101,1515,1,2,,26719642,3016,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
102,1527,1,3,,26719642,3016,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
103,1529,1,1,,26719642,3016,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
104,1530,1,1,,26719642,3016,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
105,1531,1,1,,26719642,3016,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
106,1533,1,1,,26719642,3016,Inactive,15610402.0,888704.0,,,Rml C and D inhibition 384-well mixture HTS from 1536-well compound plates,Screening,,
107,1533,1,1,,26719642,3016,Inactive,15610601.0,887352.0,,,Rml C and D inhibition 384-well mixture HTS from 1536-well compound plates,Screening,,
108,1556,1,4,,26719642,3016,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
109,1565,2,2,,26719642,3016,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
110,1566,2,3,,26719642,3016,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
111,1578,3,2,,26719642,3016,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
112,1580,1,1,,8150113,3016,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
113,1581,1,1,,8150113,3016,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
114,1582,1,1,,8150113,3016,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
115,1583,1,1,,8150113,3016,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
116,1584,1,1,,8150113,3016,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
117,1585,1,1,,8150113,3016,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
118,1586,1,1,,8150113,3016,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
119,1587,1,1,,8150113,3016,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
120,1588,1,1,,8150113,3016,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
121,1589,1,1,,8150113,3016,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
122,1590,1,1,,8150113,3016,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
123,1593,1,1,,8150113,3016,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
124,1594,1,1,,8150113,3016,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
125,1595,1,1,,8150113,3016,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
126,1596,1,1,,8150113,3016,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
127,1597,1,1,,8150113,3016,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
128,1598,1,1,,8150113,3016,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
129,1599,1,1,,8150113,3016,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
130,1600,1,1,,8150113,3016,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
131,1601,1,1,,8150113,3016,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
132,1602,1,1,,8150113,3016,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
133,1603,1,1,,8150113,3016,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
134,1604,1,1,,8150113,3016,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
135,1605,1,1,,8150113,3016,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
136,1606,1,1,,8150113,3016,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
137,1607,1,1,,8150113,3016,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
138,1608,1,1,,8150113,3016,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
139,1609,1,1,,8150113,3016,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
140,1610,1,1,,8150113,3016,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
141,1612,1,1,,8150113,3016,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
142,1613,1,1,,8150113,3016,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
143,1614,1,1,,8150113,3016,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
144,1616,1,1,,8150113,3016,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
145,1619,1,2,,26719642,3016,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
146,1625,2,2,,26719642,3016,Inactive,,,,EC50,HCS for Compounds that Up-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
147,1626,1,2,,26719642,3016,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
148,1628,2,2,,26719642,3016,Inactive,,,,IC50,HCS for Compounds that Down-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
149,1631,3,1,,26719642,3016,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
150,1634,3,1,,26719642,3016,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
151,1654,2,2,,26719642,3016,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
152,1656,2,2,,26719642,3016,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
153,1665,2,2,,26719642,3016,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
154,1700,1,2,,26719642,3016,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
155,1706,1,2,,26719642,3016,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
156,1721,1,2,,26719642,3016,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
157,1722,1,2,,26719642,3016,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
158,1766,1,1,,26719642,3016,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
159,1766,1,1,,26719642,3016,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
160,1768,1,1,,26719642,3016,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
161,1768,1,1,,26719642,3016,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
162,1775,1,2,,26719642,3016,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
163,1776,1,2,,26719642,3016,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
164,1777,3,2,,26719642,3016,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
165,1778,3,3,,26719642,3016,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
166,1779,2,2,,26719642,3016,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
167,1789,1,2,,26719642,3016,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
168,1800,1,2,,26719642,3016,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
169,1817,2,2,,26719642,3016,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
170,1822,1,3,,26719642,3016,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
171,1825,1,1,,26719642,3016,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
172,1845,1,2,,26719642,3016,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
173,1861,2,1,,26719642,3016,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
174,1863,2,1,,26719642,3016,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
175,1865,1,1,,26719642,3016,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
176,1868,1,4,,26719642,3016,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
177,1903,2,3,,26719642,3016,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
178,1961,2,2,,26719642,3016,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
179,1984,1,3,,26719642,3016,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
180,1986,1,2,,26719642,3016,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
181,2006,3,2,,26719642,3016,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
182,2006,3,2,,26719642,3016,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
183,2006,3,2,,26719642,3016,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
184,2012,3,2,,26719642,3016,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
185,2013,2,2,,26719642,3016,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
186,2014,3,2,,26719642,3016,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
187,2058,3,2,,26719642,3016,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
188,2071,2,2,,26719642,3016,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
189,2073,2,3,,26719642,3016,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
190,2073,2,3,,26719642,3016,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
191,2100,1,1,,26719642,3016,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
192,2101,1,1,,26719642,3016,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
193,2107,1,1,,26719642,3016,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
194,2112,1,1,,26719642,3016,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
195,2147,1,1,,26719642,3016,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
196,2240,1,1,,85788516,3016,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
197,2241,1,1,,85788516,3016,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
198,2242,1,1,,26719642,3016,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
199,2275,1,1,,85788516,3016,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
200,2288,1,1,,26719642,3016,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
201,2289,1,1,,26719642,3016,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
202,2313,1,1,,85788516,3016,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
203,2314,1,2,,26719642,3016,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
204,2314,1,2,,26719642,3016,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
205,2315,1,2,,26719642,3016,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
206,2315,1,2,,26719642,3016,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
207,2322,1,1,,85788516,3016,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
208,2330,1,1,,85788516,3016,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
209,2451,1,2,,26719642,3016,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
210,2472,1,2,,26719642,3016,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
211,2517,2,1,,26719642,3016,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
212,2528,1,2,,26719642,3016,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
213,2546,1,1,,26719642,3016,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
214,2549,1,1,,26719642,3016,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
215,2551,1,1,,26719642,3016,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
216,2662,2,1,,26719642,3016,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
217,2675,1,1,,26719642,3016,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
218,2676,1,2,,26719642,3016,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
219,2685,1,1,,26719642,3016,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
220,2732,1,1,,26719642,3016,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
221,3491,8,5,,103164353,3016,Inconclusive,,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,Other,,
222,4134,8,4,,103164353,3016,Inconclusive,,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,Other,,
223,4535,8,5,,103164353,3016,Inconclusive,,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,Other,,
224,4551,8,7,,103164353,3016,Inconclusive,2494923.0,100379622.0,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,Other,,
225,7783,3,4,,103164353,3016,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
226,8002,5,2,,103164353,3016,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
227,13304,3,3,,103164353,3016,Unspecified,,,,,-Log C was determined by performing the electroshock minimum test,Other,7381845.0,
228,13305,3,3,,103164353,3016,Unspecified,,,,,-Log C was determined by performing the foot shock test,Other,7381845.0,
229,13306,3,3,,103164353,3016,Unspecified,,,,,-Log C was determined by performing the incl screen test,Other,7381845.0,
230,13307,3,3,,103164353,3016,Unspecified,,,,,-Log C was determined by performing the maximum electroshock test,Other,7381845.0,
231,13308,3,3,,103164353,3016,Unspecified,,,,,-Log C was determined by performing the pentylenetetrazole test,Other,7381845.0,
232,15120,3,3,,103164353,3016,Unspecified,,,,,Percent of the drug absorbed after administration to humans was determined,Other,10346926.0,
233,16092,4,4,,103164353,3016,Unspecified,,,,,Clearance into cortex from rat plasma or PBS,Other,9406596.0,
234,18847,3,4,,103164353,3016,Unspecified,,,,,Percent of drug absorbed by human intestine after oral administration,Other,11020286.0,
235,19006,4,3,,103164353,3016,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
236,19262,5,1,,103164353,3016,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
237,19424,3,4,,103164353,3016,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
238,19427,3,3,,103164353,3016,Unspecified,,,,,HPLC capacity factor (k),Other,10956200.0,
239,21849,7,1,,103164353,3016,Unspecified,,,,,In vitro clearance in dog in 1000000 cells,Other,10602692.0,
240,21851,7,1,,103164353,3016,Unspecified,,,,,In vitro clearance in human in 1000000 cells,Other,10602692.0,
241,21852,7,1,,103164353,3016,Unspecified,,,,,In vitro clearance in rat in 1000000 cells,Other,10602692.0,
242,21853,6,2,,103164353,3016,Unspecified,,,,,In vivo clearance in dog,Other,10602692.0,
243,21856,6,2,,103164353,3016,Unspecified,,,,,In vivo clearance in human,Other,10602692.0,
244,21858,6,2,,103164353,3016,Unspecified,,,,,In vivo clearance in rat,Other,10602692.0,
245,22293,4,4,,103164353,3016,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
246,23479,3,3,,103164353,3016,Unspecified,,,,,Partition coefficient (logP),Other,7359533.0,
247,26304,4,4,,103164353,3016,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
248,26380,3,3,,103164353,3016,Inconclusive,,,,,Dissociation constant (pKa),Other,14971904.0,
249,27580,3,3,,103164353,3016,Unspecified,,,,,Partition coefficient (logP),Other,10956200.0,
250,28233,3,3,,103164353,3016,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
251,28235,3,3,,103164353,3016,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
252,28236,3,3,,103164353,3016,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
253,28392,3,3,,103164353,3016,Unspecified,,,,,Apparent permeability coefficient (Papp) (Caco-2 cell monolayer),Other,11384238.0,
254,28399,3,3,,103164353,3016,Unspecified,,,,,Cellular permeability (Pc) (Caco-2 cell monolayer),Other,11384238.0,
255,28956,3,3,,103164353,3016,Unspecified,,,,,Partition coefficient (logP) (dodecane),Other,11754587.0,
256,28957,3,3,,103164353,3016,Unspecified,,,,,Partition coefficient (logP),Other,11754587.0,
257,29360,4,3,,103164353,3016,Inconclusive,,,,,Ionization constant (pKa),Other,10891117.0,
258,29421,3,3,,103164353,3016,Unspecified,,,,,Partition coefficient (logP) (HPLC),Other,10956200.0,
259,29423,3,4,,103164353,3016,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
260,29811,4,3,,103164353,3016,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
261,29844,3,3,,103164353,3016,Unspecified,,,,,Fraction absorbed after oral administration in humans,Other,11384238.0,
262,29925,5,2,,103164353,3016,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
263,32979,4,7,,103164353,3016,Unspecified,,,7.0,Ki,Displacement of [3H]-Ro- 15-4513 from alpha-6-beta-2-gamma-2 GABA-A receptor subunits expressed in Sf9 cell membranes,Confirmatory,8145225.0,
264,33556,3,7,,103164353,3016,Unspecified,,,,,The ability concentration.),Other,10821711.0,
265,35392,3,7,,103164353,3016,Unspecified,,,,,In vitro efficacy calculated by chlorine current assay on alpha-1-beta-2-gamma-2 (GABA-A) receptor subtype,Other,8809170.0,
266,39905,11,2,,103164353,3016,Active,120758.0,289606.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
267,39905,11,2,,103164353,3016,Active,120761.0,24947.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
268,39905,11,2,,103164353,3016,Active,120763.0,140675.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
269,39905,11,2,,103164353,3016,Active,120764.0,29707.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
270,39905,11,2,,103164353,3016,Active,120769.0,25450.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
271,39905,11,2,,103164353,3016,Active,120782.0,140674.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
272,39905,11,2,,103164353,3016,Active,120788.0,29709.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
273,39905,11,2,,103164353,3016,Active,120790.0,79211.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
274,39905,11,2,,103164353,3016,Active,232127.0,29708.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
275,39905,11,2,,103164353,3016,Active,544363.0,29689.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
276,39905,11,2,,103164353,3016,Active,3023821.0,81658.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
277,39905,11,2,,103164353,3016,Active,13959374.0,65191.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
278,39905,11,2,,103164353,3016,Active,51317298.0,29705.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
279,39905,11,2,,103164353,3016,Active,52000955.0,24922.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
280,39905,11,2,,103164353,3016,Active,52000957.0,25451.0,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
281,39905,11,2,,103164353,3016,Active,81902501.0,,0.0206,IC50,Inhibition of [3H]-Ro- 15-1788 binding to GABA-A benzodiazepine receptor in rat brain membrane,Confirmatory,7699711.0,
282,39916,3,8,,103164353,3016,Unspecified,120758.0,289606.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
283,39916,3,8,,103164353,3016,Unspecified,120761.0,24947.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
284,39916,3,8,,103164353,3016,Unspecified,120763.0,140675.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
285,39916,3,8,,103164353,3016,Unspecified,120764.0,29707.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
286,39916,3,8,,103164353,3016,Unspecified,120769.0,25450.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
287,39916,3,8,,103164353,3016,Unspecified,120782.0,140674.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
288,39916,3,8,,103164353,3016,Unspecified,120788.0,29709.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
289,39916,3,8,,103164353,3016,Unspecified,120790.0,79211.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
290,39916,3,8,,103164353,3016,Unspecified,232127.0,29708.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
291,39916,3,8,,103164353,3016,Unspecified,544363.0,29689.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
292,39916,3,8,,103164353,3016,Unspecified,3023821.0,81658.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
293,39916,3,8,,103164353,3016,Unspecified,13959374.0,65191.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
294,39916,3,8,,103164353,3016,Unspecified,51317298.0,29705.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
295,39916,3,8,,103164353,3016,Unspecified,52000955.0,24922.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
296,39916,3,8,,103164353,3016,Unspecified,52000957.0,25451.0,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
297,39916,3,8,,103164353,3016,Unspecified,81902501.0,,,,Inhibition of [3H]Flunitrazepam binding to rat cerebral cortex at 0.12 uM,Other,,
298,39918,8,5,,103164353,3016,Active,130253.0,24230.0,0.213,Kd,Binding affinity constant for peripheral (mitochondrial) Benzodiazepine receptor,Confirmatory,7473601.0,
299,39930,7,5,,103164353,3016,Active,120758.0,289606.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
300,39930,7,5,,103164353,3016,Active,120761.0,24947.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
301,39930,7,5,,103164353,3016,Active,120763.0,140675.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
302,39930,7,5,,103164353,3016,Active,120764.0,29707.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
303,39930,7,5,,103164353,3016,Active,120769.0,25450.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
304,39930,7,5,,103164353,3016,Active,120782.0,140674.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
305,39930,7,5,,103164353,3016,Active,120788.0,29709.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
306,39930,7,5,,103164353,3016,Active,120790.0,79211.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
307,39930,7,5,,103164353,3016,Active,232127.0,29708.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
308,39930,7,5,,103164353,3016,Active,544363.0,29689.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
309,39930,7,5,,103164353,3016,Active,3023821.0,81658.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
310,39930,7,5,,103164353,3016,Active,13959374.0,65191.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
311,39930,7,5,,103164353,3016,Active,51317298.0,29705.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
312,39930,7,5,,103164353,3016,Active,52000955.0,24922.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
313,39930,7,5,,103164353,3016,Active,52000957.0,25451.0,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
314,39930,7,5,,103164353,3016,Active,81902501.0,,0.0049,Ki,Binding affinity against benzodiazepine receptor (BzR) in rat cortical membranes determined by competition experiments with radiolabeled [3H]flunitrazepam (Fnz),Confirmatory,8809170.0,
315,39931,7,5,,103164353,3016,Active,120758.0,289606.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
316,39931,7,5,,103164353,3016,Active,120761.0,24947.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
317,39931,7,5,,103164353,3016,Active,120763.0,140675.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
318,39931,7,5,,103164353,3016,Active,120764.0,29707.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
319,39931,7,5,,103164353,3016,Active,120769.0,25450.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
320,39931,7,5,,103164353,3016,Active,120782.0,140674.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
321,39931,7,5,,103164353,3016,Active,120788.0,29709.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
322,39931,7,5,,103164353,3016,Active,120790.0,79211.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
323,39931,7,5,,103164353,3016,Active,232127.0,29708.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
324,39931,7,5,,103164353,3016,Active,544363.0,29689.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
325,39931,7,5,,103164353,3016,Active,3023821.0,81658.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
326,39931,7,5,,103164353,3016,Active,13959374.0,65191.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
327,39931,7,5,,103164353,3016,Active,51317298.0,29705.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
328,39931,7,5,,103164353,3016,Active,52000955.0,24922.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
329,39931,7,5,,103164353,3016,Active,52000957.0,25451.0,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
330,39931,7,5,,103164353,3016,Active,81902501.0,,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,8917654.0,
331,39938,7,5,,103164353,3016,Active,120758.0,289606.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
332,39938,7,5,,103164353,3016,Active,120761.0,24947.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
333,39938,7,5,,103164353,3016,Active,120763.0,140675.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
334,39938,7,5,,103164353,3016,Active,120764.0,29707.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
335,39938,7,5,,103164353,3016,Active,120769.0,25450.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
336,39938,7,5,,103164353,3016,Active,120782.0,140674.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
337,39938,7,5,,103164353,3016,Active,120788.0,29709.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
338,39938,7,5,,103164353,3016,Active,120790.0,79211.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
339,39938,7,5,,103164353,3016,Active,232127.0,29708.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
340,39938,7,5,,103164353,3016,Active,544363.0,29689.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
341,39938,7,5,,103164353,3016,Active,3023821.0,81658.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
342,39938,7,5,,103164353,3016,Active,13959374.0,65191.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
343,39938,7,5,,103164353,3016,Active,51317298.0,29705.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
344,39938,7,5,,103164353,3016,Active,52000955.0,24922.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
345,39938,7,5,,103164353,3016,Active,52000957.0,25451.0,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
346,39938,7,5,,103164353,3016,Active,81902501.0,,0.005,Ki,Displacement of [3H]diazepam from rat cerebral cortex benzodiazepine receptor,Confirmatory,8709114.0,
347,39939,7,5,,103164353,3016,Active,120758.0,289606.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
348,39939,7,5,,103164353,3016,Active,120761.0,24947.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
349,39939,7,5,,103164353,3016,Active,120763.0,140675.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
350,39939,7,5,,103164353,3016,Active,120764.0,29707.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
351,39939,7,5,,103164353,3016,Active,120769.0,25450.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
352,39939,7,5,,103164353,3016,Active,120782.0,140674.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
353,39939,7,5,,103164353,3016,Active,120788.0,29709.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
354,39939,7,5,,103164353,3016,Active,120790.0,79211.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
355,39939,7,5,,103164353,3016,Active,232127.0,29708.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
356,39939,7,5,,103164353,3016,Active,544363.0,29689.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
357,39939,7,5,,103164353,3016,Active,3023821.0,81658.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
358,39939,7,5,,103164353,3016,Active,13959374.0,65191.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
359,39939,7,5,,103164353,3016,Active,51317298.0,29705.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
360,39939,7,5,,103164353,3016,Active,52000955.0,24922.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
361,39939,7,5,,103164353,3016,Active,52000957.0,25451.0,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
362,39939,7,5,,103164353,3016,Active,81902501.0,,0.0105,Ki,Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes,Confirmatory,8709126.0,
363,40070,4,9,,103164353,3016,Unspecified,120758.0,289606.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
364,40070,4,9,,103164353,3016,Unspecified,120761.0,24947.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
365,40070,4,9,,103164353,3016,Unspecified,120763.0,140675.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
366,40070,4,9,,103164353,3016,Unspecified,120764.0,29707.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
367,40070,4,9,,103164353,3016,Unspecified,120769.0,25450.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
368,40070,4,9,,103164353,3016,Unspecified,120782.0,140674.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
369,40070,4,9,,103164353,3016,Unspecified,120788.0,29709.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
370,40070,4,9,,103164353,3016,Unspecified,120790.0,79211.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
371,40070,4,9,,103164353,3016,Unspecified,232127.0,29708.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
372,40070,4,9,,103164353,3016,Unspecified,544363.0,29689.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
373,40070,4,9,,103164353,3016,Unspecified,3023821.0,81658.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
374,40070,4,9,,103164353,3016,Unspecified,13959374.0,65191.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
375,40070,4,9,,103164353,3016,Unspecified,51317298.0,29705.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
376,40070,4,9,,103164353,3016,Unspecified,52000955.0,24922.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
377,40070,4,9,,103164353,3016,Unspecified,52000957.0,25451.0,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
378,40070,4,9,,103164353,3016,Unspecified,81902501.0,,0.006999999999999999,Ki,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A Benzodiazepine receptor of synaptosomal membranes from rat brain,Confirmatory,,
379,40228,7,5,,103164353,3016,Active,120758.0,289606.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
380,40228,7,5,,103164353,3016,Active,120761.0,24947.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
381,40228,7,5,,103164353,3016,Active,120763.0,140675.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
382,40228,7,5,,103164353,3016,Active,120764.0,29707.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
383,40228,7,5,,103164353,3016,Active,120769.0,25450.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
384,40228,7,5,,103164353,3016,Active,120782.0,140674.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
385,40228,7,5,,103164353,3016,Active,120788.0,29709.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
386,40228,7,5,,103164353,3016,Active,120790.0,79211.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
387,40228,7,5,,103164353,3016,Active,232127.0,29708.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
388,40228,7,5,,103164353,3016,Active,544363.0,29689.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
389,40228,7,5,,103164353,3016,Active,3023821.0,81658.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
390,40228,7,5,,103164353,3016,Active,13959374.0,65191.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
391,40228,7,5,,103164353,3016,Active,51317298.0,29705.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
392,40228,7,5,,103164353,3016,Active,52000955.0,24922.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
393,40228,7,5,,103164353,3016,Active,52000957.0,25451.0,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
394,40228,7,5,,103164353,3016,Active,81902501.0,,0.006999999999999999,IC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor of rat cerebral cortex membranes,Confirmatory,1681105.0,
395,40230,9,1,,103164353,3016,Active,,,0.006,IC50,Concentration that inhibits binding of 1.5 nM [3H]diazepam to rat brain benzodiazepine receptor,Confirmatory,2540330.0,
396,40231,7,5,,103164353,3016,Active,120758.0,289606.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
397,40231,7,5,,103164353,3016,Active,120761.0,24947.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
398,40231,7,5,,103164353,3016,Active,120763.0,140675.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
399,40231,7,5,,103164353,3016,Active,120764.0,29707.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
400,40231,7,5,,103164353,3016,Active,120769.0,25450.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
401,40231,7,5,,103164353,3016,Active,120782.0,140674.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
402,40231,7,5,,103164353,3016,Active,120788.0,29709.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
403,40231,7,5,,103164353,3016,Active,120790.0,79211.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
404,40231,7,5,,103164353,3016,Active,232127.0,29708.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
405,40231,7,5,,103164353,3016,Active,544363.0,29689.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
406,40231,7,5,,103164353,3016,Active,3023821.0,81658.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
407,40231,7,5,,103164353,3016,Active,13959374.0,65191.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
408,40231,7,5,,103164353,3016,Active,51317298.0,29705.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
409,40231,7,5,,103164353,3016,Active,52000955.0,24922.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
410,40231,7,5,,103164353,3016,Active,52000957.0,25451.0,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
411,40231,7,5,,103164353,3016,Active,81902501.0,,0.006,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,2573731.0,
412,40236,7,5,,103164353,3016,Active,120758.0,289606.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
413,40236,7,5,,103164353,3016,Active,120761.0,24947.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
414,40236,7,5,,103164353,3016,Active,120763.0,140675.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
415,40236,7,5,,103164353,3016,Active,120764.0,29707.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
416,40236,7,5,,103164353,3016,Active,120769.0,25450.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
417,40236,7,5,,103164353,3016,Active,120782.0,140674.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
418,40236,7,5,,103164353,3016,Active,120788.0,29709.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
419,40236,7,5,,103164353,3016,Active,120790.0,79211.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
420,40236,7,5,,103164353,3016,Active,232127.0,29708.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
421,40236,7,5,,103164353,3016,Active,544363.0,29689.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
422,40236,7,5,,103164353,3016,Active,3023821.0,81658.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
423,40236,7,5,,103164353,3016,Active,13959374.0,65191.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
424,40236,7,5,,103164353,3016,Active,51317298.0,29705.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
425,40236,7,5,,103164353,3016,Active,52000955.0,24922.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
426,40236,7,5,,103164353,3016,Active,52000957.0,25451.0,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
427,40236,7,5,,103164353,3016,Active,81902501.0,,0.006,IC50,Effect on [3H]flunitrazepam binding to Benzodiazepine receptor,Confirmatory,1674542.0,
428,40239,7,2,,103164353,3016,Active,,,0.077,IC50,Inhibition of radiolabeled antagonist [3H]-Ro- 15-1788 binding to benzodiazepine receptor from rat cortical membranes,Confirmatory,2552115.0,
429,40241,7,1,,103164353,3016,Active,,,0.006,IC50,In vitro inhibitory concentration of compound against benzodiazepine receptor from rat cerebral cortex using [3H]- flunitrazepam was evaluated,Confirmatory,8145224.0,
430,40361,4,9,,103164353,3016,Unspecified,120758.0,289606.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
431,40361,4,9,,103164353,3016,Unspecified,120761.0,24947.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
432,40361,4,9,,103164353,3016,Unspecified,120763.0,140675.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
433,40361,4,9,,103164353,3016,Unspecified,120764.0,29707.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
434,40361,4,9,,103164353,3016,Unspecified,120769.0,25450.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
435,40361,4,9,,103164353,3016,Unspecified,120782.0,140674.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
436,40361,4,9,,103164353,3016,Unspecified,120788.0,29709.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
437,40361,4,9,,103164353,3016,Unspecified,120790.0,79211.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
438,40361,4,9,,103164353,3016,Unspecified,232127.0,29708.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
439,40361,4,9,,103164353,3016,Unspecified,544363.0,29689.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
440,40361,4,9,,103164353,3016,Unspecified,3023821.0,81658.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
441,40361,4,9,,103164353,3016,Unspecified,13959374.0,65191.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
442,40361,4,9,,103164353,3016,Unspecified,51317298.0,29705.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
443,40361,4,9,,103164353,3016,Unspecified,52000955.0,24922.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
444,40361,4,9,,103164353,3016,Unspecified,52000957.0,25451.0,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
445,40361,4,9,,103164353,3016,Unspecified,81902501.0,,1.0,IC50,Inhibition of Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
446,40373,7,5,,103164353,3016,Active,120758.0,289606.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
447,40373,7,5,,103164353,3016,Active,120761.0,24947.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
448,40373,7,5,,103164353,3016,Active,120763.0,140675.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
449,40373,7,5,,103164353,3016,Active,120764.0,29707.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
450,40373,7,5,,103164353,3016,Active,120769.0,25450.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
451,40373,7,5,,103164353,3016,Active,120782.0,140674.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
452,40373,7,5,,103164353,3016,Active,120788.0,29709.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
453,40373,7,5,,103164353,3016,Active,120790.0,79211.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
454,40373,7,5,,103164353,3016,Active,232127.0,29708.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
455,40373,7,5,,103164353,3016,Active,544363.0,29689.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
456,40373,7,5,,103164353,3016,Active,3023821.0,81658.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
457,40373,7,5,,103164353,3016,Active,13959374.0,65191.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
458,40373,7,5,,103164353,3016,Active,51317298.0,29705.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
459,40373,7,5,,103164353,3016,Active,52000955.0,24922.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
460,40373,7,5,,103164353,3016,Active,52000957.0,25451.0,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
461,40373,7,5,,103164353,3016,Active,81902501.0,,0.006,Ki,Displacement of [3H]- flunitrazepam from rat GABA-A benzodiazepine receptor,Confirmatory,8145225.0,
462,40381,7,2,,103164353,3016,Active,,,0.0066,Ki,Binding affinity for Diazepam-Sensitive fraction of GABA-A benzodiazepine receptors,Confirmatory,8386769.0,
463,40503,7,1,,103164353,3016,Active,,,0.00502,Ki,Displacing potential to [3H]diazepam binding to benzodiazepine receptor in Wistar rat cerebral cortex,Confirmatory,2542554.0,
464,40513,7,5,,103164353,3016,Active,120758.0,289606.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
465,40513,7,5,,103164353,3016,Active,120761.0,24947.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
466,40513,7,5,,103164353,3016,Active,120763.0,140675.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
467,40513,7,5,,103164353,3016,Active,120764.0,29707.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
468,40513,7,5,,103164353,3016,Active,120769.0,25450.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
469,40513,7,5,,103164353,3016,Active,120782.0,140674.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
470,40513,7,5,,103164353,3016,Active,120788.0,29709.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
471,40513,7,5,,103164353,3016,Active,120790.0,79211.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
472,40513,7,5,,103164353,3016,Active,232127.0,29708.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
473,40513,7,5,,103164353,3016,Active,544363.0,29689.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
474,40513,7,5,,103164353,3016,Active,3023821.0,81658.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
475,40513,7,5,,103164353,3016,Active,13959374.0,65191.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
476,40513,7,5,,103164353,3016,Active,51317298.0,29705.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
477,40513,7,5,,103164353,3016,Active,52000955.0,24922.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
478,40513,7,5,,103164353,3016,Active,52000957.0,25451.0,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
479,40513,7,5,,103164353,3016,Active,81902501.0,,0.0044,IC50,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptors in rat forebrain,Confirmatory,1680197.0,
480,40519,9,1,,103164353,3016,Active,,,0.006,IC50,Inhibition of specific binding of 1.5 nM [3H]diazepam to rat brain benzodiazepine receptors,Confirmatory,1967311.0,
481,40520,9,5,,103164353,3016,Active,120758.0,289606.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
482,40520,9,5,,103164353,3016,Active,120761.0,24947.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
483,40520,9,5,,103164353,3016,Active,120763.0,140675.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
484,40520,9,5,,103164353,3016,Active,120764.0,29707.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
485,40520,9,5,,103164353,3016,Active,120769.0,25450.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
486,40520,9,5,,103164353,3016,Active,120782.0,140674.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
487,40520,9,5,,103164353,3016,Active,120788.0,29709.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
488,40520,9,5,,103164353,3016,Active,120790.0,79211.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
489,40520,9,5,,103164353,3016,Active,232127.0,29708.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
490,40520,9,5,,103164353,3016,Active,544363.0,29689.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
491,40520,9,5,,103164353,3016,Active,3023821.0,81658.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
492,40520,9,5,,103164353,3016,Active,13959374.0,65191.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
493,40520,9,5,,103164353,3016,Active,51317298.0,29705.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
494,40520,9,5,,103164353,3016,Active,52000955.0,24922.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
495,40520,9,5,,103164353,3016,Active,52000957.0,25451.0,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
496,40520,9,5,,103164353,3016,Active,81902501.0,,0.0154,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A Benzodiazepine receptor of Wistar rat cerebral cortex,Confirmatory,1977911.0,
497,40521,9,1,,103164353,3016,Active,,,0.006,IC50,Inhibitory concentration against specific binding of [3H]diazepam to Benzodiazepine receptor in rat brain,Confirmatory,2163452.0,
498,40522,7,5,,103164353,3016,Active,120758.0,289606.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
499,40522,7,5,,103164353,3016,Active,120761.0,24947.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
500,40522,7,5,,103164353,3016,Active,120763.0,140675.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
501,40522,7,5,,103164353,3016,Active,120764.0,29707.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
502,40522,7,5,,103164353,3016,Active,120769.0,25450.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
503,40522,7,5,,103164353,3016,Active,120782.0,140674.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
504,40522,7,5,,103164353,3016,Active,120788.0,29709.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
505,40522,7,5,,103164353,3016,Active,120790.0,79211.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
506,40522,7,5,,103164353,3016,Active,232127.0,29708.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
507,40522,7,5,,103164353,3016,Active,544363.0,29689.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
508,40522,7,5,,103164353,3016,Active,3023821.0,81658.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
509,40522,7,5,,103164353,3016,Active,13959374.0,65191.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
510,40522,7,5,,103164353,3016,Active,51317298.0,29705.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
511,40522,7,5,,103164353,3016,Active,52000955.0,24922.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
512,40522,7,5,,103164353,3016,Active,52000957.0,25451.0,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
513,40522,7,5,,103164353,3016,Active,81902501.0,,0.013999999999999999,Ki,Displacement of [3H]flunitrazepam from GABA-A Benzodiazepine receptor of rat brain membranes,Confirmatory,1975276.0,
514,40525,7,1,,103164353,3016,Active,,,0.0206,IC50,Agonistic activity against specific binding of radioligand [3H]Ro-151788 to GABA-A Benzodiazepine receptor in rat cortex,Confirmatory,8388472.0,
515,40661,7,2,,103164353,3016,Active,,,0.006,IC50,In vitro for inhibition of [3H]diazepam towards Benzodiazepine receptor from rat,Confirmatory,6113284.0,
516,40664,6,4,,103164353,3016,Inconclusive,,,,,In vitro inhibition of [3H]-diazepam binding towards Benzodiazepine receptor at 1 uM; Not tested.,Other,6113284.0,
517,40666,11,1,,103164353,3016,Active,,,0.005,Ki,In vitro inhibition of [3H]diazepam binding to benzodiazepine receptor in rat cerebral cortical membrane,Confirmatory,6127411.0,
518,40670,7,1,,103164353,3016,Active,,,0.0085,Ki,In vitro affinity against Benzodiazepine receptor binding to rat cortical membranes (using [3H]- flumazenil as radioligand).,Confirmatory,10543878.0,
519,40671,7,2,,103164353,3016,Active,,,0.0049,Ki,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cortical membranes,Confirmatory,10197957.0,
520,40817,9,5,,103164353,3016,Active,120758.0,289606.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
521,40817,9,5,,103164353,3016,Active,120761.0,24947.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
522,40817,9,5,,103164353,3016,Active,120763.0,140675.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
523,40817,9,5,,103164353,3016,Active,120764.0,29707.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
524,40817,9,5,,103164353,3016,Active,120769.0,25450.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
525,40817,9,5,,103164353,3016,Active,120782.0,140674.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
526,40817,9,5,,103164353,3016,Active,120788.0,29709.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
527,40817,9,5,,103164353,3016,Active,120790.0,79211.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
528,40817,9,5,,103164353,3016,Active,232127.0,29708.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
529,40817,9,5,,103164353,3016,Active,544363.0,29689.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
530,40817,9,5,,103164353,3016,Active,3023821.0,81658.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
531,40817,9,5,,103164353,3016,Active,13959374.0,65191.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
532,40817,9,5,,103164353,3016,Active,51317298.0,29705.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
533,40817,9,5,,103164353,3016,Active,52000955.0,24922.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
534,40817,9,5,,103164353,3016,Active,52000957.0,25451.0,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
535,40817,9,5,,103164353,3016,Active,81902501.0,,0.006999999999999999,IC50,Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor,Confirmatory,2885419.0,
536,40822,7,1,,103164353,3016,Active,,,0.0054,IC50,Binding affinity measured by [3H]diazepam binding assay in rat,Confirmatory,6138436.0,
537,40823,7,3,,103164353,3016,Active,120758.0,289606.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
538,40823,7,3,,103164353,3016,Active,120761.0,24947.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
539,40823,7,3,,103164353,3016,Active,120763.0,140675.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
540,40823,7,3,,103164353,3016,Active,120764.0,29707.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
541,40823,7,3,,103164353,3016,Active,120769.0,25450.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
542,40823,7,3,,103164353,3016,Active,120782.0,140674.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
543,40823,7,3,,103164353,3016,Active,120788.0,29709.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
544,40823,7,3,,103164353,3016,Active,120790.0,79211.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
545,40823,7,3,,103164353,3016,Active,232127.0,29708.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
546,40823,7,3,,103164353,3016,Active,544363.0,29689.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
547,40823,7,3,,103164353,3016,Active,3023821.0,81658.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
548,40823,7,3,,103164353,3016,Active,13959374.0,65191.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
549,40823,7,3,,103164353,3016,Active,51317298.0,29705.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
550,40823,7,3,,103164353,3016,Active,52000955.0,24922.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
551,40823,7,3,,103164353,3016,Active,52000957.0,25451.0,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
552,40823,7,3,,103164353,3016,Active,81902501.0,,0.0054,IC50,Displacement of [3H]diazepam binding in rat brain membranes,Confirmatory,6138437.0,
553,40826,9,5,,103164353,3016,Active,120758.0,289606.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
554,40826,9,5,,103164353,3016,Active,120761.0,24947.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
555,40826,9,5,,103164353,3016,Active,120763.0,140675.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
556,40826,9,5,,103164353,3016,Active,120764.0,29707.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
557,40826,9,5,,103164353,3016,Active,120769.0,25450.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
558,40826,9,5,,103164353,3016,Active,120782.0,140674.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
559,40826,9,5,,103164353,3016,Active,120788.0,29709.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
560,40826,9,5,,103164353,3016,Active,120790.0,79211.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
561,40826,9,5,,103164353,3016,Active,232127.0,29708.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
562,40826,9,5,,103164353,3016,Active,544363.0,29689.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
563,40826,9,5,,103164353,3016,Active,3023821.0,81658.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
564,40826,9,5,,103164353,3016,Active,13959374.0,65191.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
565,40826,9,5,,103164353,3016,Active,51317298.0,29705.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
566,40826,9,5,,103164353,3016,Active,52000955.0,24922.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
567,40826,9,5,,103164353,3016,Active,52000957.0,25451.0,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
568,40826,9,5,,103164353,3016,Active,81902501.0,,0.006999999999999999,IC50,Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain,Confirmatory,2848124.0,
569,40830,7,2,,103164353,3016,Active,,,0.005,IC50,In vitro displacement of [3H]diazepam from GABA-A benzodiazepine receptor,Confirmatory,6131127.0,
570,40831,7,5,,103164353,3016,Active,120758.0,289606.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
571,40831,7,5,,103164353,3016,Active,120761.0,24947.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
572,40831,7,5,,103164353,3016,Active,120763.0,140675.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
573,40831,7,5,,103164353,3016,Active,120764.0,29707.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
574,40831,7,5,,103164353,3016,Active,120769.0,25450.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
575,40831,7,5,,103164353,3016,Active,120782.0,140674.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
576,40831,7,5,,103164353,3016,Active,120788.0,29709.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
577,40831,7,5,,103164353,3016,Active,120790.0,79211.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
578,40831,7,5,,103164353,3016,Active,232127.0,29708.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
579,40831,7,5,,103164353,3016,Active,544363.0,29689.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
580,40831,7,5,,103164353,3016,Active,3023821.0,81658.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
581,40831,7,5,,103164353,3016,Active,13959374.0,65191.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
582,40831,7,5,,103164353,3016,Active,51317298.0,29705.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
583,40831,7,5,,103164353,3016,Active,52000955.0,24922.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
584,40831,7,5,,103164353,3016,Active,52000957.0,25451.0,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
585,40831,7,5,,103164353,3016,Active,81902501.0,,0.0054,IC50,In vitro inhibition of [3H]diazepam binding to rat GABA-A benzodiazepine receptor,Confirmatory,6681844.0,
586,40832,7,5,,103164353,3016,Active,120758.0,289606.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
587,40832,7,5,,103164353,3016,Active,120761.0,24947.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
588,40832,7,5,,103164353,3016,Active,120763.0,140675.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
589,40832,7,5,,103164353,3016,Active,120764.0,29707.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
590,40832,7,5,,103164353,3016,Active,120769.0,25450.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
591,40832,7,5,,103164353,3016,Active,120782.0,140674.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
592,40832,7,5,,103164353,3016,Active,120788.0,29709.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
593,40832,7,5,,103164353,3016,Active,120790.0,79211.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
594,40832,7,5,,103164353,3016,Active,232127.0,29708.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
595,40832,7,5,,103164353,3016,Active,544363.0,29689.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
596,40832,7,5,,103164353,3016,Active,3023821.0,81658.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
597,40832,7,5,,103164353,3016,Active,13959374.0,65191.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
598,40832,7,5,,103164353,3016,Active,51317298.0,29705.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
599,40832,7,5,,103164353,3016,Active,52000955.0,24922.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
600,40832,7,5,,103164353,3016,Active,52000957.0,25451.0,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
601,40832,7,5,,103164353,3016,Active,81902501.0,,0.006,IC50,In vitro inhibition of binding to the benzodiazepine receptor in rat cerebral cortical membrane using [3H]diazepam as radioligand,Confirmatory,2842507.0,
602,40835,9,5,,103164353,3016,Active,120758.0,289606.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
603,40835,9,5,,103164353,3016,Active,120761.0,24947.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
604,40835,9,5,,103164353,3016,Active,120763.0,140675.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
605,40835,9,5,,103164353,3016,Active,120764.0,29707.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
606,40835,9,5,,103164353,3016,Active,120769.0,25450.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
607,40835,9,5,,103164353,3016,Active,120782.0,140674.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
608,40835,9,5,,103164353,3016,Active,120788.0,29709.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
609,40835,9,5,,103164353,3016,Active,120790.0,79211.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
610,40835,9,5,,103164353,3016,Active,232127.0,29708.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
611,40835,9,5,,103164353,3016,Active,544363.0,29689.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
612,40835,9,5,,103164353,3016,Active,3023821.0,81658.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
613,40835,9,5,,103164353,3016,Active,13959374.0,65191.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
614,40835,9,5,,103164353,3016,Active,51317298.0,29705.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
615,40835,9,5,,103164353,3016,Active,52000955.0,24922.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
616,40835,9,5,,103164353,3016,Active,52000957.0,25451.0,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
617,40835,9,5,,103164353,3016,Active,81902501.0,,0.03,IC50,Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex,Confirmatory,2985787.0,
618,40965,8,2,,103164353,3016,Active,,,5.6,Kd,In vitro binding to GABA-A benzodiazepine receptor of rat cerebral cortical membranes,Confirmatory,6325688.0,
619,40966,7,5,,103164353,3016,Active,120758.0,289606.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
620,40966,7,5,,103164353,3016,Active,120761.0,24947.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
621,40966,7,5,,103164353,3016,Active,120763.0,140675.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
622,40966,7,5,,103164353,3016,Active,120764.0,29707.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
623,40966,7,5,,103164353,3016,Active,120769.0,25450.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
624,40966,7,5,,103164353,3016,Active,120782.0,140674.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
625,40966,7,5,,103164353,3016,Active,120788.0,29709.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
626,40966,7,5,,103164353,3016,Active,120790.0,79211.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
627,40966,7,5,,103164353,3016,Active,232127.0,29708.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
628,40966,7,5,,103164353,3016,Active,544363.0,29689.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
629,40966,7,5,,103164353,3016,Active,3023821.0,81658.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
630,40966,7,5,,103164353,3016,Active,13959374.0,65191.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
631,40966,7,5,,103164353,3016,Active,51317298.0,29705.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
632,40966,7,5,,103164353,3016,Active,52000955.0,24922.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
633,40966,7,5,,103164353,3016,Active,52000957.0,25451.0,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
634,40966,7,5,,103164353,3016,Active,81902501.0,,0.00502,Ki,Displacement of [3H]-diazepam from GABA-A benzodiazepine receptor of rat cerebral cortex,Confirmatory,3029371.0,
635,40967,7,2,,103164353,3016,Active,120758.0,289606.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
636,40967,7,2,,103164353,3016,Active,120761.0,24947.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
637,40967,7,2,,103164353,3016,Active,120763.0,140675.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
638,40967,7,2,,103164353,3016,Active,120764.0,29707.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
639,40967,7,2,,103164353,3016,Active,120769.0,25450.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
640,40967,7,2,,103164353,3016,Active,120782.0,140674.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
641,40967,7,2,,103164353,3016,Active,120788.0,29709.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
642,40967,7,2,,103164353,3016,Active,120790.0,79211.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
643,40967,7,2,,103164353,3016,Active,232127.0,29708.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
644,40967,7,2,,103164353,3016,Active,544363.0,29689.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
645,40967,7,2,,103164353,3016,Active,3023821.0,81658.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
646,40967,7,2,,103164353,3016,Active,13959374.0,65191.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
647,40967,7,2,,103164353,3016,Active,51317298.0,29705.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
648,40967,7,2,,103164353,3016,Active,52000955.0,24922.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
649,40967,7,2,,103164353,3016,Active,52000957.0,25451.0,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
650,40967,7,2,,103164353,3016,Active,81902501.0,,0.00502,Ki,Binding affinity against benzodiazepine (BZ) receptor by displacing [3H]diazepam in cerebral cortex of Wistar rats,Confirmatory,2842502.0,
651,40968,7,5,,103164353,3016,Active,120758.0,289606.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
652,40968,7,5,,103164353,3016,Active,120761.0,24947.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
653,40968,7,5,,103164353,3016,Active,120763.0,140675.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
654,40968,7,5,,103164353,3016,Active,120764.0,29707.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
655,40968,7,5,,103164353,3016,Active,120769.0,25450.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
656,40968,7,5,,103164353,3016,Active,120782.0,140674.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
657,40968,7,5,,103164353,3016,Active,120788.0,29709.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
658,40968,7,5,,103164353,3016,Active,120790.0,79211.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
659,40968,7,5,,103164353,3016,Active,232127.0,29708.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
660,40968,7,5,,103164353,3016,Active,544363.0,29689.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
661,40968,7,5,,103164353,3016,Active,3023821.0,81658.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
662,40968,7,5,,103164353,3016,Active,13959374.0,65191.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
663,40968,7,5,,103164353,3016,Active,51317298.0,29705.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
664,40968,7,5,,103164353,3016,Active,52000955.0,24922.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
665,40968,7,5,,103164353,3016,Active,52000957.0,25451.0,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
666,40968,7,5,,103164353,3016,Active,81902501.0,,0.0029,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
667,40969,4,5,,103164353,3016,Active,,,0.0018,Ki,Inhibition of [3H]diazepam binding to GABA-A central benzodiazepine receptor of rat brain homogenate,Confirmatory,2836588.0,
668,40970,7,2,,103164353,3016,Active,,,0.0029,Ki,In vitro binding affinity against benzodiazepine receptor using [3H]diazepam as radioligand,Confirmatory,2993620.0,
669,40974,7,2,,103164353,3016,Active,,,0.0081,IC50,In vitro displacement of [3H]-diazepam from GABA-A Benzodiazepine receptor,Confirmatory,6127410.0,
670,40987,5,4,,103164353,3016,Unspecified,,,8090960.0,IC50,Binding affinity of compound towards Benzodiazepine receptor in a competition assay,Confirmatory,8978853.0,
671,40995,5,4,,103164353,3016,Unspecified,,,8090960.0,IC50,Binding affinity towards benzodiazepine/GABA A receptor.,Confirmatory,7861419.0,
672,40997,7,5,,103164353,3016,Active,120758.0,289606.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
673,40997,7,5,,103164353,3016,Active,120761.0,24947.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
674,40997,7,5,,103164353,3016,Active,120763.0,140675.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
675,40997,7,5,,103164353,3016,Active,120764.0,29707.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
676,40997,7,5,,103164353,3016,Active,120769.0,25450.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
677,40997,7,5,,103164353,3016,Active,120782.0,140674.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
678,40997,7,5,,103164353,3016,Active,120788.0,29709.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
679,40997,7,5,,103164353,3016,Active,120790.0,79211.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
680,40997,7,5,,103164353,3016,Active,232127.0,29708.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
681,40997,7,5,,103164353,3016,Active,544363.0,29689.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
682,40997,7,5,,103164353,3016,Active,3023821.0,81658.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
683,40997,7,5,,103164353,3016,Active,13959374.0,65191.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
684,40997,7,5,,103164353,3016,Active,51317298.0,29705.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
685,40997,7,5,,103164353,3016,Active,52000955.0,24922.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
686,40997,7,5,,103164353,3016,Active,52000957.0,25451.0,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
687,40997,7,5,,103164353,3016,Active,81902501.0,,0.005,IC50,In vitro inhibition of binding to GABA-A central benzodiazepine-receptor of rat brain,Confirmatory,6121916.0,
688,40998,7,7,,103164353,3016,Unspecified,120758.0,289606.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
689,40998,7,7,,103164353,3016,Unspecified,120761.0,24947.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
690,40998,7,7,,103164353,3016,Unspecified,120763.0,140675.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
691,40998,7,7,,103164353,3016,Unspecified,120764.0,29707.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
692,40998,7,7,,103164353,3016,Unspecified,120769.0,25450.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
693,40998,7,7,,103164353,3016,Unspecified,120782.0,140674.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
694,40998,7,7,,103164353,3016,Unspecified,120788.0,29709.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
695,40998,7,7,,103164353,3016,Unspecified,120790.0,79211.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
696,40998,7,7,,103164353,3016,Unspecified,232127.0,29708.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
697,40998,7,7,,103164353,3016,Unspecified,544363.0,29689.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
698,40998,7,7,,103164353,3016,Unspecified,3023821.0,81658.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
699,40998,7,7,,103164353,3016,Unspecified,13959374.0,65191.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
700,40998,7,7,,103164353,3016,Unspecified,51317298.0,29705.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
701,40998,7,7,,103164353,3016,Unspecified,52000955.0,24922.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
702,40998,7,7,,103164353,3016,Unspecified,52000957.0,25451.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
703,40998,7,7,,103164353,3016,Unspecified,81902501.0,,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after ip administration in rats,Other,6121916.0,
704,41000,6,7,,103164353,3016,Unspecified,120758.0,289606.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
705,41000,6,7,,103164353,3016,Unspecified,120761.0,24947.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
706,41000,6,7,,103164353,3016,Unspecified,120763.0,140675.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
707,41000,6,7,,103164353,3016,Unspecified,120764.0,29707.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
708,41000,6,7,,103164353,3016,Unspecified,120769.0,25450.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
709,41000,6,7,,103164353,3016,Unspecified,120782.0,140674.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
710,41000,6,7,,103164353,3016,Unspecified,120788.0,29709.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
711,41000,6,7,,103164353,3016,Unspecified,120790.0,79211.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
712,41000,6,7,,103164353,3016,Unspecified,232127.0,29708.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
713,41000,6,7,,103164353,3016,Unspecified,544363.0,29689.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
714,41000,6,7,,103164353,3016,Unspecified,3023821.0,81658.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
715,41000,6,7,,103164353,3016,Unspecified,13959374.0,65191.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
716,41000,6,7,,103164353,3016,Unspecified,51317298.0,29705.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
717,41000,6,7,,103164353,3016,Unspecified,52000955.0,24922.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
718,41000,6,7,,103164353,3016,Unspecified,52000957.0,25451.0,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
719,41000,6,7,,103164353,3016,Unspecified,81902501.0,,,,In vivo inhibition of binding to GABA-A central benzodiazepine-receptor after po administration in rats,Other,6121916.0,
720,41742,7,2,,103164353,3016,Active,,,0.013999999999999999,Ki,Binding affinity to rat benzodiazepine receptor,Confirmatory,12372537.0,
721,41852,7,5,,103164353,3016,Active,120752.0,780973.0,0.01,Ki,Displacement of [3H]Ro-151788 from GABA-A benzodiazepine receptor of bovine brain membranes,Confirmatory,10377227.0,
722,41852,7,5,,103164353,3016,Active,120756.0,282236.0,0.01,Ki,Displacement of [3H]Ro-151788 from GABA-A benzodiazepine receptor of bovine brain membranes,Confirmatory,10377227.0,
723,41852,7,5,,103164353,3016,Active,120759.0,282237.0,0.01,Ki,Displacement of [3H]Ro-151788 from GABA-A benzodiazepine receptor of bovine brain membranes,Confirmatory,10377227.0,
724,41852,7,5,,103164353,3016,Active,120766.0,282239.0,0.01,Ki,Displacement of [3H]Ro-151788 from GABA-A benzodiazepine receptor of bovine brain membranes,Confirmatory,10377227.0,
725,41852,7,5,,103164353,3016,Active,120784.0,282240.0,0.01,Ki,Displacement of [3H]Ro-151788 from GABA-A benzodiazepine receptor of bovine brain membranes,Confirmatory,10377227.0,
726,41852,7,5,,103164353,3016,Active,143811394.0,282238.0,0.01,Ki,Displacement of [3H]Ro-151788 from GABA-A benzodiazepine receptor of bovine brain membranes,Confirmatory,10377227.0,
727,41860,7,1,,103164353,3016,Active,,,0.01,Ki,Binding affinity towards Benzodiazepine receptor from bovine brain membrane using [3H]Ro-151788 as radioligand,Confirmatory,12477354.0,
728,41862,7,1,,103164353,3016,Active,,,0.013000000000000001,IC50,Affinity to displace [3H]flunitrazepam from Benzodiazepine receptor in bovine brain membrane,Confirmatory,2167984.0,
729,41870,9,5,,103164353,3016,Active,120752.0,780973.0,0.01,Ki,In vitro inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of bovine cerebral cortical membranes at 10 uM,Confirmatory,1319492.0,
730,41870,9,5,,103164353,3016,Active,120756.0,282236.0,0.01,Ki,In vitro inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of bovine cerebral cortical membranes at 10 uM,Confirmatory,1319492.0,
731,41870,9,5,,103164353,3016,Active,120759.0,282237.0,0.01,Ki,In vitro inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of bovine cerebral cortical membranes at 10 uM,Confirmatory,1319492.0,
732,41870,9,5,,103164353,3016,Active,120766.0,282239.0,0.01,Ki,In vitro inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of bovine cerebral cortical membranes at 10 uM,Confirmatory,1319492.0,
733,41870,9,5,,103164353,3016,Active,120784.0,282240.0,0.01,Ki,In vitro inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of bovine cerebral cortical membranes at 10 uM,Confirmatory,1319492.0,
734,41870,9,5,,103164353,3016,Active,143811394.0,282238.0,0.01,Ki,In vitro inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of bovine cerebral cortical membranes at 10 uM,Confirmatory,1319492.0,
735,41983,3,9,,103164353,3016,Unspecified,120752.0,780973.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,1319492.0,
736,41983,3,9,,103164353,3016,Unspecified,120756.0,282236.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,1319492.0,
737,41983,3,9,,103164353,3016,Unspecified,120759.0,282237.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,1319492.0,
738,41983,3,9,,103164353,3016,Unspecified,120766.0,282239.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,1319492.0,
739,41983,3,9,,103164353,3016,Unspecified,120784.0,282240.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,1319492.0,
740,41983,3,9,,103164353,3016,Unspecified,143811394.0,282238.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,1319492.0,
741,41986,7,5,,103164353,3016,Active,120752.0,780973.0,0.01,Ki,Inhibition of [3H]Ro-151788 binding to GABA-A central benzodiazepine receptor of bovine brain membranes,Confirmatory,12519068.0,
742,41986,7,5,,103164353,3016,Active,120756.0,282236.0,0.01,Ki,Inhibition of [3H]Ro-151788 binding to GABA-A central benzodiazepine receptor of bovine brain membranes,Confirmatory,12519068.0,
743,41986,7,5,,103164353,3016,Active,120759.0,282237.0,0.01,Ki,Inhibition of [3H]Ro-151788 binding to GABA-A central benzodiazepine receptor of bovine brain membranes,Confirmatory,12519068.0,
744,41986,7,5,,103164353,3016,Active,120766.0,282239.0,0.01,Ki,Inhibition of [3H]Ro-151788 binding to GABA-A central benzodiazepine receptor of bovine brain membranes,Confirmatory,12519068.0,
745,41986,7,5,,103164353,3016,Active,120784.0,282240.0,0.01,Ki,Inhibition of [3H]Ro-151788 binding to GABA-A central benzodiazepine receptor of bovine brain membranes,Confirmatory,12519068.0,
746,41986,7,5,,103164353,3016,Active,143811394.0,282238.0,0.01,Ki,Inhibition of [3H]Ro-151788 binding to GABA-A central benzodiazepine receptor of bovine brain membranes,Confirmatory,12519068.0,
747,41991,3,10,,103164353,3016,Unspecified,120752.0,780973.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,12519068.0,
748,41991,3,10,,103164353,3016,Unspecified,120756.0,282236.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,12519068.0,
749,41991,3,10,,103164353,3016,Unspecified,120759.0,282237.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,12519068.0,
750,41991,3,10,,103164353,3016,Unspecified,120766.0,282239.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,12519068.0,
751,41991,3,10,,103164353,3016,Unspecified,120784.0,282240.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,12519068.0,
752,41991,3,10,,103164353,3016,Unspecified,143811394.0,282238.0,,,"Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)",Other,12519068.0,
753,41994,8,3,,103164353,3016,Active,,,0.025,IC50,Displacement of 3[H]Flunitrazepam from GABA-A central benzodiazepine receptor of bovine brain membranes,Confirmatory,2821257.0,
754,41996,9,5,,103164353,3016,Active,120752.0,780973.0,0.040999999999999995,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A central Benzodiazepine receptor of bovine brain membranes,Confirmatory,2984422.0,
755,41996,9,5,,103164353,3016,Active,120756.0,282236.0,0.040999999999999995,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A central Benzodiazepine receptor of bovine brain membranes,Confirmatory,2984422.0,
756,41996,9,5,,103164353,3016,Active,120759.0,282237.0,0.040999999999999995,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A central Benzodiazepine receptor of bovine brain membranes,Confirmatory,2984422.0,
757,41996,9,5,,103164353,3016,Active,120766.0,282239.0,0.040999999999999995,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A central Benzodiazepine receptor of bovine brain membranes,Confirmatory,2984422.0,
758,41996,9,5,,103164353,3016,Active,120784.0,282240.0,0.040999999999999995,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A central Benzodiazepine receptor of bovine brain membranes,Confirmatory,2984422.0,
759,41996,9,5,,103164353,3016,Active,143811394.0,282238.0,0.040999999999999995,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A central Benzodiazepine receptor of bovine brain membranes,Confirmatory,2984422.0,
760,41998,9,5,,103164353,3016,Active,120752.0,780973.0,0.025,IC50,Inhibition of [3H]flunitrazepam binding to benzodiazepine receptor in bovine brain membrane,Confirmatory,2826782.0,
761,41998,9,5,,103164353,3016,Active,120756.0,282236.0,0.025,IC50,Inhibition of [3H]flunitrazepam binding to benzodiazepine receptor in bovine brain membrane,Confirmatory,2826782.0,
762,41998,9,5,,103164353,3016,Active,120759.0,282237.0,0.025,IC50,Inhibition of [3H]flunitrazepam binding to benzodiazepine receptor in bovine brain membrane,Confirmatory,2826782.0,
763,41998,9,5,,103164353,3016,Active,120766.0,282239.0,0.025,IC50,Inhibition of [3H]flunitrazepam binding to benzodiazepine receptor in bovine brain membrane,Confirmatory,2826782.0,
764,41998,9,5,,103164353,3016,Active,120784.0,282240.0,0.025,IC50,Inhibition of [3H]flunitrazepam binding to benzodiazepine receptor in bovine brain membrane,Confirmatory,2826782.0,
765,41998,9,5,,103164353,3016,Active,143811394.0,282238.0,0.025,IC50,Inhibition of [3H]flunitrazepam binding to benzodiazepine receptor in bovine brain membrane,Confirmatory,2826782.0,
766,42009,7,4,,103164353,3016,Active,,,0.0141,IC50,Binding affinity to the benzodiazepine receptor assayed using 0.5 nM [3H]flunitrazapam as radioligand in guinea pig cerebellum,Confirmatory,,
767,42014,7,4,,103164353,3016,Active,,,0.013999999999999999,IC50,In vitro displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of guinea pig cerebellum,Confirmatory,,
768,42018,3,9,,103164353,3016,Unspecified,,,,,Binding affinity to the benzodiazepine receptor assayed using 0.5 nM [3H]flunitrazapam as radioligand in guinea pig cerebellum,Other,,
769,42149,9,5,,103164353,3016,Active,120757.0,14395.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
770,42149,9,5,,103164353,3016,Active,120760.0,14396.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
771,42149,9,5,,103164353,3016,Active,120792.0,14403.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
772,42149,9,5,,103164353,3016,Active,1730183.0,14400.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
773,42149,9,5,,103164353,3016,Active,13959377.0,14397.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
774,42149,9,5,,103164353,3016,Active,13959379.0,57249.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
775,42149,9,5,,103164353,3016,Active,20141351.0,14406.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
776,42149,9,5,,103164353,3016,Active,51317299.0,14394.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
777,42149,9,5,,103164353,3016,Active,52000959.0,14402.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
778,42149,9,5,,103164353,3016,Active,62901524.0,216643.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
779,42149,9,5,,103164353,3016,Active,66774012.0,110886.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
780,42149,9,5,,103164353,3016,Active,341941084.0,14399.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
781,42149,9,5,,103164353,3016,Active,408360110.0,14405.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
782,42149,9,5,,103164353,3016,Active,408360111.0,14407.0,0.012,IC50,Displacement of [3H]flunitrazepam from GABA-A central benzodiazepine receptor of mouse brain,Confirmatory,,
783,42162,8,7,,103164353,3016,Unspecified,120757.0,14395.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
784,42162,8,7,,103164353,3016,Unspecified,120760.0,14396.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
785,42162,8,7,,103164353,3016,Unspecified,120792.0,14403.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
786,42162,8,7,,103164353,3016,Unspecified,1730183.0,14400.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
787,42162,8,7,,103164353,3016,Unspecified,13959377.0,14397.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
788,42162,8,7,,103164353,3016,Unspecified,13959379.0,57249.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
789,42162,8,7,,103164353,3016,Unspecified,20141351.0,14406.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
790,42162,8,7,,103164353,3016,Unspecified,51317299.0,14394.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
791,42162,8,7,,103164353,3016,Unspecified,52000959.0,14402.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
792,42162,8,7,,103164353,3016,Unspecified,62901524.0,216643.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
793,42162,8,7,,103164353,3016,Unspecified,66774012.0,110886.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
794,42162,8,7,,103164353,3016,Unspecified,341941084.0,14399.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
795,42162,8,7,,103164353,3016,Unspecified,408360110.0,14405.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
796,42162,8,7,,103164353,3016,Unspecified,408360111.0,14407.0,,,Inhibition of binding to GABA-A central benzodiazepine receptor,Other,6330354.0,
797,42169,9,5,,103164353,3016,Unspecified,120757.0,14395.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
798,42169,9,5,,103164353,3016,Unspecified,120760.0,14396.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
799,42169,9,5,,103164353,3016,Unspecified,120792.0,14403.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
800,42169,9,5,,103164353,3016,Unspecified,1730183.0,14400.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
801,42169,9,5,,103164353,3016,Unspecified,13959377.0,14397.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
802,42169,9,5,,103164353,3016,Unspecified,13959379.0,57249.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
803,42169,9,5,,103164353,3016,Unspecified,20141351.0,14406.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
804,42169,9,5,,103164353,3016,Unspecified,51317299.0,14394.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
805,42169,9,5,,103164353,3016,Unspecified,52000959.0,14402.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
806,42169,9,5,,103164353,3016,Unspecified,62901524.0,216643.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
807,42169,9,5,,103164353,3016,Unspecified,66774012.0,110886.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
808,42169,9,5,,103164353,3016,Unspecified,341941084.0,14399.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
809,42169,9,5,,103164353,3016,Unspecified,408360110.0,14405.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
810,42169,9,5,,103164353,3016,Unspecified,408360111.0,14407.0,85.0,Ki,Binding affinity for umolar GABA-A central benzodiazepine receptor,Confirmatory,6330354.0,
811,42310,3,9,,103164353,3016,Unspecified,120758.0,289606.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
812,42310,3,9,,103164353,3016,Unspecified,120761.0,24947.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
813,42310,3,9,,103164353,3016,Unspecified,120763.0,140675.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
814,42310,3,9,,103164353,3016,Unspecified,120764.0,29707.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
815,42310,3,9,,103164353,3016,Unspecified,120769.0,25450.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
816,42310,3,9,,103164353,3016,Unspecified,120782.0,140674.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
817,42310,3,9,,103164353,3016,Unspecified,120788.0,29709.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
818,42310,3,9,,103164353,3016,Unspecified,120790.0,79211.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
819,42310,3,9,,103164353,3016,Unspecified,232127.0,29708.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
820,42310,3,9,,103164353,3016,Unspecified,544363.0,29689.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
821,42310,3,9,,103164353,3016,Unspecified,3023821.0,81658.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
822,42310,3,9,,103164353,3016,Unspecified,13959374.0,65191.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
823,42310,3,9,,103164353,3016,Unspecified,51317298.0,29705.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
824,42310,3,9,,103164353,3016,Unspecified,52000955.0,24922.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
825,42310,3,9,,103164353,3016,Unspecified,52000957.0,25451.0,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
826,42310,3,9,,103164353,3016,Unspecified,81902501.0,,,,"In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)",Other,8709126.0,
827,42311,3,9,,103164353,3016,Unspecified,120758.0,289606.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
828,42311,3,9,,103164353,3016,Unspecified,120761.0,24947.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
829,42311,3,9,,103164353,3016,Unspecified,120763.0,140675.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
830,42311,3,9,,103164353,3016,Unspecified,120764.0,29707.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
831,42311,3,9,,103164353,3016,Unspecified,120769.0,25450.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
832,42311,3,9,,103164353,3016,Unspecified,120782.0,140674.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
833,42311,3,9,,103164353,3016,Unspecified,120788.0,29709.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
834,42311,3,9,,103164353,3016,Unspecified,120790.0,79211.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
835,42311,3,9,,103164353,3016,Unspecified,232127.0,29708.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
836,42311,3,9,,103164353,3016,Unspecified,544363.0,29689.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
837,42311,3,9,,103164353,3016,Unspecified,3023821.0,81658.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
838,42311,3,9,,103164353,3016,Unspecified,13959374.0,65191.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
839,42311,3,9,,103164353,3016,Unspecified,51317298.0,29705.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
840,42311,3,9,,103164353,3016,Unspecified,52000955.0,24922.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
841,42311,3,9,,103164353,3016,Unspecified,52000957.0,25451.0,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
842,42311,3,9,,103164353,3016,Unspecified,81902501.0,,,,Inhibition of [3H]flunitrazepam [3H]FNZ) binding to GABA-A benzodiazepine receptor of cortical membranes +/- 100 uM GABA,Other,,
843,42333,7,2,,103164353,3016,Active,,,0.0056,IC50,Binding affinity against central benzodiazepine receptor(CBR).,Confirmatory,8863805.0,
844,42335,7,5,,103164353,3016,Active,120758.0,289606.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
845,42335,7,5,,103164353,3016,Active,120761.0,24947.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
846,42335,7,5,,103164353,3016,Active,120763.0,140675.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
847,42335,7,5,,103164353,3016,Active,120764.0,29707.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
848,42335,7,5,,103164353,3016,Active,120769.0,25450.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
849,42335,7,5,,103164353,3016,Active,120782.0,140674.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
850,42335,7,5,,103164353,3016,Active,120788.0,29709.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
851,42335,7,5,,103164353,3016,Active,120790.0,79211.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
852,42335,7,5,,103164353,3016,Active,232127.0,29708.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
853,42335,7,5,,103164353,3016,Active,544363.0,29689.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
854,42335,7,5,,103164353,3016,Active,3023821.0,81658.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
855,42335,7,5,,103164353,3016,Active,13959374.0,65191.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
856,42335,7,5,,103164353,3016,Active,51317298.0,29705.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
857,42335,7,5,,103164353,3016,Active,52000955.0,24922.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
858,42335,7,5,,103164353,3016,Active,52000957.0,25451.0,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
859,42335,7,5,,103164353,3016,Active,81902501.0,,0.004,IC50,Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain,Confirmatory,1846920.0,
860,42338,7,5,,103164353,3016,Active,120758.0,289606.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
861,42338,7,5,,103164353,3016,Active,120761.0,24947.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
862,42338,7,5,,103164353,3016,Active,120763.0,140675.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
863,42338,7,5,,103164353,3016,Active,120764.0,29707.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
864,42338,7,5,,103164353,3016,Active,120769.0,25450.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
865,42338,7,5,,103164353,3016,Active,120782.0,140674.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
866,42338,7,5,,103164353,3016,Active,120788.0,29709.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
867,42338,7,5,,103164353,3016,Active,120790.0,79211.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
868,42338,7,5,,103164353,3016,Active,232127.0,29708.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
869,42338,7,5,,103164353,3016,Active,544363.0,29689.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
870,42338,7,5,,103164353,3016,Active,3023821.0,81658.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
871,42338,7,5,,103164353,3016,Active,13959374.0,65191.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
872,42338,7,5,,103164353,3016,Active,51317298.0,29705.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
873,42338,7,5,,103164353,3016,Active,52000955.0,24922.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
874,42338,7,5,,103164353,3016,Active,52000957.0,25451.0,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
875,42338,7,5,,103164353,3016,Active,81902501.0,,0.0093,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebellum,Confirmatory,2573731.0,
876,42340,7,5,,103164353,3016,Active,120758.0,289606.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
877,42340,7,5,,103164353,3016,Active,120761.0,24947.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
878,42340,7,5,,103164353,3016,Active,120763.0,140675.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
879,42340,7,5,,103164353,3016,Active,120764.0,29707.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
880,42340,7,5,,103164353,3016,Active,120769.0,25450.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
881,42340,7,5,,103164353,3016,Active,120782.0,140674.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
882,42340,7,5,,103164353,3016,Active,120788.0,29709.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
883,42340,7,5,,103164353,3016,Active,120790.0,79211.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
884,42340,7,5,,103164353,3016,Active,232127.0,29708.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
885,42340,7,5,,103164353,3016,Active,544363.0,29689.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
886,42340,7,5,,103164353,3016,Active,3023821.0,81658.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
887,42340,7,5,,103164353,3016,Active,13959374.0,65191.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
888,42340,7,5,,103164353,3016,Active,51317298.0,29705.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
889,42340,7,5,,103164353,3016,Active,52000955.0,24922.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
890,42340,7,5,,103164353,3016,Active,52000957.0,25451.0,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
891,42340,7,5,,103164353,3016,Active,81902501.0,,0.0073,IC50,Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cortex,Confirmatory,2573731.0,
892,48704,3,3,,103164353,3016,Unspecified,,,,,Minimum effective dose required for drug induced ataxia (observable symptomatology) in cat when administered perorally,Other,6138436.0,
893,52275,10,5,,103164353,3016,Unspecified,2495000.0,100719593.0,100.0,IC50,Half-maximal inhibition of [125I]CCK-33 binding to guinea pig brain(cortex) cholecystokinin receptor,Confirmatory,2885419.0,
894,52280,9,1,,103164353,3016,Unspecified,,,100.0,IC50,Half-maximal inhibition of [125I]-CCK-8(+) binding to cholecystokinin receptor from guinea pig brain tissue,Confirmatory,2848124.0,
895,52410,9,2,,103164353,3016,Unspecified,,,100.0,IC50,Half-maximal inhibition of [125I]-CCK-33 binding to rat pancreas cholecystokinin receptor,Confirmatory,2885419.0,
896,52413,9,2,,103164353,3016,Unspecified,,,100.0,IC50,Half-maximal inhibition of [125I]CCK-33 binding to cholecystokinin A receptor from rat pancreatic tissue,Confirmatory,2848124.0,
897,71235,6,2,,103164353,3016,Active,,,0.0078,Ki,Displacement of [3H]-Ro-15-1788 from rat GABA-A receptor alpha-2-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12477354.0,
898,71245,8,5,,103164353,3016,Active,120761.0,24947.0,0.0139,Ki,Displacement of [3H]Ro-151788 from rat GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12477354.0,
899,71245,8,5,,103164353,3016,Active,120788.0,29709.0,0.0139,Ki,Displacement of [3H]Ro-151788 from rat GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12477354.0,
900,71245,8,5,,103164353,3016,Active,52000957.0,25451.0,0.0139,Ki,Displacement of [3H]Ro-151788 from rat GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12477354.0,
901,71249,6,2,,103164353,3016,Active,,,0.0098,Ki,Displacement of [3H]Ro-151788 from rat GABA-A receptor alpha-5-beta-3-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12477354.0,
902,71266,7,2,,103164353,3016,Unspecified,,,3.0,Ki,Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-6-beta-3-gamma-2,Confirmatory,10633039.0,
903,71289,3,6,,103164353,3016,Unspecified,,,,,Ability to displace [3H]flunitrazepam ([3H]-FNP) binding to mouse brain after intraperitoneal administration at a dose 10 umol/kg,Other,2536440.0,
904,71558,7,1,,103164353,3016,Unspecified,120758.0,289606.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
905,71558,7,1,,103164353,3016,Unspecified,120761.0,24947.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
906,71558,7,1,,103164353,3016,Unspecified,120763.0,140675.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
907,71558,7,1,,103164353,3016,Unspecified,120764.0,29707.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
908,71558,7,1,,103164353,3016,Unspecified,120769.0,25450.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
909,71558,7,1,,103164353,3016,Unspecified,120782.0,140674.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
910,71558,7,1,,103164353,3016,Unspecified,120788.0,29709.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
911,71558,7,1,,103164353,3016,Unspecified,120790.0,79211.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
912,71558,7,1,,103164353,3016,Unspecified,232127.0,29708.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
913,71558,7,1,,103164353,3016,Unspecified,544363.0,29689.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
914,71558,7,1,,103164353,3016,Unspecified,3023821.0,81658.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
915,71558,7,1,,103164353,3016,Unspecified,13959374.0,65191.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
916,71558,7,1,,103164353,3016,Unspecified,51317298.0,29705.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
917,71558,7,1,,103164353,3016,Unspecified,52000955.0,24922.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
918,71558,7,1,,103164353,3016,Unspecified,52000957.0,25451.0,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
919,71558,7,1,,103164353,3016,Unspecified,81902501.0,,,,Displacement of [3H]diazepam binding in rat brain membranes,Other,3001304.0,
920,71673,3,8,,103164353,3016,Unspecified,120758.0,289606.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
921,71673,3,8,,103164353,3016,Unspecified,120761.0,24947.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
922,71673,3,8,,103164353,3016,Unspecified,120763.0,140675.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
923,71673,3,8,,103164353,3016,Unspecified,120764.0,29707.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
924,71673,3,8,,103164353,3016,Unspecified,120769.0,25450.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
925,71673,3,8,,103164353,3016,Unspecified,120782.0,140674.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
926,71673,3,8,,103164353,3016,Unspecified,120788.0,29709.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
927,71673,3,8,,103164353,3016,Unspecified,120790.0,79211.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
928,71673,3,8,,103164353,3016,Unspecified,232127.0,29708.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
929,71673,3,8,,103164353,3016,Unspecified,544363.0,29689.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
930,71673,3,8,,103164353,3016,Unspecified,3023821.0,81658.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
931,71673,3,8,,103164353,3016,Unspecified,13959374.0,65191.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
932,71673,3,8,,103164353,3016,Unspecified,51317298.0,29705.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
933,71673,3,8,,103164353,3016,Unspecified,52000955.0,24922.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
934,71673,3,8,,103164353,3016,Unspecified,52000957.0,25451.0,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
935,71673,3,8,,103164353,3016,Unspecified,81902501.0,,,,In vitro displacement of [35S]TBPS from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 10 uM,Other,11086734.0,
936,71678,3,10,,103164353,3016,Unspecified,120758.0,289606.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
937,71678,3,10,,103164353,3016,Unspecified,120761.0,24947.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
938,71678,3,10,,103164353,3016,Unspecified,120763.0,140675.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
939,71678,3,10,,103164353,3016,Unspecified,120764.0,29707.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
940,71678,3,10,,103164353,3016,Unspecified,120769.0,25450.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
941,71678,3,10,,103164353,3016,Unspecified,120782.0,140674.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
942,71678,3,10,,103164353,3016,Unspecified,120788.0,29709.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
943,71678,3,10,,103164353,3016,Unspecified,120790.0,79211.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
944,71678,3,10,,103164353,3016,Unspecified,232127.0,29708.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
945,71678,3,10,,103164353,3016,Unspecified,544363.0,29689.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
946,71678,3,10,,103164353,3016,Unspecified,3023821.0,81658.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
947,71678,3,10,,103164353,3016,Unspecified,13959374.0,65191.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
948,71678,3,10,,103164353,3016,Unspecified,51317298.0,29705.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
949,71678,3,10,,103164353,3016,Unspecified,52000955.0,24922.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
950,71678,3,10,,103164353,3016,Unspecified,52000957.0,25451.0,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
951,71678,3,10,,103164353,3016,Unspecified,81902501.0,,,,Displacement of [3H]flunitrazepam from GABA-A receptor of rat brain membrane preparations at 10 nM,Other,11086734.0,
952,71682,3,8,,103164353,3016,Unspecified,120758.0,289606.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
953,71682,3,8,,103164353,3016,Unspecified,120761.0,24947.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
954,71682,3,8,,103164353,3016,Unspecified,120763.0,140675.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
955,71682,3,8,,103164353,3016,Unspecified,120764.0,29707.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
956,71682,3,8,,103164353,3016,Unspecified,120769.0,25450.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
957,71682,3,8,,103164353,3016,Unspecified,120782.0,140674.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
958,71682,3,8,,103164353,3016,Unspecified,120788.0,29709.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
959,71682,3,8,,103164353,3016,Unspecified,120790.0,79211.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
960,71682,3,8,,103164353,3016,Unspecified,232127.0,29708.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
961,71682,3,8,,103164353,3016,Unspecified,544363.0,29689.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
962,71682,3,8,,103164353,3016,Unspecified,3023821.0,81658.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
963,71682,3,8,,103164353,3016,Unspecified,13959374.0,65191.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
964,71682,3,8,,103164353,3016,Unspecified,51317298.0,29705.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
965,71682,3,8,,103164353,3016,Unspecified,52000955.0,24922.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
966,71682,3,8,,103164353,3016,Unspecified,52000957.0,25451.0,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
967,71682,3,8,,103164353,3016,Unspecified,81902501.0,,,,In vitro displacement of [3H]muscimol from Gamma-aminobutyric acid A receptor of rat brain membrane preparations at 100 uM,Other,11086734.0,
968,71697,7,3,,103164353,3016,Active,120758.0,289606.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
969,71697,7,3,,103164353,3016,Active,120761.0,24947.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
970,71697,7,3,,103164353,3016,Active,120763.0,140675.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
971,71697,7,3,,103164353,3016,Active,120764.0,29707.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
972,71697,7,3,,103164353,3016,Active,120769.0,25450.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
973,71697,7,3,,103164353,3016,Active,120782.0,140674.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
974,71697,7,3,,103164353,3016,Active,120788.0,29709.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
975,71697,7,3,,103164353,3016,Active,120790.0,79211.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
976,71697,7,3,,103164353,3016,Active,232127.0,29708.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
977,71697,7,3,,103164353,3016,Active,544363.0,29689.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
978,71697,7,3,,103164353,3016,Active,3023821.0,81658.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
979,71697,7,3,,103164353,3016,Active,13959374.0,65191.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
980,71697,7,3,,103164353,3016,Active,51317298.0,29705.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
981,71697,7,3,,103164353,3016,Active,52000955.0,24922.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
982,71697,7,3,,103164353,3016,Active,52000957.0,25451.0,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
983,71697,7,3,,103164353,3016,Active,81902501.0,,0.091,IC50,Ability to allosterically modulate the binding of [35S]TBPS to gamma-aminobutyric-acid A receptor in rat brain cortical P2 membranes.,Confirmatory,9016329.0,
984,71825,7,5,,103164353,3016,Active,120758.0,289606.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
985,71825,7,5,,103164353,3016,Active,120761.0,24947.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
986,71825,7,5,,103164353,3016,Active,120763.0,140675.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
987,71825,7,5,,103164353,3016,Active,120764.0,29707.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
988,71825,7,5,,103164353,3016,Active,120769.0,25450.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
989,71825,7,5,,103164353,3016,Active,120782.0,140674.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
990,71825,7,5,,103164353,3016,Active,120788.0,29709.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
991,71825,7,5,,103164353,3016,Active,120790.0,79211.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
992,71825,7,5,,103164353,3016,Active,232127.0,29708.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
993,71825,7,5,,103164353,3016,Active,544363.0,29689.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
994,71825,7,5,,103164353,3016,Active,3023821.0,81658.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
995,71825,7,5,,103164353,3016,Active,13959374.0,65191.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
996,71825,7,5,,103164353,3016,Active,51317298.0,29705.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
997,71825,7,5,,103164353,3016,Active,52000955.0,24922.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
998,71825,7,5,,103164353,3016,Active,52000957.0,25451.0,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
999,71825,7,5,,103164353,3016,Active,81902501.0,,0.027999999999999997,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the absence of GABA.,Confirmatory,7837226.0,
1000,71826,7,5,,103164353,3016,Active,120758.0,289606.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1001,71826,7,5,,103164353,3016,Active,120761.0,24947.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1002,71826,7,5,,103164353,3016,Active,120763.0,140675.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1003,71826,7,5,,103164353,3016,Active,120764.0,29707.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1004,71826,7,5,,103164353,3016,Active,120769.0,25450.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1005,71826,7,5,,103164353,3016,Active,120782.0,140674.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1006,71826,7,5,,103164353,3016,Active,120788.0,29709.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1007,71826,7,5,,103164353,3016,Active,120790.0,79211.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1008,71826,7,5,,103164353,3016,Active,232127.0,29708.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1009,71826,7,5,,103164353,3016,Active,544363.0,29689.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1010,71826,7,5,,103164353,3016,Active,3023821.0,81658.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1011,71826,7,5,,103164353,3016,Active,13959374.0,65191.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1012,71826,7,5,,103164353,3016,Active,51317298.0,29705.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1013,71826,7,5,,103164353,3016,Active,52000955.0,24922.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1014,71826,7,5,,103164353,3016,Active,52000957.0,25451.0,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1015,71826,7,5,,103164353,3016,Active,81902501.0,,0.013000000000000001,IC50,Binding affinity against benzodiazepine site of gamma-aminobutyric-acid A receptor of rat cerebral cortex by using [3H]flunitrazepam in the presence of GABA 1 mM.,Confirmatory,7837226.0,
1016,71827,7,2,,103164353,3016,Active,,,0.027999999999999997,IC50,Binding affinity against the BZD site of the Gamma-aminobutyric acid A receptor in rat cerebral cortex using radioligand ([3H]flunitrazepam) assay in the absence of Gamma-aminobutyric acid,Confirmatory,,
1017,71828,7,2,,103164353,3016,Active,,,0.013000000000000001,IC50,Binding affinity against the BZD site of the Gamma-aminobutyric acid A receptor in rat cerebral cortex using radioligand ([3H]flunitrazepam) assay in the presence of Gamma-aminobutyric acid,Confirmatory,,
1018,71840,9,5,,103164353,3016,Active,120758.0,289606.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1019,71840,9,5,,103164353,3016,Active,120761.0,24947.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1020,71840,9,5,,103164353,3016,Active,120763.0,140675.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1021,71840,9,5,,103164353,3016,Active,120764.0,29707.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1022,71840,9,5,,103164353,3016,Active,120769.0,25450.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1023,71840,9,5,,103164353,3016,Active,120782.0,140674.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1024,71840,9,5,,103164353,3016,Active,120788.0,29709.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1025,71840,9,5,,103164353,3016,Active,120790.0,79211.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1026,71840,9,5,,103164353,3016,Active,232127.0,29708.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1027,71840,9,5,,103164353,3016,Active,544363.0,29689.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1028,71840,9,5,,103164353,3016,Active,3023821.0,81658.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1029,71840,9,5,,103164353,3016,Active,13959374.0,65191.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1030,71840,9,5,,103164353,3016,Active,51317298.0,29705.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1031,71840,9,5,,103164353,3016,Active,52000955.0,24922.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1032,71840,9,5,,103164353,3016,Active,52000957.0,25451.0,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1033,71840,9,5,,103164353,3016,Active,81902501.0,,0.012,IC50,In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]flunitrazepam,Confirmatory,2170646.0,
1034,71985,9,5,,103164353,3016,Active,120758.0,289606.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1035,71985,9,5,,103164353,3016,Active,120761.0,24947.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1036,71985,9,5,,103164353,3016,Active,120763.0,140675.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1037,71985,9,5,,103164353,3016,Active,120764.0,29707.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1038,71985,9,5,,103164353,3016,Active,120769.0,25450.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1039,71985,9,5,,103164353,3016,Active,120782.0,140674.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1040,71985,9,5,,103164353,3016,Active,120788.0,29709.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1041,71985,9,5,,103164353,3016,Active,120790.0,79211.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1042,71985,9,5,,103164353,3016,Active,232127.0,29708.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1043,71985,9,5,,103164353,3016,Active,544363.0,29689.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1044,71985,9,5,,103164353,3016,Active,3023821.0,81658.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1045,71985,9,5,,103164353,3016,Active,13959374.0,65191.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1046,71985,9,5,,103164353,3016,Active,51317298.0,29705.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1047,71985,9,5,,103164353,3016,Active,52000955.0,24922.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1048,71985,9,5,,103164353,3016,Active,52000957.0,25451.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1049,71985,9,5,,103164353,3016,Active,81902501.0,,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat cerebellar tissue,Confirmatory,11086734.0,
1050,71986,9,5,,103164353,3016,Active,120758.0,289606.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1051,71986,9,5,,103164353,3016,Active,120761.0,24947.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1052,71986,9,5,,103164353,3016,Active,120763.0,140675.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1053,71986,9,5,,103164353,3016,Active,120764.0,29707.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1054,71986,9,5,,103164353,3016,Active,120769.0,25450.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1055,71986,9,5,,103164353,3016,Active,120782.0,140674.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1056,71986,9,5,,103164353,3016,Active,120788.0,29709.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1057,71986,9,5,,103164353,3016,Active,120790.0,79211.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1058,71986,9,5,,103164353,3016,Active,232127.0,29708.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1059,71986,9,5,,103164353,3016,Active,544363.0,29689.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1060,71986,9,5,,103164353,3016,Active,3023821.0,81658.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1061,71986,9,5,,103164353,3016,Active,13959374.0,65191.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1062,71986,9,5,,103164353,3016,Active,51317298.0,29705.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1063,71986,9,5,,103164353,3016,Active,52000955.0,24922.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1064,71986,9,5,,103164353,3016,Active,52000957.0,25451.0,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1065,71986,9,5,,103164353,3016,Active,81902501.0,,0.02,IC50,Displacement of [3H]flunitrazepam from GABA-A receptor of rat forebrain tissue,Confirmatory,11086734.0,
1066,72003,3,8,,103164353,3016,Unspecified,120758.0,289606.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1067,72003,3,8,,103164353,3016,Unspecified,120761.0,24947.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1068,72003,3,8,,103164353,3016,Unspecified,120763.0,140675.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1069,72003,3,8,,103164353,3016,Unspecified,120764.0,29707.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1070,72003,3,8,,103164353,3016,Unspecified,120769.0,25450.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1071,72003,3,8,,103164353,3016,Unspecified,120782.0,140674.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1072,72003,3,8,,103164353,3016,Unspecified,120788.0,29709.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1073,72003,3,8,,103164353,3016,Unspecified,120790.0,79211.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1074,72003,3,8,,103164353,3016,Unspecified,232127.0,29708.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1075,72003,3,8,,103164353,3016,Unspecified,544363.0,29689.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1076,72003,3,8,,103164353,3016,Unspecified,3023821.0,81658.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1077,72003,3,8,,103164353,3016,Unspecified,13959374.0,65191.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1078,72003,3,8,,103164353,3016,Unspecified,51317298.0,29705.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1079,72003,3,8,,103164353,3016,Unspecified,52000955.0,24922.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1080,72003,3,8,,103164353,3016,Unspecified,52000957.0,25451.0,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1081,72003,3,8,,103164353,3016,Unspecified,81902501.0,,,,Inhibition of [35S]TBPS binding to Gamma-aminobutyric acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA at 0.01 uM,Other,,
1082,72136,7,5,,103164353,3016,Active,120758.0,289606.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1083,72136,7,5,,103164353,3016,Active,120761.0,24947.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1084,72136,7,5,,103164353,3016,Active,120763.0,140675.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1085,72136,7,5,,103164353,3016,Active,120764.0,29707.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1086,72136,7,5,,103164353,3016,Active,120769.0,25450.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1087,72136,7,5,,103164353,3016,Active,120782.0,140674.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1088,72136,7,5,,103164353,3016,Active,120788.0,29709.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1089,72136,7,5,,103164353,3016,Active,120790.0,79211.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1090,72136,7,5,,103164353,3016,Active,232127.0,29708.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1091,72136,7,5,,103164353,3016,Active,544363.0,29689.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1092,72136,7,5,,103164353,3016,Active,3023821.0,81658.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1093,72136,7,5,,103164353,3016,Active,13959374.0,65191.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1094,72136,7,5,,103164353,3016,Active,51317298.0,29705.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1095,72136,7,5,,103164353,3016,Active,52000955.0,24922.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1096,72136,7,5,,103164353,3016,Active,52000957.0,25451.0,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1097,72136,7,5,,103164353,3016,Active,81902501.0,,0.0049,Ki,Inhibition of [3H]flunitrazepam binding to GABA-A receptor of rat cortical membranes,Confirmatory,8568803.0,
1098,72138,6,2,,103164353,3016,Active,,,0.02,Ki,"Binding affinity to rat chimeric GABA-A receptor C6, alpha1-alpha6 chimeric subunit co-expressed with beta-2 gamma2 subunits in HEK293 cells",Confirmatory,7799410.0,
1099,72144,3,8,,103164353,3016,Unspecified,120758.0,289606.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1100,72144,3,8,,103164353,3016,Unspecified,120761.0,24947.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1101,72144,3,8,,103164353,3016,Unspecified,120763.0,140675.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1102,72144,3,8,,103164353,3016,Unspecified,120764.0,29707.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1103,72144,3,8,,103164353,3016,Unspecified,120769.0,25450.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1104,72144,3,8,,103164353,3016,Unspecified,120782.0,140674.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1105,72144,3,8,,103164353,3016,Unspecified,120788.0,29709.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1106,72144,3,8,,103164353,3016,Unspecified,120790.0,79211.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1107,72144,3,8,,103164353,3016,Unspecified,232127.0,29708.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1108,72144,3,8,,103164353,3016,Unspecified,544363.0,29689.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1109,72144,3,8,,103164353,3016,Unspecified,3023821.0,81658.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1110,72144,3,8,,103164353,3016,Unspecified,13959374.0,65191.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1111,72144,3,8,,103164353,3016,Unspecified,51317298.0,29705.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1112,72144,3,8,,103164353,3016,Unspecified,52000955.0,24922.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1113,72144,3,8,,103164353,3016,Unspecified,52000957.0,25451.0,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1114,72144,3,8,,103164353,3016,Unspecified,81902501.0,,,,Inhibition of [35S]TBPS binding to GABA-A receptor complex,Other,8145225.0,
1115,72297,7,2,,103164353,3016,Active,120758.0,289606.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1116,72297,7,2,,103164353,3016,Active,120761.0,24947.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1117,72297,7,2,,103164353,3016,Active,120763.0,140675.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1118,72297,7,2,,103164353,3016,Active,120764.0,29707.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1119,72297,7,2,,103164353,3016,Active,120769.0,25450.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1120,72297,7,2,,103164353,3016,Active,120782.0,140674.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1121,72297,7,2,,103164353,3016,Active,120788.0,29709.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1122,72297,7,2,,103164353,3016,Active,120790.0,79211.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1123,72297,7,2,,103164353,3016,Active,232127.0,29708.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1124,72297,7,2,,103164353,3016,Active,544363.0,29689.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1125,72297,7,2,,103164353,3016,Active,3023821.0,81658.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1126,72297,7,2,,103164353,3016,Active,13959374.0,65191.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1127,72297,7,2,,103164353,3016,Active,51317298.0,29705.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1128,72297,7,2,,103164353,3016,Active,52000955.0,24922.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1129,72297,7,2,,103164353,3016,Active,52000957.0,25451.0,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1130,72297,7,2,,103164353,3016,Active,81902501.0,,0.0049,IC50,In vitro inhibitory against Gamma-aminobutyric acid A receptor from rat cerebral cortex using [3H]flunitrazepam as the radioligand,Confirmatory,10386933.0,
1131,72305,3,8,,103164353,3016,Unspecified,120758.0,289606.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1132,72305,3,8,,103164353,3016,Unspecified,120761.0,24947.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1133,72305,3,8,,103164353,3016,Unspecified,120763.0,140675.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1134,72305,3,8,,103164353,3016,Unspecified,120764.0,29707.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1135,72305,3,8,,103164353,3016,Unspecified,120769.0,25450.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1136,72305,3,8,,103164353,3016,Unspecified,120782.0,140674.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1137,72305,3,8,,103164353,3016,Unspecified,120788.0,29709.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1138,72305,3,8,,103164353,3016,Unspecified,120790.0,79211.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1139,72305,3,8,,103164353,3016,Unspecified,232127.0,29708.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1140,72305,3,8,,103164353,3016,Unspecified,544363.0,29689.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1141,72305,3,8,,103164353,3016,Unspecified,3023821.0,81658.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1142,72305,3,8,,103164353,3016,Unspecified,13959374.0,65191.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1143,72305,3,8,,103164353,3016,Unspecified,51317298.0,29705.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1144,72305,3,8,,103164353,3016,Unspecified,52000955.0,24922.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1145,72305,3,8,,103164353,3016,Unspecified,52000957.0,25451.0,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1146,72305,3,8,,103164353,3016,Unspecified,81902501.0,,,,"In vitro inhibition of [35S]TBPS binding in rat brain membranes, activity expressed as [35S]TBPS shift value",Other,8568803.0,
1147,72444,3,9,,103164353,3016,Unspecified,120758.0,289606.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1148,72444,3,9,,103164353,3016,Unspecified,120761.0,24947.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1149,72444,3,9,,103164353,3016,Unspecified,120763.0,140675.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1150,72444,3,9,,103164353,3016,Unspecified,120764.0,29707.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1151,72444,3,9,,103164353,3016,Unspecified,120769.0,25450.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1152,72444,3,9,,103164353,3016,Unspecified,120782.0,140674.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1153,72444,3,9,,103164353,3016,Unspecified,120788.0,29709.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1154,72444,3,9,,103164353,3016,Unspecified,120790.0,79211.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1155,72444,3,9,,103164353,3016,Unspecified,232127.0,29708.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1156,72444,3,9,,103164353,3016,Unspecified,544363.0,29689.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1157,72444,3,9,,103164353,3016,Unspecified,3023821.0,81658.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1158,72444,3,9,,103164353,3016,Unspecified,13959374.0,65191.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1159,72444,3,9,,103164353,3016,Unspecified,51317298.0,29705.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1160,72444,3,9,,103164353,3016,Unspecified,52000955.0,24922.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1161,72444,3,9,,103164353,3016,Unspecified,52000957.0,25451.0,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1162,72444,3,9,,103164353,3016,Unspecified,81902501.0,,,,Inhibition of [35S]-TBPS binding to GABA-A Benzodiazepine receptor of rat brain membranes,Other,10197957.0,
1163,72448,3,10,,103164353,3016,Unspecified,27808653.0,2554.0,,,Ability to affect GABA-induced chloride current in Xenopus oocytes transiently expressing human GABA-A alpha-1-beta-2-gamma-2 receptors using two-electrode voltage-clamp electrophysiology at test concentration of 1 uM,Other,10890169.0,
1164,72448,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Ability to affect GABA-induced chloride current in Xenopus oocytes transiently expressing human GABA-A alpha-1-beta-2-gamma-2 receptors using two-electrode voltage-clamp electrophysiology at test concentration of 1 uM,Other,10890169.0,
1165,72448,3,10,,103164353,3016,Unspecified,292495010.0,2561.0,,,Ability to affect GABA-induced chloride current in Xenopus oocytes transiently expressing human GABA-A alpha-1-beta-2-gamma-2 receptors using two-electrode voltage-clamp electrophysiology at test concentration of 1 uM,Other,10890169.0,
1166,72467,8,5,,103164353,3016,Active,120773.0,2562.0,0.013999999999999999,Ki,Binding affinity for human GABA-A receptor alpha-4-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1167,72467,8,5,,103164353,3016,Active,27808653.0,2554.0,0.013999999999999999,Ki,Binding affinity for human GABA-A receptor alpha-4-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1168,72467,8,5,,103164353,3016,Active,116242488.0,2566.0,0.013999999999999999,Ki,Binding affinity for human GABA-A receptor alpha-4-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1169,72477,8,5,,103164353,3016,Active,120773.0,2562.0,0.02,Ki,Binding affinity for human GABA-A receptor alpha-2-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1170,72477,8,5,,103164353,3016,Active,116242488.0,2566.0,0.02,Ki,Binding affinity for human GABA-A receptor alpha-2-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1171,72477,8,5,,103164353,3016,Active,126302547.0,2555.0,0.02,Ki,Binding affinity for human GABA-A receptor alpha-2-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1172,72585,7,1,,103164353,3016,Active,,,0.0049,IC50,In vitro affinity for BZD site on GABA-A receptor from rat cerebral cortex using radioligand [3H]flunitrazepam,Confirmatory,12161138.0,
1173,72593,3,10,,103164353,3016,Unspecified,120758.0,289606.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1174,72593,3,10,,103164353,3016,Unspecified,120761.0,24947.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1175,72593,3,10,,103164353,3016,Unspecified,120763.0,140675.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1176,72593,3,10,,103164353,3016,Unspecified,120764.0,29707.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1177,72593,3,10,,103164353,3016,Unspecified,120769.0,25450.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1178,72593,3,10,,103164353,3016,Unspecified,120782.0,140674.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1179,72593,3,10,,103164353,3016,Unspecified,120788.0,29709.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1180,72593,3,10,,103164353,3016,Unspecified,120790.0,79211.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1181,72593,3,10,,103164353,3016,Unspecified,232127.0,29708.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1182,72593,3,10,,103164353,3016,Unspecified,544363.0,29689.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1183,72593,3,10,,103164353,3016,Unspecified,3023821.0,81658.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1184,72593,3,10,,103164353,3016,Unspecified,13959374.0,65191.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1185,72593,3,10,,103164353,3016,Unspecified,51317298.0,29705.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1186,72593,3,10,,103164353,3016,Unspecified,52000955.0,24922.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1187,72593,3,10,,103164353,3016,Unspecified,52000957.0,25451.0,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1188,72593,3,10,,103164353,3016,Unspecified,81902501.0,,,,Binding to GABA-A receptor complex relative to TBPS binding to picrotoxin convulsant site,Other,8917654.0,
1189,72594,3,7,,103164353,3016,Unspecified,,,,,In vitro efficacy by [35S]t-butyl-bicyclophosphorothionate (TBPS) binding to the picrotoxin convulsant site on the GABA-A receptor chloride complex.,Other,8809170.0,
1190,72595,9,3,,103164353,3016,Unspecified,,,74.0,IC50,Displacement of [35S]TBPS from GABA-A receptor complex at low umolar concentration,Confirmatory,,
1191,72620,8,5,,103164353,3016,Active,120773.0,2562.0,0.015,Ki,Binding affinity for human GABA-A receptor alpha-3-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1192,72620,8,5,,103164353,3016,Active,462149.0,2556.0,0.015,Ki,Binding affinity for human GABA-A receptor alpha-3-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1193,72620,8,5,,103164353,3016,Active,116242488.0,2566.0,0.015,Ki,Binding affinity for human GABA-A receptor alpha-3-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1194,72625,8,5,,103164353,3016,Active,120773.0,2562.0,0.011000000000000001,Ki,Binding affinity for human GABA-A receptor alpha-5-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1195,72625,8,5,,103164353,3016,Active,399519.0,2558.0,0.011000000000000001,Ki,Binding affinity for human GABA-A receptor alpha-5-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1196,72625,8,5,,103164353,3016,Active,116242488.0,2566.0,0.011000000000000001,Ki,Binding affinity for human GABA-A receptor alpha-5-beta-3-gamma-2 subunits in L(tk-) cells,Confirmatory,15027873.0,
1197,72640,7,2,,103164353,3016,Active,,,0.012,Ki,Binding affinity evaluated by ability to displace [3H]Ro-151788 from recombinant human Gamma-aminobutyric acid A receptor alpha-1-beta-2-gamma-2 expressed in L(tk-)cells,Confirmatory,10890169.0,
1198,72722,3,10,,103164353,3016,Unspecified,120788.0,29709.0,,,"Percent GABA current elicited in Xenopus laevis oocytes expressing rat GABA-A alpha-1-beta-2-gamma-2 subunits at 1 uM [(-)inhibition, (+)stimulation]",Other,11086734.0,
1199,72722,3,10,,103164353,3016,Unspecified,51317298.0,29705.0,,,"Percent GABA current elicited in Xenopus laevis oocytes expressing rat GABA-A alpha-1-beta-2-gamma-2 subunits at 1 uM [(-)inhibition, (+)stimulation]",Other,11086734.0,
1200,72722,3,10,,103164353,3016,Unspecified,52000957.0,25451.0,,,"Percent GABA current elicited in Xenopus laevis oocytes expressing rat GABA-A alpha-1-beta-2-gamma-2 subunits at 1 uM [(-)inhibition, (+)stimulation]",Other,11086734.0,
1201,72732,3,6,,103164353,3016,Unspecified,,,,,In vitro GABA-mediated chloride current in A293 cells expressing GABA-A benzodiazepine receptor alpha-1-beta-2-gamma-2 subunits at 5 uM,Other,10197957.0,
1202,72733,3,6,,103164353,3016,Unspecified,,,,,In vitro GABA-mediated chloride current in A293 cells expressing GABA-A benzodiazepine receptor alpha-3-beta-2-gamma-2 subunits at 5 uM,Other,10197957.0,
1203,72765,8,5,,103164353,3016,Active,120788.0,29709.0,0.013999999999999999,Ki,Displacement of [3H]Ro-151788 from rat GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12477354.0,
1204,72765,8,5,,103164353,3016,Active,51317298.0,29705.0,0.013999999999999999,Ki,Displacement of [3H]Ro-151788 from rat GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12477354.0,
1205,72765,8,5,,103164353,3016,Active,52000957.0,25451.0,0.013999999999999999,Ki,Displacement of [3H]Ro-151788 from rat GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12477354.0,
1206,72766,8,5,,103164353,3016,Active,120788.0,29709.0,0.013999999999999999,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12519068.0,
1207,72766,8,5,,103164353,3016,Active,51317298.0,29705.0,0.013999999999999999,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12519068.0,
1208,72766,8,5,,103164353,3016,Active,52000957.0,25451.0,0.013999999999999999,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12519068.0,
1209,72779,3,6,,103164353,3016,Unspecified,,,,,In vitro efficacy for GABA-A alpha-1-beta-2-gamma-2 subtype expressed in A293 cells in Cl- current assay,Other,8917654.0,
1210,72780,6,3,,103164353,3016,Active,,,0.013000000000000001,Ki,Displacement of [3H]flunitrazepam from alpha-1-beta-2-gamma-2 GABA-A receptor subunits expressed in Sf9 cell membranes,Confirmatory,8145225.0,
1211,72906,7,1,,103164353,3016,Active,,,0.013000000000000001,Ki,Displacement of [3H]Flunitrazepam from GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in Sf9 cells,Confirmatory,8568803.0,
1212,72912,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-1-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1213,72912,3,10,,103164353,3016,Unspecified,27808653.0,2554.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-1-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1214,72912,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-1-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1215,72916,11,1,,103164353,3016,Active,,,0.0143,Ki,Binding affinity towards human alpha-1-beta-3-gamma-2 GABA-A receptor using [3H]Ro-151788 expressed in L(tk-) cells,Confirmatory,15214791.0,
1216,72927,7,2,,103164353,3016,Active,,,0.013999999999999999,Ki,Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-1-beta-3-gamma-2,Confirmatory,10633039.0,
1217,73070,8,5,,103164353,3016,Active,120758.0,289606.0,0.02,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-2-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12519068.0,
1218,73070,8,5,,103164353,3016,Active,120788.0,29709.0,0.02,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-2-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12519068.0,
1219,73070,8,5,,103164353,3016,Active,52000957.0,25451.0,0.02,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-2-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12519068.0,
1220,73072,8,5,,103164353,3016,Unspecified,120788.0,29709.0,7.0,Ki,Displacement of [3H]-Ro- 15-4513 from alpha-6 beta2 gamma2 subunits of Rat GABA-A receptor expressed in Sf-9 insect cell membranes,Confirmatory,8917654.0,
1221,73072,8,5,,103164353,3016,Unspecified,232127.0,29708.0,7.0,Ki,Displacement of [3H]-Ro- 15-4513 from alpha-6 beta2 gamma2 subunits of Rat GABA-A receptor expressed in Sf-9 insect cell membranes,Confirmatory,8917654.0,
1222,73072,8,5,,103164353,3016,Unspecified,52000957.0,25451.0,7.0,Ki,Displacement of [3H]-Ro- 15-4513 from alpha-6 beta2 gamma2 subunits of Rat GABA-A receptor expressed in Sf-9 insect cell membranes,Confirmatory,8917654.0,
1223,73075,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-2-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1224,73075,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-2-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1225,73075,3,10,,103164353,3016,Unspecified,126302547.0,2555.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-2-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1226,73077,7,2,,103164353,3016,Active,,,0.0066,Ki,Binding affinity evaluated by ability to displace [3H]-Ro-15-1788 from recombinant human Gamma-aminobutyric acid A receptor alpha-2-beta-3-gamma-2 expressed in L(tk-)cells,Confirmatory,10890169.0,
1227,73078,11,1,,103164353,3016,Active,,,0.0262,Ki,Binding affinity towards human gamma-aminobutyric-acid A receptor alpha-2-beta-3-gamma-2 using [3H]Ro-151788 expressed in L(tk-) cells,Confirmatory,15214791.0,
1228,73089,8,2,,103164353,3016,Active,,,0.02,Ki,Binding affinity to human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-2-beta-3-gamma-2,Confirmatory,10633039.0,
1229,73220,8,5,,103164353,3016,Active,120761.0,24947.0,0.015,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12519068.0,
1230,73220,8,5,,103164353,3016,Active,120788.0,29709.0,0.015,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12519068.0,
1231,73220,8,5,,103164353,3016,Active,52000957.0,25451.0,0.015,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,12519068.0,
1232,73224,7,1,,103164353,3016,Active,,,0.01,Ki,Displacement of [3H]flunitrazepam from GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in Sf9 cells,Confirmatory,8568803.0,
1233,73229,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-3-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1234,73229,3,10,,103164353,3016,Unspecified,462149.0,2556.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-3-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1235,73229,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-3-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1236,73232,7,2,,103164353,3016,Active,,,0.033,Ki,Binding affinity evaluated by ability to displace [3H]Ro-151788 from recombinant human Gamma-aminobutyric acid A receptor alpha-3-beta-3-gamma-2 expressed in L(tk-)cells,Confirmatory,10890169.0,
1237,73233,11,1,,103164353,3016,Active,,,0.0237,Ki,Binding affinity towards human gamma-aminobutyric-acid A receptor alpha-3-beta-3-gamma-2 using [3H]Ro-151788 expressed in L(tk-) cells,Confirmatory,15214791.0,
1238,73244,8,2,,103164353,3016,Active,,,0.015,Ki,Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-3-beta-3-gamma-2,Confirmatory,10633039.0,
1239,73376,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-5-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1240,73376,3,10,,103164353,3016,Unspecified,399519.0,2558.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-5-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1241,73376,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Percent change in electrophysiological response in Xenopus oocytes expressing alpha-5-beta-3-gamma-2 GABA-A receptor,Other,15214791.0,
1242,73378,11,1,,103164353,3016,Active,,,0.0112,Ki,Binding affinity towards human alpha-5-beta-3-gamma-2 GABA-A receptor using [3H]Ro-151788 expressed in L(tk-) cells,Confirmatory,15214791.0,
1243,73523,7,2,,103164353,3016,Active,,,0.011000000000000001,Ki,Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-5-beta-3-gamma-2,Confirmatory,10633039.0,
1244,73534,8,5,,103164353,3016,Active,120764.0,29707.0,0.011000000000000001,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-5-beta-3-gamma-2 subunits expressed in HEK 293 cells,Confirmatory,12519068.0,
1245,73534,8,5,,103164353,3016,Active,120788.0,29709.0,0.011000000000000001,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-5-beta-3-gamma-2 subunits expressed in HEK 293 cells,Confirmatory,12519068.0,
1246,73534,8,5,,103164353,3016,Active,52000955.0,24922.0,0.011000000000000001,Ki,Binding affinity for recombinant rat GABA-A receptor alpha-5-beta-3-gamma-2 subunits expressed in HEK 293 cells,Confirmatory,12519068.0,
1247,73539,10,1,,103164353,3016,Unspecified,,,7.0,Ki,Displacement of [3H]-Ro-15-4513 from GABA-A receptor alpha-6-beta-2-gamma-2 subunits expressed in Sf9 cells,Confirmatory,8568803.0,
1248,106808,6,2,,103164353,3016,Unspecified,,,,,Prevention of metrazole induced convulsions in the antimetrazole test.,Other,6131127.0,
1249,107095,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in mice using light-dark box and % time spent in light was reported at 0.3 mg/kg peroral dose,Other,12477354.0,
1250,107096,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in mice using light-dark box and % time spent in light was reported at 1 mg/kg peroral dose,Other,12477354.0,
1251,107099,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in mice using light-dark box and % time spent in light was reported at 3 mg/kg peroral dose,Other,12477354.0,
1252,108874,3,3,,103164353,3016,Active,,,,,Acute electroshock physical dependence activity was evaluated; A=Active at 15 mg/Kg,Other,8568803.0,
1253,109527,3,3,,103164353,3016,Unspecified,,,,,Antifighting activity was measured by the antagonism against foot-shock induced fighting,Other,7190614.0,
1254,109761,3,4,,103164353,3016,Unspecified,,,,,No. rats showing anti-amnesic activity after oral administration of a dose of 5 mg/kg in mice; Number of mice which prolonged latency more than twice the duration of mice administered Scopolamine singly/number of mice tested 1/10,Other,1977911.0,
1255,109841,3,6,,103164353,3016,Unspecified,,,,,Ability to displace [3H]flunitrazepam ([3H]-FNP) binding to mouse brain after intraperitoneal administration at a dose 320 umol/kg,Other,2536440.0,
1256,109842,3,4,,103164353,3016,Unspecified,,,,,Ability to displace [3H]Flunitrazepam ([3H]-FNP) binding to mouse brain after intraperitoneal administration at a dose 3.2 umol/kg,Other,2536440.0,
1257,110034,5,1,,103164353,3016,Unspecified,,,,,Anticonvulsant effect of DMCM-induced seizures in mice expressed as effective dose,Other,8510100.0,
1258,110220,6,2,,103164353,3016,Unspecified,,,,,Ability to inhibit pentylenetetrazole (PTZ) induced convulsions n mice after peroral administration at 125 mg/Kg,Other,3029371.0,
1259,110223,6,2,,103164353,3016,Unspecified,,,,,Ability to prevent the tonic extensor component induced by 106.25 mg/kg sc of pentylenetetrazole,Other,8035421.0,
1260,110684,3,11,,103164353,3016,Unspecified,120757.0,14395.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1261,110684,3,11,,103164353,3016,Unspecified,120760.0,14396.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1262,110684,3,11,,103164353,3016,Unspecified,120792.0,14403.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1263,110684,3,11,,103164353,3016,Unspecified,1730183.0,14400.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1264,110684,3,11,,103164353,3016,Unspecified,13959377.0,14397.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1265,110684,3,11,,103164353,3016,Unspecified,13959379.0,57249.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1266,110684,3,11,,103164353,3016,Unspecified,20141351.0,14406.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1267,110684,3,11,,103164353,3016,Unspecified,51317299.0,14394.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1268,110684,3,11,,103164353,3016,Unspecified,52000959.0,14402.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1269,110684,3,11,,103164353,3016,Unspecified,62901524.0,216643.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1270,110684,3,11,,103164353,3016,Unspecified,66774012.0,110886.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1271,110684,3,11,,103164353,3016,Unspecified,341941084.0,14399.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1272,110684,3,11,,103164353,3016,Unspecified,408360110.0,14405.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1273,110684,3,11,,103164353,3016,Unspecified,408360111.0,14407.0,,,In vivo activity of compound was evaluated against benzodiazepine receptor in mice,Other,8145224.0,
1274,110865,3,3,,103164353,3016,Unspecified,,,,,Latency step was determined after oral administration of a dose of 5 mg/kg in mice,Other,1977911.0,
1275,111031,3,3,,103164353,3016,Unspecified,,,,,Number of mice impaired to that of number of mice tested at 10 mg/kg; 10/10,Other,1674542.0,
1276,111033,3,3,,103164353,3016,Unspecified,,,,,Number of mice impaired to that of number of mice tested when administered along with 1 at 10 mg/kg; 5/10,Other,1674542.0,
1277,111034,3,3,,103164353,3016,Unspecified,,,,,Number of mice impaired to that of number of mice tested when administered along with 1 at 20 mg/kg; 0/10,Other,1674542.0,
1278,111173,3,3,,103164353,3016,Unspecified,,,,,Percent anticonvulsant activity against PTZ induced attack in mice at peroral dose of 0.3 mg/kg,Other,12519068.0,
1279,111174,3,3,,103164353,3016,Unspecified,,,,,Percent anticonvulsant activity against PTZ induced attack in mice at peroral dose of 1 mg/kg,Other,12519068.0,
1280,111175,3,3,,103164353,3016,Unspecified,,,,,Percent anticonvulsant activity against pentylenetetrazole (PTZ)-induced attacks at 0.3 mg/kg peroral dose,Other,12477354.0,
1281,111176,3,3,,103164353,3016,Unspecified,,,,,Percent anticonvulsant activity against pentylenetetrazole (PTZ)-induced attacks at 1 mg/kg peroral dose,Other,12477354.0,
1282,111179,3,3,,103164353,3016,Unspecified,,,,,Percent anticonvulsant activity against pentylenetetrazole (PTZ)-induced attacks at 3 mg/kg peroral dose,Other,12477354.0,
1283,111353,3,3,,103164353,3016,Unspecified,,,,,Spontaneous motor activity of mice was estimated after 60 minutes of oral administration.,Other,7190614.0,
1284,112189,6,2,,103164353,3016,Unspecified,,,,,The ability to block the tonic-clonic component of seizures induced by metrazole in mice after intraperitoneal administration.,Other,7837226.0,
1285,112325,6,2,,103164353,3016,Unspecified,,,,,Ethanol potentiation activity was measured as loss of righting reflex in male CF-1 mice after oral administration,Other,8568803.0,
1286,112326,6,2,,103164353,3016,Unspecified,,,,,Ethanol potentiation activity was measured as loss of traction response in male CF-1 mice after oral administration,Other,8568803.0,
1287,112397,6,2,,103164353,3016,Unspecified,,,,,Yohimbine induced seizures by administrating sc and the compound which do not exhibit at least one clonic seizure within 60 min was recorded,Other,8035421.0,
1288,112455,6,2,,103164353,3016,Unspecified,,,,,Compound was tested for anticonvulsant potency using the 3-MPA (3-mercaptopropionic acid) test in mice upon peroral administration,Other,9484507.0,
1289,112456,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant potency using the maximal electroshock test in mice,Other,9484507.0,
1290,112459,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant potency using the PTX (picrotoxin) test in mice by peroral administration,Other,9484507.0,
1291,112460,6,2,,103164353,3016,Unspecified,,,,,Compound was tested for anticonvulsant potency using the STRY (strychnine) test in mice upon peroral administration,Other,9484507.0,
1292,112461,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant potency using the intravenous-BIC (bicuculline) test in mice,Other,9484507.0,
1293,112905,6,2,,103164353,3016,Unspecified,,,,,Agonist activity was evaluated by inhibition of the PTZ-induced convulsions at a PTZ dose of 125 mg/ kg,Other,2542554.0,
1294,112958,6,3,,103164353,3016,Unspecified,,,,,Test ability to block the tonic-clonic component of seizures induced by metrazole in mice.,Other,,
1295,112976,6,3,,103164353,3016,Unspecified,,,,,Tested for skeletal muscle relaxant activity using horizontal screen assay.,Other,,
1296,113267,6,2,,103164353,3016,Unspecified,,,,,Anti-morphine activity against the morphine-induced Straub's tail reaction in mice on peroral administration,Other,6131132.0,
1297,113271,6,2,,103164353,3016,Unspecified,,,,,Antiaggressive anxiolytic activity in the electroshock-induced fighting test in mice (po); Range (0.92-2.07),Other,1977910.0,
1298,113288,7,2,,103164353,3016,Unspecified,,,,,"Antagonistic effect against PTZ (80 mg/kg, sc) convulsant action in mice",Other,9748357.0,
1299,113320,6,2,,103164353,3016,Unspecified,,,,,Dose required to prevent convulsion and death in 50% of mice during a 2 hr observation was obtained by graphical interpolation anti-pentylenetetrazole,Other,7190614.0,
1300,113361,9,1,,103164353,3016,Unspecified,,,,,In vivo effective dose required for inhibition of pentylenetetrazole (PTZ)-induced seizures in mice intraperitoneally,Other,12161138.0,
1301,113362,6,2,,103164353,3016,Unspecified,,,,,In vivo effective dose required for inhibition of pentylenetetrazole (PTZ)-induced seizures in mice perorally,Other,12161138.0,
1302,113418,6,2,,103164353,3016,Unspecified,,,,,"Antianxiety activity, by anti-pentylenetetrazole test carried out on 50-54 day old mice (po)",Other,6681844.0,
1303,113419,6,2,,103164353,3016,Unspecified,,,,,"Antianxiety activity, by inclined screen procedure carried out on 50-54 day old mice(po)",Other,6681844.0,
1304,113420,6,2,,103164353,3016,Unspecified,,,,,"Antianxiety activity, by rotarod test carried out on 50-54 day old mice (po)",Other,6681844.0,
1305,113508,6,2,,103164353,3016,Unspecified,,,,,In vivo efficacy was evaluated for their ability to antagonize metrazole induced clonic convulsants in rat after ip injection.,Other,10197957.0,
1306,113530,6,2,,103164353,3016,Unspecified,,,,,In vivo inhibitory activity against metrazole-induced seizures in mice by intraperitoneal administration,Other,10386933.0,
1307,113532,6,2,,103164353,3016,Unspecified,,,,,In vivo inhibitory activity against metrazole-induced seizures in mice by peroral administration,Other,10386933.0,
1308,113609,4,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity against prevention of tonic extensor seizures in 50% mice in the presence of bicuculline (ip administration); 0.13-0.25,Other,2993620.0,
1309,113611,4,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity against prevention of tonic extensor seizures in 50% mice in the presence of metrazole (ip administration); 0.11-0.28,Other,2993620.0,
1310,113642,7,2,,103164353,3016,Unspecified,,,,,Effect on the antagonism of bicuculline-induced tonic-extensor convulsions (B),Other,6103959.0,
1311,113644,7,2,,103164353,3016,Unspecified,,,,,Effect on the antagonism of nicotine-induced death (D),Other,6103959.0,
1312,113646,7,2,,103164353,3016,Unspecified,,,,,Effect on the antagonism of nicotine-induced tonic-extensor convulsions (TE) in mice,Other,6103959.0,
1313,113648,7,2,,103164353,3016,Unspecified,,,,,Effect on the antagonism of oxotremorine-induced hypothermia (OX),Other,6103959.0,
1314,113650,6,2,,103164353,3016,Unspecified,,,,,Effect on the antagonism of pentylenetetrazole-induced clonic convulsions (P),Other,6103959.0,
1315,113652,7,2,,103164353,3016,Unspecified,,,,,Effect of test compound on the potentiation of apomorphine-induced gnawing (AG) in aggregated mice,Other,6103959.0,
1316,113655,7,2,,103164353,3016,Unspecified,,,,,Effect on the potentiation of gamma-butyrolactone-induced sleep (gamma-B),Other,6103959.0,
1317,113656,7,2,,103164353,3016,Unspecified,,,,,Effect on the potentiation of yohimbine-induced toxicity (Y) in aggregated mice,Other,6103959.0,
1318,113658,7,2,,103164353,3016,Unspecified,,,,,Effect on the prolongation of hypoxic survival time (HS),Other,6103959.0,
1319,113661,6,2,,103164353,3016,Unspecified,,,,,Effect on alcohol induced sleep was determined in ethanol potentiation test; Range (0.41-1.79),Other,1977910.0,
1320,113663,6,2,,103164353,3016,Unspecified,,,,,Effect on antagonism of nicotine-induced death (D) in Carworth farms male albino mice,Other,6105215.0,
1321,113664,6,2,,103164353,3016,Unspecified,,,,,Effect on antagonism of nicotine-induced tonic-extensor convulsions (TE) in Carworth farms male albino mice,Other,6105215.0,
1322,113666,6,2,,103164353,3016,Unspecified,,,,,Effect on bicuculline-induced tonic-extensor convulsions (B) in Carworth farms male albino mice,Other,6105215.0,
1323,113673,6,2,,103164353,3016,Unspecified,,,,,Effect on hexobarbital induced sleep was determined in hexobarbital potentiation test; Range (1.93-4.60),Other,1977910.0,
1324,113678,6,2,,103164353,3016,Unspecified,,,,,Effect on loss of traction (Tr) in Carworth farms male albino mice,Other,6105215.0,
1325,113679,6,2,,103164353,3016,Unspecified,,,,,Effect on pentylenetetrazole-induced clonic convulsions (P) in Carworth farms male albino mice,Other,6105215.0,
1326,113820,6,2,,103164353,3016,Unspecified,,,,,Effect on potentiation of gamma-butyrolactone-induced sleep (gamma-B) in Carworth farms male albino mice,Other,6105215.0,
1327,113823,6,2,,103164353,3016,Unspecified,,,,,Effect on prolongation of hypoxic survival time (HS) in Carworth farms male albino mice,Other,6105215.0,
1328,114126,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in mice using the maximal electroshock seizure test.,Other,8035421.0,
1329,114137,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant activity against bicuculline induced seizures in mice,Other,8035421.0,
1330,114384,6,2,,103164353,3016,Unspecified,,,,,Tested for NMDLA induced seizures and protection against full generalized tonic seizures was recorded; Percentage of protection at 30 mg/kg per os.,Other,8035421.0,
1331,114392,6,2,,103164353,3016,Unspecified,,,,,Tested for antagonism of bicuculline-induced tonic-extensor convulsions (B) in mice,Other,6103958.0,
1332,114393,6,2,,103164353,3016,Unspecified,,,,,Tested for antagonism of nicotine-induced death (D) in mice,Other,6103958.0,
1333,114394,6,2,,103164353,3016,Unspecified,,,,,Tested for antagonism of nicotine-induced tonic extensor convulsions (TE) in mice,Other,6103958.0,
1334,114395,6,2,,103164353,3016,Unspecified,,,,,Tested for antagonism of oxotremorine hypothermia (OX) in mice,Other,6103958.0,
1335,114396,6,2,,103164353,3016,Unspecified,,,,,Tested for antagonism of pentylenetetrazole-induced clonic convulsions (P) in mice,Other,6103958.0,
1336,114407,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant activity to prevent pentamethylenetetrazole (MTZ) induced lethality in mice after oral administration,Other,6103962.0,
1337,114415,6,2,,103164353,3016,Unspecified,,,,,Antipsychotic activity to prevent amphetamine induced lethality in mice after oral administration,Other,6103962.0,
1338,114462,6,2,,103164353,3016,Unspecified,,,,,Ataxic activity in mice by rotarod test; Range (2.99-5.35),Other,1977910.0,
1339,114561,6,2,,103164353,3016,Unspecified,,,,,Tested for potentiation of gamma-butyrolactone induced sleep (gamma-B) in mice,Other,6103958.0,
1340,114562,6,2,,103164353,3016,Unspecified,,,,,Tested for potentiation of yohimbine toxicity in aggregated mice(Y),Other,6103958.0,
1341,114563,6,2,,103164353,3016,Unspecified,,,,,Prolongation of hypoxic survival time (HS) in mice,Other,6103958.0,
1342,114565,6,2,,103164353,3016,Unspecified,,,,,Tested for stereotyped gnawing and licking behavior of mice pretreated with apomorphine (AG),Other,6103958.0,
1343,114575,6,2,,103164353,3016,Unspecified,,,,,Tested for the abolition of the hand leg tonic extensor component of the seizure induced by a 0.96 mg/kg sc injection of strychnine,Other,8035421.0,
1344,114825,6,2,,103164353,3016,Unspecified,,,,,In vitro ability to induce convulsions in mice,Other,3029372.0,
1345,114833,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for 50% reduction of the control response was obtained by graphical interpolation rotarod performance,Other,7190614.0,
1346,114835,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for antagonist activity against 3-mercaptopropionic-acid induced seizures in mice when administered intraperitoneally,Other,8289185.0,
1347,114839,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for antagonist activity against maximal electroshock induced seizures in mice when administered intraperitoneally,Other,8289185.0,
1348,114842,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for antagonist activity against pentylenetetrazole-induced seizures in mice when administered intraperitoneally,Other,8289185.0,
1349,114848,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for antagonist activity against strychnine induced seizures in mice when administered intraperitoneally,Other,8289185.0,
1350,114856,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for inhibition of pentylenetetrazole (PTZ)-induced seizures in mice intraperitoneally,Other,12161138.0,
1351,114857,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for inhibition of pentylenetetrazole (PTZ)-induced seizures in mice perorally,Other,12161138.0,
1352,114858,9,1,,103164353,3016,Unspecified,,,,,Effective dose required for motor impairment in the horizontal screen in mouse intraperitoneally,Other,12161138.0,
1353,114859,9,1,,103164353,3016,Unspecified,,,,,Effective dose required for motor impairment in the horizontal screen in mouse perorally,Other,12161138.0,
1354,115603,3,5,,103164353,3016,Unspecified,,,,,Tested for its interaction with ethanol by its ability to potentiate the effect of ethanol on sleep.,Other,,
1355,115612,3,3,,103164353,3016,Unspecified,,,,,Minimum effective dose (MED) required for the potentiation of thiopental sodium induced loss of the righting reflex (Students t test).,Other,7190614.0,
1356,115679,3,3,,103164353,3016,Unspecified,,,,,Effects on Diazepam-Induced Myorelaxation in mice was determined,Other,1674542.0,
1357,115682,3,3,,103164353,3016,Unspecified,,,,,Effects on Diazepam-Induced Myorelaxation in mice was determined when administered along with compound 1 at 10 mg/kg,Other,1674542.0,
1358,115683,3,3,,103164353,3016,Unspecified,,,,,Effects on Diazepam-Induced Myorelaxation in mice was determined when administered along with compound 1 at 20 mg/kg,Other,1674542.0,
1359,117077,6,2,,103164353,3016,Unspecified,,,,,Lethal dose (LD50) required to inhibit the spontaneous motor activity.,Other,7190614.0,
1360,117096,6,2,,103164353,3016,Unspecified,,,,,Lethal dose tested in mice by oral administration,Other,6681844.0,
1361,118787,3,3,,103164353,3016,Unspecified,,,,,Retention for passive avoidance learning in mice at dose 1.25 mg/kg,Other,7265121.0,
1362,118789,3,3,,103164353,3016,Unspecified,,,,,Retention for passive avoidance learning in mice at dose 2.5 mg/kg,Other,7265121.0,
1363,118793,3,3,,103164353,3016,Unspecified,,,,,Retention for passive avoidance learning in mice at dose 5 mg/kg,Other,7265121.0,
1364,119151,3,3,,103164353,3016,Unspecified,,,,,Antianxiety activity was tested in mice at peroral dose of 0.3 mg/kg using light/dark box test,Other,12519068.0,
1365,119152,3,3,,103164353,3016,Unspecified,,,,,Antianxiety activity was tested in mice at peroral dose of 1 mg/kg using light/dark box test,Other,12519068.0,
1366,119176,3,4,,103164353,3016,Unspecified,,,,,"Muscle relaxant effect in mice at peroral dose of 0.3 mg/kg using rotarod test, value was expressed as no. of falls in 30 seconds",Other,12519068.0,
1367,119177,3,4,,103164353,3016,Unspecified,,,,,"Muscle relaxant effect in mice at peroral dose of 1 mg/kg using rotarod test, value was expressed as no. of falls in 30 seconds",Other,12519068.0,
1368,119507,3,5,,103164353,3016,Unspecified,,,,,Motor coordination of mouse as number of falls in 30 sec was reported after 0.3 mg/kg peroral dose using rotarod test,Other,12477354.0,
1369,119508,3,5,,103164353,3016,Unspecified,,,,,Motor coordination of mouse as number of falls in 30 sec was reported after 1 mg/kg peroral dose using rotarod test,Other,12477354.0,
1370,119511,3,5,,103164353,3016,Unspecified,,,,,Motor coordination of mouse as number of falls in 30 sec was reported after 3 mg/kg peroral dose using rotarod test,Other,12477354.0,
1371,119693,3,4,,103164353,3016,Unspecified,,,,,Ratio of effective dose required for motor impairment in the horizontal screen to the inhibition of pentylenetetrazole (PTZ)-induced seizures in mice,Other,12161138.0,
1372,119817,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in mice using light-dark box and no. of transfers between compartments were reported at 0.3 mg/kg peroral dose,Other,12477354.0,
1373,119818,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in mice using light-dark box and no. of transfers between compartments were reported at 1 mg/kg peroral dose,Other,12477354.0,
1374,119822,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in mice using light-dark box and no. of transfers between compartments were reported at 3 mg/kg peroral dose,Other,12477354.0,
1375,121847,3,3,,103164353,3016,Unspecified,,,,,Central nervous system toxicity was performed by determining the median toxic dose in the rotarod test,Other,8035421.0,
1376,121857,3,4,,103164353,3016,Unspecified,,,,,Compound was tested for toxicity using neurological impairment measured by rotarod test in mice,Other,9484507.0,
1377,122474,3,3,,103164353,3016,Unspecified,,,,,Antianxiety activity was tested in mice at peroral dose of 0.3 mg/kg in light,Other,12519068.0,
1378,122475,3,3,,103164353,3016,Unspecified,,,,,Antianxiety activity was tested in mice at peroral dose of 1 mg/kg in light,Other,12519068.0,
1379,122716,3,3,,103164353,3016,Unspecified,,,,,The antianxiety activity for the compound at a dose of 0.3 mg/kg was evaluated as number of crosses by mice in the light/dark box experiment. p<0.05,Other,10377227.0,
1380,122717,3,3,,103164353,3016,Unspecified,,,,,The antianxiety activity for the compound at a dose of 1 mg/kg was evaluated as number of crosses by mice in the light/dark box experiment.,Other,10377227.0,
1381,122718,3,3,,103164353,3016,Unspecified,,,,,The antianxiety activity for the compound at a dose of 3 mg/kg was evaluated as number of crosses by mice in the light/dark box experiment.,Other,10377227.0,
1382,122792,3,3,,103164353,3016,Unspecified,,,,,Tested for effect on central nervous system in mice at 100 mg/kg peroral dose barbiturate-sleeping time (BST),Other,7914928.0,
1383,122803,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity against PTZ induced attacks at 0.1 mg/Kg dose in mice,Other,10377227.0,
1384,122804,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity against PTZ induced attacks at 0.3 mg/Kg dose in mice,Other,10377227.0,
1385,122850,3,5,,103164353,3016,Unspecified,,,,,Muscle relaxant effect measured by rotarod test at 0.1 mg/Kg dose in mice,Other,10377227.0,
1386,122851,3,5,,103164353,3016,Unspecified,,,,,Muscle relaxant effect measured by rotarod test at 0.3 mg/Kg dose in mice,Other,10377227.0,
1387,122852,3,5,,103164353,3016,Unspecified,,,,,Muscle relaxant effect measured by rotarod test at 1 mg/Kg dose in mice,Other,10377227.0,
1388,122858,3,5,,103164353,3016,Unspecified,,,,,Muscle relaxant effect measured by rotarod test at 3 mg/Kg dose in mice,Other,10377227.0,
1389,122926,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity against PTZ induced attacks at 1 mg/Kg dose in mice,Other,10377227.0,
1390,122927,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity against PTZ induced attacks at 3 mg/Kg dose in mice,Other,10377227.0,
1391,122928,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity against maximal electroshock (MES) -induced hind limb extension for a dose of 1 mg/kg,Other,10377227.0,
1392,122929,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity against maximal electroshock (MES) -induced hind limb extension for a dose of 3 mg/kg,Other,10377227.0,
1393,123129,4,2,,103164353,3016,Unspecified,,,,,In vivo acute electroshock physical dependence activity in mice.() value is drug MA50/V122MA50,Other,10197957.0,
1394,123784,3,3,,103164353,3016,Unspecified,,,,,The compound was evaluated for the percentage lethality against maximal electroshock (MES) -induced hind limb extension for a dose of 1 mg/kg.,Other,10377227.0,
1395,123785,3,3,,103164353,3016,Unspecified,,,,,"The compound was evaluated for the percentage lethality against maximal electroshock (MES) -induced hind limb extension for a dose of 3 mg/kg.*P<0.05,",Other,10377227.0,
1396,123811,3,3,,103164353,3016,Unspecified,,,,,Tested for effect on central nervous system in mice at 100 mg/kg peroral dose for spontaneous motor activity (SMA) expressed as percentage relative to control,Other,7914928.0,
1397,123952,3,3,,103164353,3016,Unspecified,,,,,Locomotor activity in maximal electroshock seizure+ indicates increase at 100 mg/kg,Other,8035421.0,
1398,124223,3,3,,103164353,3016,Unspecified,,,,,In vivo efficacy is evaluated by percent control of cerebellar GMP content in CF1 mice and result is expressed as crebrellar GMP levels in (drug+stress) treated mice and mice under stress.,Other,10197957.0,
1399,124298,3,4,,103164353,3016,Unspecified,,,,,Protection of mice against maximal electroshock (MES)-induced convulsions after administration of 38 mg/kg,Other,3029372.0,
1400,124460,3,3,,103164353,3016,Unspecified,,,,,The percentage time in light by the animals was calculated for the compound at a dose of 0.3 mg/kg in the light/dark box experiment.,Other,10377227.0,
1401,124461,3,3,,103164353,3016,Unspecified,,,,,The percentage time in light by the animals was calculated for the compound at a dose of 1 mg/kg in the light/dark box experiment*** indicates P<0.001.,Other,10377227.0,
1402,124462,3,3,,103164353,3016,Unspecified,,,,,The percentage time in light by the animals was calculated for the compound at a dose of 3 mg/kg in the light/dark box experiment.,Other,10377227.0,
1403,125041,3,3,,103164353,3016,Unspecified,,,,,Compound was tested for activity using primate conflict test in monkey.,Other,2573731.0,
1404,125298,3,3,,103164353,3016,Unspecified,,,,,Lessening of memory impairment measured in mice; time of latency in seconds at an intraperitoneal dose of 3 mg/kg.,Other,1977911.0,
1405,126491,3,3,,103164353,3016,Unspecified,,,,,Highest dose required for depressant effect when administered perorally,Other,6138436.0,
1406,126644,3,3,,103164353,3016,Unspecified,,,,,Minimum effective dose required for anticonflict effect in monkey when administered perorally,Other,6138436.0,
1407,127702,2,5,,103164353,3016,Unspecified,,,,,Anxiolytic activity in mice at 100 ug/kg,Other,,
1408,127859,6,2,,103164353,3016,Unspecified,,,,,"Compound was evaluated in vivo for reserpine hypothermia after oral administration in mouse. Minimum active dose was reported, with the percent reversal at 10 mg/kg in parenthesis.",Other,6716399.0,
1409,128035,6,2,,103164353,3016,Unspecified,,,,,Antagonism of pentylenetetrazole-induced convulsion in mice by oral administration.,Other,6110780.0,
1410,128039,7,2,,103164353,3016,Unspecified,,,,,Anticonvulsant activity against pentylenetetrazole-induced clonic seizures in mice,Other,1681105.0,
1411,128041,6,2,,103164353,3016,Unspecified,,,,,Compound was tested for anticonvulsant activity against pentylenetetrazole-induced clonic seizures in mice at dose 80 mg/kg.,Other,1681105.0,
1412,128132,6,2,,103164353,3016,Unspecified,,,,,Ability to inhibit seizures induced by electroshock in mice administered per orally,Other,2213838.0,
1413,128134,6,2,,103164353,3016,Unspecified,,,,,Ability to inhibit seizures induced by mercaptopropionic acid in mice administered per orally,Other,2213838.0,
1414,128136,7,2,,103164353,3016,Unspecified,,,,,Ability to inhibit seizures induced by pentylenetetrazole in mice administered per orally,Other,2213838.0,
1415,128166,6,2,,103164353,3016,Unspecified,,,,,Activity was measured by rotarod test by intraperitoneal administration in mouse.,Other,2836588.0,
1416,128167,6,2,,103164353,3016,Unspecified,,,,,Activity tested to antagonise cyclic GMP after administration of isoniazid in mouse brain,Other,2536440.0,
1417,128173,6,4,,103164353,3016,Unspecified,,,,,Antagonism of mercaptopropionic acid (MPA) induced convulsions in mouse,Other,2536440.0,
1418,128302,6,2,,103164353,3016,Unspecified,,,,,Agonist activity was evaluated by mouse pentylenetetrazole (PTZ) convulsant test after p.o. administration,Other,8709114.0,
1419,128305,6,2,,103164353,3016,Unspecified,,,,,Agonist activity was evaluated by the inhibition of the pentylenetetrazole (PTZ) induced convulsions after peroral administration,Other,2842502.0,
1420,129024,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant activity when bicuculline given subcutaneously in mouse,Other,2836588.0,
1421,129139,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant activity when lethal dose of strychnine given subcutaneously in mouse,Other,2836588.0,
1422,129141,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant activity when maximal electroshock is induced in mouse,Other,2836588.0,
1423,129287,6,2,,103164353,3016,Unspecified,,,,,Antifighting potency against the foot shock induced fighting behavior in mice on peroral administration,Other,6131132.0,
1424,129461,6,2,,103164353,3016,Unspecified,,,,,Cataleptogenic action in mice on peroral administration,Other,6131132.0,
1425,129965,6,2,,103164353,3016,Unspecified,,,,,"Compound was evaluated for horizontal wire test and percent of mice not grasping wire, it was administered intraperitoneally",Other,1975276.0,
1426,129966,6,2,,103164353,3016,Unspecified,,,,,"Compound was evaluated for horizontal wire test and percent of mice not grasping wire, it was administered perorally",Other,1975276.0,
1427,130033,4,3,,103164353,3016,Unspecified,,,,,Evaluated for seizure threshold test at a dose 0.2 mg/kg &MMT is the maximal metrazole threshold to tonic flexion.,Other,6330354.0,
1428,130034,3,3,,103164353,3016,Unspecified,,,,,Evaluated for seizure threshold test at a dose 0.2 mg/kg &MST is the metrazole seizure threshold to persistent clonus,Other,6330354.0,
1429,130038,3,3,,103164353,3016,Unspecified,,,,,Evaluated for seizure threshold test at a dose 1.0 mg/kg &MST is the metrazole seizure threshold to persistent clonus,Other,6330354.0,
1430,130039,3,3,,103164353,3016,Unspecified,,,,,Evaluated for seizure threshold test at a dose 1.0 mg/kg &MMT is the maximal metrazole threshold to tonic flexion.,Other,6330354.0,
1431,130126,6,2,,103164353,3016,Unspecified,,,,,Compound was evaluated for maximal electroshock antagonism (MES) against mice (values in parentheses indicates 95% confidence limits),Other,6716399.0,
1432,131026,6,2,,103164353,3016,Unspecified,,,,,Compound was tested for the anticonvulsant activity in pentamethylenetetrazole mouse epilepsy model,Other,9934486.0,
1433,131235,6,2,,103164353,3016,Unspecified,,,,,Muscle relaxation activity using the rotarod performance test in mice by oral administration.,Other,6110780.0,
1434,131352,7,2,,103164353,3016,Unspecified,,,,,Dose that prevented tonic extensor seizures and death in 50% of the mice.(ip),Other,2836588.0,
1435,131353,6,2,,103164353,3016,Unspecified,,,,,Dose that prevents convulsions in 50% of the CF1 male mice tested after administration of 70 mg/kg of metrazole by intravenous route,Other,6127410.0,
1436,131372,6,2,,103164353,3016,Unspecified,,,,,Effective dose (ED50) was determined in sc Met (pentylenetetrazole) seizure threshold test,Other,6330354.0,
1437,131394,6,2,,103164353,3016,Unspecified,,,,,Neurotoxicity against mice in rotarod test,Other,1681105.0,
1438,131868,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for ethanol interaction in mouse when administered perorally,Other,6138436.0,
1439,131889,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for the percentage change in seizure threshold by anti-pentylenetetrazole test in mouse when administered perorally,Other,1975276.0,
1440,132084,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for anxiolytic activity in mice in rotarod test,Other,6138437.0,
1441,132086,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for anxiolytic activity in mice when administered perorally (Antipentylene tetrazole test),Other,6138436.0,
1442,132087,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for anxiolytic activity in mice when administered perorally (Inclined screen test),Other,6138436.0,
1443,132088,6,2,,103164353,3016,Unspecified,,,,,Effective dose required for anxiolytic activity in mice when administered perorally (Rotarod test),Other,6138436.0,
1444,132243,6,2,,103164353,3016,Unspecified,,,,,Effective dose required to prevent convulsions in mice after iv administration of 70 mg/kg of metrazole compound in antipentylene tetrazole test,Other,6138437.0,
1445,132416,6,2,,103164353,3016,Unspecified,,,,,Evaluated for muscle-relaxant action in mice on peroral administration,Other,6131132.0,
1446,132949,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity by light/dark exploratory behavioral test in mice,Other,1681105.0,
1447,132962,3,4,,103164353,3016,Unspecified,,,,,Compound was tested for the sedative effect by using mouse rotarod test,Other,9934486.0,
1448,133112,3,3,,103164353,3016,Unspecified,,,,,Potentiation of ethanol (EtOH) induced sleep time in mice,Other,1681105.0,
1449,134240,6,2,,103164353,3016,Unspecified,,,,,Acute toxicity expressed as LD50 in mice after oral administration.,Other,6110780.0,
1450,134421,6,2,,103164353,3016,Unspecified,,,,,Compound was evaluated for lethal dose in mouse in groups of ten (values in parentheses indicates 95% confidence limits),Other,6716399.0,
1451,134938,3,3,,103164353,3016,Active,,,,,Mouse behavior activity was determined; D = Depressant,Other,6716399.0,
1452,135326,5,2,,103164353,3016,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
1453,136091,3,4,,103164353,3016,Unspecified,,,,,Compound was determined in rotarod test and expressed as TD50,Other,6330354.0,
1454,137602,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity by light/dark exploratory behavioral test in mice,Other,1681105.0,
1455,139100,3,3,,103164353,3016,Unspecified,,,,,Logarithm of effective dose evaluated using the foot-shock test in mice,Other,6876077.0,
1456,139244,3,3,,103164353,3016,Unspecified,,,,,Righting ability was determined in mice before rapid rolling (aroused),Other,6716399.0,
1457,139245,3,3,,103164353,3016,Unspecified,,,,,Righting ability was determined in mice before rapid rolling (unaroused),Other,6716399.0,
1458,140702,5,2,,103164353,3016,Unspecified,,,,,Evaluated for hypothermic activity in mice at 30 mg/kg on peroral administration,Other,6131132.0,
1459,140869,3,4,,103164353,3016,Unspecified,,,,,"Antagonism of Diazepam muscle relaxant effect by compound (3 mg/kg, ip) was measured by the fallen/treated mice.",Other,2836588.0,
1460,165929,6,2,,103164353,3016,Unspecified,,,80.0,EC50,Lymphotoxic activity against immortalized Ramos B cells in culture,Confirmatory,12951119.0,
1461,168589,3,3,,103164353,3016,Unspecified,,,,,Anticonflict activity was measured in male wistar rats; number of shocks received in 5 min at a dose of 3 mg/kg ip,Other,1977911.0,
1462,169088,5,1,,103164353,3016,Unspecified,,,,,Antagonism of metrazole-induced clonic convulsions in rats after ip injection,Other,8917654.0,
1463,171057,3,3,,103164353,3016,Unspecified,,,,,Percentage change punished lever presses from mean score on 6-8 rats at 5 mg/kg po1h pretest,Other,9572885.0,
1464,171076,3,3,,103164353,3016,Unspecified,,,,,Percentage change unpunished lever presses from mean score on 6-8 rats at 5 mg/kg po1h pretest,Other,9572885.0,
1465,171214,2,4,,103164353,3016,Unspecified,,,,,Punished responding phase in Geller-Seifter test was determined at 1 hr post-dose of 5 mg/Kg p.o.,Other,,
1466,171219,2,4,,103164353,3016,Unspecified,,,,,Punished responding phase in Geller-Seifter test was determined at 2 hr post-dose of 5 mg/Kg p.o.,Other,,
1467,171371,3,4,,103164353,3016,Unspecified,,,,,Conditioned Avoidance response activity (CR2) at 10 mg/kg (i.p.) (No. of rats with blocked response/No. of treated rats),Other,2836588.0,
1468,172397,3,3,,103164353,3016,Unspecified,,,,,Compound tested for its effect on Nonconflict(VI) operant responding of rats at a dose of 10.0 mg/kg administered perorally.,Other,1680197.0,
1469,172398,3,3,,103164353,3016,Unspecified,,,,,Compound tested for its effect on Nonconflict(VI) operant responding of rats at a dose of 3.0 mg/kg administered perorally.,Other,1680197.0,
1470,172399,3,3,,103164353,3016,Unspecified,,,,,Compound tested for its effect on Nonconflict(VI) operant responding of rats at a dose of 30.0 mg/kg administered perorally.,Other,1680197.0,
1471,172406,3,3,,103164353,3016,Unspecified,,,,,Compound tested for its effect on conflict(FR) operant responding of rats at a dose of 10.0 mg/kg administered perorally.,Other,1680197.0,
1472,172407,3,3,,103164353,3016,Unspecified,,,,,Compound tested for its effect on conflict(FR) operant responding of rats at a dose of 3.0 mg/kg administered perorally.,Other,1680197.0,
1473,172408,3,3,,103164353,3016,Unspecified,,,,,Compound tested for its effect on conflict(FR) operant responding of rats at a dose of 30.0 mg/kg administered perorally.,Other,1680197.0,
1474,172936,3,3,,103164353,3016,Unspecified,,,,,Chloride ion influx in rat cerebrocortical membranes,Other,8145225.0,
1475,172969,3,3,,103164353,3016,Unspecified,,,,,No. rats showing anticonflict activity after oral administration of a dose of 10 mg/kg; Number of rats which received shocks more than twice vs shocks received in control rats to that of number of rats tested 25/43,Other,1977911.0,
1476,173052,2,4,,103164353,3016,Unspecified,,,,,Percent change in punished responding phase (FR) after administration of 10 mg/Kg oral dose in rat Geller-Seifter test,Other,,
1477,173249,2,4,,103164353,3016,Unspecified,,,,,Percent change in variable interval unpunished responding phase (VI) after administration of 10 mg/Kg oral dose in rat Geller-Seifter test,Other,,
1478,175771,3,3,,103164353,3016,Unspecified,,,,,Lowest dose required for depressant effect (significant decrease in unpunished responding) in rat when administered perorally,Other,6138436.0,
1479,176151,6,2,,103164353,3016,Unspecified,,,,,Compound was tested in vivo for activity to induce sedation or ataxia in rat using rotarod test,Other,2573731.0,
1480,176153,6,2,,103164353,3016,Unspecified,,,,,Compound was tested in vivo for antagonistic activity against metrazole-induced convulsions in rat,Other,2573731.0,
1481,176300,6,2,,103164353,3016,Unspecified,,,,,Anxiolytic response measured by antagonism of pentylenetetrazole discriminative stimuli in rats.,Other,1680197.0,
1482,176404,6,2,,103164353,3016,Unspecified,,,,,Evaluated for neuroleptic-like property using anti-methamphetamine test in rats on peroral administration,Other,6131132.0,
1483,176407,5,2,,103164353,3016,Unspecified,,,,,Evaluated for neuroleptic-like property using open-field test in rats(increase in ambulation at 3 to 20 mg/kg on peroral administration; Increase,Other,6131132.0,
1484,177059,6,2,,103164353,3016,Unspecified,,,,,In vivo protection against pentylenetetrazole-induced convulsions in the rat.,Other,6113284.0,
1485,177740,6,2,,103164353,3016,Unspecified,,,,,Activity was measured by rotarod test by peroral administration in rat,Other,2836588.0,
1486,177961,6,2,,103164353,3016,Unspecified,,,,,Antagonistic activity against metrazole-induced clonic convulsions in rat after ip injection,Other,8568803.0,
1487,178135,6,2,,103164353,3016,Unspecified,,,,,Compound was tested for activity against ethanol-induced impairment of rotarod performance in rat.,Other,2573731.0,
1488,178197,6,2,,103164353,3016,Unspecified,,,,,Effective dose in blocking conditioned avoidance responding (CAR) in the rat when administered intraperitoneally,Other,2565400.0,
1489,178307,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant efficacy when administered perorally was determined in rat metrazole anticonvulsant test,Other,6121916.0,
1490,179149,4,3,,103164353,3016,Unspecified,,,,,Effect of Compound administered 60 min before the test in the conflict drinking test in rat (n = 8 rats/group) at 2.5 mg/kg,Other,15115407.0,
1491,179150,3,3,,103164353,3016,Unspecified,,,,,Effect of Compound administered 60 min before the test in the conflict drinking test in rat (n = 8 rats/group) at 5 mg/kg,Other,15115407.0,
1492,179166,3,3,,103164353,3016,Active,,,,,Effect on diarrhea after oral administration of 10 mg/kg in rat was determined; '+' weak effect,Other,1977910.0,
1493,179167,3,3,,103164353,3016,Active,,,,,Effect on diarrhea after oral administration of 20 mg/kg in rat was determined; '++' strong effect,Other,1977910.0,
1494,179289,3,3,,103164353,3016,Inactive,,,,,Effect on jumping after oral administration of 10 mg/kg in rat was determined; '-' No effect,Other,1977910.0,
1495,179291,3,3,,103164353,3016,Active,,,,,Effect on jumping after oral administration of 20 mg/kg in rat was determined; +' weak effect,Other,1977910.0,
1496,179296,3,3,,103164353,3016,Active,,,,,Effect on piloerection after oral administration of 10 mg/kg in rat was determined; '+' weak effect,Other,1977910.0,
1497,179298,3,3,,103164353,3016,Active,,,,,Effect on piloerection after oral administration of 20 mg/kg in rat was determined; '++' strong effect,Other,1977910.0,
1498,179307,3,3,,103164353,3016,Active,,,,,Effect on restlessness after oral administration of 10 mg/kg in rat was determined; '+' weak effect,Other,1977910.0,
1499,179309,3,3,,103164353,3016,Active,,,,,Effect on restlessness after oral administration of 20 mg/kg in rat was determined; +' weak effect,Other,1977910.0,
1500,179311,3,3,,103164353,3016,Inactive,,,,,Effect on salivation after oral administration of 10 mg/kg in rat was determined; '-' No effect,Other,1977910.0,
1501,179313,3,3,,103164353,3016,Active,,,,,Effect on salivation after oral administration of 20 mg/kg in rat was determined; +' weak effect,Other,1977910.0,
1502,179316,3,3,,103164353,3016,Inactive,,,,,Effect on tremor after oral administration of 10 mg/kg in rat was determined; '-' No effect,Other,1977910.0,
1503,179318,3,3,,103164353,3016,Active,,,,,Effect on tremor after oral administration of 20 mg/kg in rat was determined; +' weak effect,Other,1977910.0,
1504,179507,3,4,,103164353,3016,Unspecified,,,,,Ratio of IC50 values for [3H]-Ro- 15-1788 binding in absence and presence of added GABA (rat cerebral cortex),Other,1681105.0,
1505,180359,6,2,,103164353,3016,Unspecified,,,,,"The compound was tested for antagonistic activity against metrazole induced convulsions in rats, after ip administration",Other,8145225.0,
1506,180952,4,3,,103164353,3016,Unspecified,,,,,Antianxiety effect was assessed by the cook-davidson behavior test,Other,6121916.0,
1507,180953,3,3,,103164353,3016,Unspecified,,,,,Antianxiety effect was assessed by the cook-davidson behavior test at 1 mg/kg of compound administered perorally.,Other,6121916.0,
1508,180954,3,3,,103164353,3016,Unspecified,,,,,Antianxiety effect was assessed by the cook-davidson behavior test at 10 mg/kg of compound administered perorally.,Other,6121916.0,
1509,180955,3,3,,103164353,3016,Unspecified,,,,,Antianxiety effect was assessed by the cook-davidson behavior test at 3 mg/kg of compound administered perorally.,Other,6121916.0,
1510,180956,3,3,,103164353,3016,Unspecified,,,,,Antianxiety effect was assessed by the cook-davidson behavior test at 30 mg/kg of compound administered perorally.,Other,6121916.0,
1511,181673,7,6,,103164353,3016,Active,120782.0,140674.0,0.005,IC50,Anxiolytic activity by displacement of [3H]diazepam from GABA-A receptor in rat synaptosomal membranes,Confirmatory,6105221.0,
1512,184545,3,4,,103164353,3016,Unspecified,,,,,In vivo motor activity determined in rat at 1.7 mg/kg of ip administration,Other,12482441.0,
1513,184649,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity by vogel punished drinking test in rats,Other,1681105.0,
1514,184668,2,4,,103164353,3016,Unspecified,,,,,"Compound was tested for its ability to release (i.e., disinhibit) behavior that had been suppressed by punishment in rats (vogel conflict test).",Other,,
1515,184685,3,3,,103164353,3016,Unspecified,,,,,In vivo minimal effective dose for anticonflict activity by intraperitoneal administration in rats by the Vogel conflict procedure.,Other,2993620.0,
1516,184686,5,1,,103164353,3016,Unspecified,,,,,In vivo minimum effective dose required for anticonflict effect in rat perorally,Other,12161138.0,
1517,184687,5,1,,103164353,3016,Unspecified,,,,,In vivo minimum effective dose required for anticonflict in rat intraperitoneally,Other,12161138.0,
1518,184688,5,1,,103164353,3016,Unspecified,,,,,In vivo minimum effective dose required for potentiation of EtOH-induced sleep time in rat,Other,12161138.0,
1519,184689,3,3,,103164353,3016,Unspecified,,,,,Inhibition of experimentally-induced conflict in rats following i.p. administration.,Other,10386933.0,
1520,184691,3,3,,103164353,3016,Unspecified,,,,,Inhibitory activity determined by experimentally-induced conflict test in rats after oral administration,Other,10386933.0,
1521,184838,5,2,,103164353,3016,Unspecified,,,,,Minimal effective dose (MED) that significantly increased the number of shocks.(ip),Other,2836588.0,
1522,184839,3,4,,103164353,3016,Unspecified,,,,,"Minimal effective dose (MED, ip) that significantly increased the number of shocks (anticonflict)",Other,2836588.0,
1523,184846,5,1,,103164353,3016,Unspecified,,,,,Minimal effective oral dose to cause VI response decrement in rats.,Other,1680197.0,
1524,184848,5,1,,103164353,3016,Unspecified,,,,,Minimal effective oral dose to cause ethanol interaction in rats.,Other,1680197.0,
1525,184849,5,1,,103164353,3016,Unspecified,,,,,Minimal effective oral dose to cause increase in conflict response in rats after po administration.,Other,1680197.0,
1526,185013,3,3,,103164353,3016,Unspecified,,,,,Minimum effective dose (po) tested for its anxiolytic activity in rat using the shock-induced suppression of drinking (SSD) test.,Other,2573731.0,
1527,185021,3,3,,103164353,3016,Unspecified,,,,,Minimum effective dose required for anticonflict effect in rat when administered perorally,Other,6138436.0,
1528,185028,3,3,,103164353,3016,Unspecified,,,,,Minimum effective dose as dose required to release behavior in suppressed rats by conflict test after intraperitoneal administration.,Other,7837226.0,
1529,185031,3,3,,103164353,3016,Unspecified,,,,,Minimum effective dose required for anticonflict in rat after intraperitoneal administration of the compound,Other,12161138.0,
1530,185032,3,3,,103164353,3016,Unspecified,,,,,Minimum effective dose required for anticonflict in rat after peroral administration of the compound,Other,12161138.0,
1531,185051,2,4,,103164353,3016,Unspecified,,,,,Minimum effective peroral dose in Geller-Seifter paradigm,Other,,
1532,185194,2,4,,103164353,3016,Unspecified,,,,,Tested for minimum effective dose required to cause motor in coordination in Geller-Seifter model in CFY rats (route of administration is peroral 30 min before testing),Other,,
1533,185198,2,4,,103164353,3016,Unspecified,,,,,"The compound was tested for its ability to release (i.e., disinhibit) behavior that had been suppressed by punishment in rats (vogel conflict test).",Other,,
1534,187250,3,3,,103164353,3016,Unspecified,,,,,Ratio of minimum effective dose for potentiation of EtOH-induced sleep time to anticonflict effect in rat,Other,12161138.0,
1535,187603,3,3,,103164353,3016,Unspecified,,,,,Loss of righting reflex recovery time (initial) in rat was determined when treated with a dose of 30 mg/Kg,Other,12372537.0,
1536,187604,3,3,,103164353,3016,Unspecified,,,,,Loss of righting reflex recovery time (total) in rat was determined when treated with a dose of 30 mg/Kg,Other,12372537.0,
1537,188916,3,3,,103164353,3016,Unspecified,,,,,Compound was administered at a dose of 2.5 mg/Kg intraperitoneally and was evaluated for shock induced suppression of drinking by rat vogel test and number of shocks taken were reported,Other,1975276.0,
1538,188919,4,3,,103164353,3016,Unspecified,,,,,Effect of Compound administered 60 min before the test in the conflict drinking test in rat (n = 8 rats/group) at 2.5 mg/kg,Other,15115407.0,
1539,188920,3,3,,103164353,3016,Unspecified,,,,,Effect of Compound administered 60 min before the test in the conflict drinking test in rat (n = 8 rats/group) at 5 mg/kg,Other,15115407.0,
1540,189432,2,4,,103164353,3016,Unspecified,,,,,Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 1 hr post-dose of 5 mg/Kg p.o. (Animals tested 8),Other,,
1541,189570,2,4,,103164353,3016,Unspecified,,,,,Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 2 hr post-dose of 5 mg/Kg p.o. (Animals tested 16),Other,,
1542,189575,2,4,,103164353,3016,Unspecified,,,,,"Number of animals responding to the above phases out of 8 tested, expressed as Nr/N",Other,,
1543,190263,3,3,,103164353,3016,Unspecified,,,,,Sedative liability index (SLI) to indicate the separation between the anxiolytic and ataxic doses in rats,Other,2573731.0,
1544,190628,3,4,,103164353,3016,Unspecified,,,,,Social interaction time determined in vivo rat at 1.7 mg/kg of ip administration,Other,12482441.0,
1545,191851,3,3,,103164353,3016,Unspecified,,,,,Antianxiety effect in cook-davidson behavior test at 1 mg/kg of compound administered perorally in rats expressed as mean percent change,Other,6121916.0,
1546,191852,3,3,,103164353,3016,Unspecified,,,,,Antianxiety effect in cook-davidson behavior test at 10 mg/kg of compound administered perorally in rats expressed as mean percent change,Other,6121916.0,
1547,191853,3,3,,103164353,3016,Unspecified,,,,,Antianxiety effect in cook-davidson behavior test at 3 mg/kg of compound administered perorally in rats expressed as mean percent change,Other,6121916.0,
1548,191854,3,3,,103164353,3016,Unspecified,,,,,Antianxiety effect in cook-davidson behavior test at 30 mg/kg of compound administered perorally in rats expressed as mean percent change,Other,6121916.0,
1549,194131,3,3,,103164353,3016,Unspecified,,,,,"ED50 value was reported as log1/C, which is the concentration required to reduce locomotor activity by 50% in rats",Other,7359533.0,
1550,194132,3,3,,103164353,3016,Unspecified,,,,,"Fourfod increase in lever pressing in punished rats, ED50 value reported as log1/C",Other,7359533.0,
1551,194134,3,3,,103164353,3016,Unspecified,,,,,"Halving of lever pressing in non punished rats, ED50 value reported as log 1/C",Other,7359533.0,
1552,195780,3,3,,103164353,3016,Unspecified,,,,,Anticonflict activity on water lick conflict test in rats is no. of shocks in 5 min; administered perorally 10 mg/kg (no. of rats),Other,7902439.0,
1553,195941,3,3,,103164353,3016,Unspecified,,,,,No of shocks of 5 min was reported after oral administration of a dose of 5 mg/kg in 43 rats; 25/43,Other,1977911.0,
1554,196364,3,3,,103164353,3016,Unspecified,,,,,In vitro [36Cl]-uptake in rat cerebrocortical synaptoneurosomes,Other,8568803.0,
1555,196544,3,5,,103164353,3016,Unspecified,,,,,Percent of maximal extent of inhibition was calculated by fitting [35S]TBPS inhibition data to a sigmoid function (rat brain cortical P2 membranes).,Other,9016329.0,
1556,205268,4,7,,103164353,3016,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
1557,205269,3,7,,103164353,3016,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM,Other,2579237.0,
1558,210588,6,2,,103164353,3016,Unspecified,,,,,Toxicity on peroral administration to mice,Other,6131132.0,
1559,212016,6,2,,103164353,3016,Unspecified,,,,,Toxicity was measured in mouse by intraperitoneal administration; value ranges from 320-1000,Other,2536440.0,
1560,212017,6,2,,103164353,3016,Unspecified,,,,,Toxicity measured in mouse by subcutaneous administration,Other,2536440.0,
1561,213410,3,8,,103164353,3016,Unspecified,,,,,Compound was tested to block the inhibition of tyrosine hydroxylase by apomorphine at 1 uM,Other,6105221.0,
1562,217794,9,5,,103164353,3016,Unspecified,116447.0,81574.0,152.0,IC50,Inhibition of [3H]BTX-B binding to neurotoxin site 2 of sodium channel of rat cerebral cortex synaptoneurosomes,Confirmatory,7562939.0,
1563,217794,9,5,,103164353,3016,Unspecified,116448.0,24766.0,152.0,IC50,Inhibition of [3H]BTX-B binding to neurotoxin site 2 of sodium channel of rat cerebral cortex synaptoneurosomes,Confirmatory,7562939.0,
1564,217794,9,5,,103164353,3016,Unspecified,116449.0,497770.0,152.0,IC50,Inhibition of [3H]BTX-B binding to neurotoxin site 2 of sodium channel of rat cerebral cortex synaptoneurosomes,Confirmatory,7562939.0,
1565,219782,8,5,,103164353,3016,Active,120788.0,29709.0,0.016,Ki,Binding affinity for rat GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1566,219782,8,5,,103164353,3016,Active,51317298.0,29705.0,0.016,Ki,Binding affinity for rat GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1567,219782,8,5,,103164353,3016,Active,52000957.0,25451.0,0.016,Ki,Binding affinity for rat GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1568,219783,8,5,,103164353,3016,Unspecified,120788.0,29709.0,10.0,Ki,Binding affinity for mutant rat GABA-A receptor alpha-1-(arg)-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1569,219783,8,5,,103164353,3016,Unspecified,51317298.0,29705.0,10.0,Ki,Binding affinity for mutant rat GABA-A receptor alpha-1-(arg)-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1570,219783,8,5,,103164353,3016,Unspecified,52000957.0,25451.0,10.0,Ki,Binding affinity for mutant rat GABA-A receptor alpha-1-(arg)-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1571,219947,8,5,,103164353,3016,Active,120761.0,24947.0,0.017,Ki,Binding affinity for rat GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1572,219947,8,5,,103164353,3016,Active,120788.0,29709.0,0.017,Ki,Binding affinity for rat GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1573,219947,8,5,,103164353,3016,Active,52000957.0,25451.0,0.017,Ki,Binding affinity for rat GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1574,219948,3,7,,103164353,3016,Unspecified,,,,,In vitro efficacy as change in chloride current against GABA-A alpha-3-beta-2-gamma-2 subunit expression,Other,8809170.0,
1575,220128,6,2,,103164353,3016,Unspecified,,,10.0,Ki,Binding affinity for rat GABA-A receptor alpha-4-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1576,220130,6,2,,103164353,3016,Active,,,0.023,Ki,Binding affinity for mutant rat GABA-A receptor alpha-4-(his)-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1577,220296,6,2,,103164353,3016,Active,,,0.015,Ki,Binding affinity for rat GABA-A receptor alpha-5--beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1578,220441,8,5,,103164353,3016,Unspecified,120788.0,29709.0,10.0,Ki,Binding affinity for rat GABA-A receptor alpha-6-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1579,220441,8,5,,103164353,3016,Unspecified,232127.0,29708.0,10.0,Ki,Binding affinity for rat GABA-A receptor alpha-6-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1580,220441,8,5,,103164353,3016,Unspecified,52000957.0,25451.0,10.0,Ki,Binding affinity for rat GABA-A receptor alpha-6-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1581,220443,8,5,,103164353,3016,Active,120788.0,29709.0,0.098,Ki,Binding affinity for mutant rat GABA-A receptor alpha-6-(his)-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1582,220443,8,5,,103164353,3016,Active,232127.0,29708.0,0.098,Ki,Binding affinity for mutant rat GABA-A receptor alpha-6-(his)-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1583,220443,8,5,,103164353,3016,Active,52000957.0,25451.0,0.098,Ki,Binding affinity for mutant rat GABA-A receptor alpha-6-(his)-beta-2-gamma-2 subunits expressed in HEK293 cells,Confirmatory,7799410.0,
1584,220445,8,5,,103164353,3016,Active,120788.0,29709.0,0.02,Ki,"Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr)beta2gamma2 subunits expressed in HEK293 cells",Confirmatory,7799410.0,
1585,220445,8,5,,103164353,3016,Active,232127.0,29708.0,0.02,Ki,"Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr)beta2gamma2 subunits expressed in HEK293 cells",Confirmatory,7799410.0,
1586,220445,8,5,,103164353,3016,Active,52000957.0,25451.0,0.02,Ki,"Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr)beta2gamma2 subunits expressed in HEK293 cells",Confirmatory,7799410.0,
1587,220446,8,5,,103164353,3016,Active,120788.0,29709.0,0.009000000000000001,Ki,"Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr,gly)beta2gamma2 subunits expressed in HEK293 cells",Confirmatory,7799410.0,
1588,220446,8,5,,103164353,3016,Active,232127.0,29708.0,0.009000000000000001,Ki,"Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr,gly)beta2gamma2 subunits expressed in HEK293 cells",Confirmatory,7799410.0,
1589,220446,8,5,,103164353,3016,Active,52000957.0,25451.0,0.009000000000000001,Ki,"Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr,gly)beta2gamma2 subunits expressed in HEK293 cells",Confirmatory,7799410.0,
1590,220448,8,5,,103164353,3016,Active,120788.0,29709.0,0.0021,Ki,"Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr,gly,val)beta2gamma2 subunits expressed in HEK293 cells",Confirmatory,7799410.0,
1591,220448,8,5,,103164353,3016,Active,232127.0,29708.0,0.0021,Ki,"Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr,gly,val)beta2gamma2 subunits expressed in HEK293 cells",Confirmatory,7799410.0,
1592,220448,8,5,,103164353,3016,Active,52000957.0,25451.0,0.0021,Ki,"Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr,gly,val)beta2gamma2 subunits expressed in HEK293 cells",Confirmatory,7799410.0,
1593,221056,6,2,,103164353,3016,Unspecified,,,,,Ability to antagonize metrazole-induced seizures (clonic and tonic) in mice after intraperitoneal injection,Other,8809170.0,
1594,221740,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity electroshock induced convulsions and % lethality obtained at dose of 10 mg/kg,Other,12477354.0,
1595,221741,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity electroshock induced convulsions and % lethality obtained at dose of 1 mg/kg,Other,12477354.0,
1596,221743,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity electroshock induced convulsions and % lethality obtained at dose of 3 mg/kg,Other,12477354.0,
1597,222195,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity electroshock induced convulsions in hind limb of mice at a dose of 10 mg/kg po,Other,12477354.0,
1598,222196,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity electroshock induced convulsions in hind limb of mice at a dose of 1 mg/kg po,Other,12477354.0,
1599,222198,3,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity electroshock induced convulsions in hind limb of mice at a dose of 3 mg/kg po,Other,12477354.0,
1600,222343,3,3,,103164353,3016,Unspecified,,,,,Acute electroshock physical dependence activity (drug MA50/V122 MA50),Other,8809170.0,
1601,223126,6,2,,103164353,3016,Unspecified,,,,,Compound was tested for ethanol potentiation expressed as loss of righting reflex (anesthesia),Other,8809170.0,
1602,223127,6,2,,103164353,3016,Unspecified,,,,,Compound was tested for ethanol potentiation expressed as the loss of traction response (muscle relaxation),Other,8809170.0,
1603,223134,6,2,,103164353,3016,Unspecified,,,,,"Dose required by the compound in vivo to antagonise the convulsant action of PTZ (80 mg/kg, sc) in 50 % mice",Other,10633040.0,
1604,223173,3,4,,103164353,3016,Unspecified,,,,,Effect on the sleeping time of mice anesthetized with halothane (treated group),Other,10649973.0,
1605,223176,4,4,,103164353,3016,Unspecified,,,,,Effect on the sleeping time of mice before halothane load (control group),Other,10649973.0,
1606,224360,3,3,,103164353,3016,Unspecified,,,,,Ability to reverse scopolamine-induced amnesia in a passive avoidance test to assess memory impairment; administered perorally 5 mg/kg (no. of mice),Other,7902439.0,
1607,225355,6,2,,103164353,3016,Unspecified,,,,,"Compound was evaluated for their ability to antagonize the muscle relaxation effects of benzodiazepine full agonist, triazolam.",Other,10197957.0,
1608,226272,3,9,,103164353,3016,Unspecified,120758.0,289606.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1609,226272,3,9,,103164353,3016,Unspecified,120761.0,24947.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1610,226272,3,9,,103164353,3016,Unspecified,120763.0,140675.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1611,226272,3,9,,103164353,3016,Unspecified,120764.0,29707.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1612,226272,3,9,,103164353,3016,Unspecified,120769.0,25450.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1613,226272,3,9,,103164353,3016,Unspecified,120782.0,140674.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1614,226272,3,9,,103164353,3016,Unspecified,120788.0,29709.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1615,226272,3,9,,103164353,3016,Unspecified,120790.0,79211.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1616,226272,3,9,,103164353,3016,Unspecified,232127.0,29708.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1617,226272,3,9,,103164353,3016,Unspecified,544363.0,29689.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1618,226272,3,9,,103164353,3016,Unspecified,3023821.0,81658.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1619,226272,3,9,,103164353,3016,Unspecified,13959374.0,65191.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1620,226272,3,9,,103164353,3016,Unspecified,51317298.0,29705.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1621,226272,3,9,,103164353,3016,Unspecified,52000955.0,24922.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1622,226272,3,9,,103164353,3016,Unspecified,52000957.0,25451.0,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1623,226272,3,9,,103164353,3016,Unspecified,81902501.0,,,,"Relative binding in the presence and absence of GABA, (IC50-GABA /IC50+GABA)",Other,,
1624,226274,3,9,,103164353,3016,Unspecified,120758.0,289606.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1625,226274,3,9,,103164353,3016,Unspecified,120761.0,24947.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1626,226274,3,9,,103164353,3016,Unspecified,120763.0,140675.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1627,226274,3,9,,103164353,3016,Unspecified,120764.0,29707.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1628,226274,3,9,,103164353,3016,Unspecified,120769.0,25450.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1629,226274,3,9,,103164353,3016,Unspecified,120782.0,140674.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1630,226274,3,9,,103164353,3016,Unspecified,120788.0,29709.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1631,226274,3,9,,103164353,3016,Unspecified,120790.0,79211.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1632,226274,3,9,,103164353,3016,Unspecified,232127.0,29708.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1633,226274,3,9,,103164353,3016,Unspecified,544363.0,29689.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1634,226274,3,9,,103164353,3016,Unspecified,3023821.0,81658.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1635,226274,3,9,,103164353,3016,Unspecified,13959374.0,65191.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1636,226274,3,9,,103164353,3016,Unspecified,51317298.0,29705.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1637,226274,3,9,,103164353,3016,Unspecified,52000955.0,24922.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1638,226274,3,9,,103164353,3016,Unspecified,52000957.0,25451.0,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1639,226274,3,9,,103164353,3016,Unspecified,81902501.0,,,,Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift),Other,2993620.0,
1640,226277,3,9,,103164353,3016,Inconclusive,120758.0,289606.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1641,226277,3,9,,103164353,3016,Inconclusive,120761.0,24947.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1642,226277,3,9,,103164353,3016,Inconclusive,120763.0,140675.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1643,226277,3,9,,103164353,3016,Inconclusive,120764.0,29707.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1644,226277,3,9,,103164353,3016,Inconclusive,120769.0,25450.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1645,226277,3,9,,103164353,3016,Inconclusive,120782.0,140674.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1646,226277,3,9,,103164353,3016,Inconclusive,120788.0,29709.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1647,226277,3,9,,103164353,3016,Inconclusive,120790.0,79211.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1648,226277,3,9,,103164353,3016,Inconclusive,232127.0,29708.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1649,226277,3,9,,103164353,3016,Inconclusive,544363.0,29689.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1650,226277,3,9,,103164353,3016,Inconclusive,3023821.0,81658.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1651,226277,3,9,,103164353,3016,Inconclusive,13959374.0,65191.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1652,226277,3,9,,103164353,3016,Inconclusive,51317298.0,29705.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1653,226277,3,9,,103164353,3016,Inconclusive,52000955.0,24922.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1654,226277,3,9,,103164353,3016,Inconclusive,52000957.0,25451.0,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1655,226277,3,9,,103164353,3016,Inconclusive,81902501.0,,,,GABA ratio of binding to rat GABA-A receptor in the presence and absence of GABA (ND=Not determined),Other,1680197.0,
1656,226427,3,7,,103164353,3016,Unspecified,,,,,Ratio of IC50 of compound to that of compound+10 uM GABA,Other,2167984.0,
1657,226428,3,9,,103164353,3016,Unspecified,120758.0,289606.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1658,226428,3,9,,103164353,3016,Unspecified,120761.0,24947.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1659,226428,3,9,,103164353,3016,Unspecified,120763.0,140675.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1660,226428,3,9,,103164353,3016,Unspecified,120764.0,29707.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1661,226428,3,9,,103164353,3016,Unspecified,120769.0,25450.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1662,226428,3,9,,103164353,3016,Unspecified,120782.0,140674.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1663,226428,3,9,,103164353,3016,Unspecified,120788.0,29709.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1664,226428,3,9,,103164353,3016,Unspecified,120790.0,79211.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1665,226428,3,9,,103164353,3016,Unspecified,232127.0,29708.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1666,226428,3,9,,103164353,3016,Unspecified,544363.0,29689.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1667,226428,3,9,,103164353,3016,Unspecified,3023821.0,81658.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1668,226428,3,9,,103164353,3016,Unspecified,13959374.0,65191.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1669,226428,3,9,,103164353,3016,Unspecified,51317298.0,29705.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1670,226428,3,9,,103164353,3016,Unspecified,52000955.0,24922.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1671,226428,3,9,,103164353,3016,Unspecified,52000957.0,25451.0,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1672,226428,3,9,,103164353,3016,Unspecified,81902501.0,,,,Ratio of Ki value without GABA and Ki value in the presence of GABA.,Other,10543878.0,
1673,226435,3,10,,103164353,3016,Unspecified,120758.0,289606.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1674,226435,3,10,,103164353,3016,Unspecified,120761.0,24947.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1675,226435,3,10,,103164353,3016,Unspecified,120763.0,140675.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1676,226435,3,10,,103164353,3016,Unspecified,120764.0,29707.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1677,226435,3,10,,103164353,3016,Unspecified,120769.0,25450.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1678,226435,3,10,,103164353,3016,Unspecified,120782.0,140674.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1679,226435,3,10,,103164353,3016,Unspecified,120788.0,29709.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1680,226435,3,10,,103164353,3016,Unspecified,120790.0,79211.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1681,226435,3,10,,103164353,3016,Unspecified,232127.0,29708.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1682,226435,3,10,,103164353,3016,Unspecified,544363.0,29689.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1683,226435,3,10,,103164353,3016,Unspecified,3023821.0,81658.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1684,226435,3,10,,103164353,3016,Unspecified,13959374.0,65191.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1685,226435,3,10,,103164353,3016,Unspecified,51317298.0,29705.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1686,226435,3,10,,103164353,3016,Unspecified,52000955.0,24922.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1687,226435,3,10,,103164353,3016,Unspecified,52000957.0,25451.0,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1688,226435,3,10,,103164353,3016,Unspecified,81902501.0,,,,GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor,Other,8386769.0,
1689,226437,3,7,,103164353,3016,Unspecified,,,,,Ratio of binding affinity to the GABA-A receptor in the presence and absence of GABA,Other,2552115.0,
1690,226438,3,8,,103164353,3016,Unspecified,,,,,Ratio of the binding in the absence and presence of GABA was determined.,Other,12161138.0,
1691,226451,3,8,,103164353,3016,Unspecified,,,,,"The GABA ratio (GR) = IC50 compound + 10 uM GABA, performed in five independent experiments was calculated for the compound.",Other,10377227.0,
1692,226454,3,7,,103164353,3016,Unspecified,,,,,GABA shift as the ratio of IC50 (no GABA) to that of IC50 (GABA); GABA shift,Other,7837226.0,
1693,226455,3,8,,103164353,3016,Unspecified,120758.0,289606.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1694,226455,3,8,,103164353,3016,Unspecified,120761.0,24947.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1695,226455,3,8,,103164353,3016,Unspecified,120763.0,140675.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1696,226455,3,8,,103164353,3016,Unspecified,120764.0,29707.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1697,226455,3,8,,103164353,3016,Unspecified,120769.0,25450.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1698,226455,3,8,,103164353,3016,Unspecified,120782.0,140674.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1699,226455,3,8,,103164353,3016,Unspecified,120788.0,29709.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1700,226455,3,8,,103164353,3016,Unspecified,120790.0,79211.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1701,226455,3,8,,103164353,3016,Unspecified,232127.0,29708.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1702,226455,3,8,,103164353,3016,Unspecified,544363.0,29689.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1703,226455,3,8,,103164353,3016,Unspecified,3023821.0,81658.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1704,226455,3,8,,103164353,3016,Unspecified,13959374.0,65191.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1705,226455,3,8,,103164353,3016,Unspecified,51317298.0,29705.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1706,226455,3,8,,103164353,3016,Unspecified,52000955.0,24922.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1707,226455,3,8,,103164353,3016,Unspecified,52000957.0,25451.0,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1708,226455,3,8,,103164353,3016,Unspecified,81902501.0,,,,GABA shift which is the ratio of binding in the absence and presence of GABA (1 mM) was determined,Other,10386933.0,
1709,226526,3,3,,103164353,3016,Unspecified,,,,,Protective index is the ratio between TD50 and ED50 values,Other,8035421.0,
1710,227697,4,3,,103164353,3016,Unspecified,,,,,Compound was evaluated for the Anti-fighting behavior.,Other,2202830.0,
1711,227698,4,3,,103164353,3016,Unspecified,,,,,Evaluation for the Anti-pentylenetetrazole effect.,Other,2202830.0,
1712,227718,7,1,,103164353,3016,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
1713,228469,4,3,,103164353,3016,Unspecified,,,,,Evaluation of inclined screen test.,Other,2202830.0,
1714,229087,3,3,,103164353,3016,Unspecified,,,,,Ethanol interaction ratio (EIR) of the compound.,Other,2573731.0,
1715,229422,4,5,,103164353,3016,Unspecified,,,,,"Selectivity of binding to pancreatic CCK and brain benzodiazepine receptors, ratio of IC50",Other,2885419.0,
1716,229555,3,8,,103164353,3016,Unspecified,120758.0,289606.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1717,229555,3,8,,103164353,3016,Unspecified,120761.0,24947.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1718,229555,3,8,,103164353,3016,Unspecified,120763.0,140675.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1719,229555,3,8,,103164353,3016,Unspecified,120764.0,29707.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1720,229555,3,8,,103164353,3016,Unspecified,120769.0,25450.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1721,229555,3,8,,103164353,3016,Unspecified,120782.0,140674.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1722,229555,3,8,,103164353,3016,Unspecified,120788.0,29709.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1723,229555,3,8,,103164353,3016,Unspecified,120790.0,79211.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1724,229555,3,8,,103164353,3016,Unspecified,232127.0,29708.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1725,229555,3,8,,103164353,3016,Unspecified,544363.0,29689.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1726,229555,3,8,,103164353,3016,Unspecified,3023821.0,81658.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1727,229555,3,8,,103164353,3016,Unspecified,13959374.0,65191.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1728,229555,3,8,,103164353,3016,Unspecified,51317298.0,29705.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1729,229555,3,8,,103164353,3016,Unspecified,52000955.0,24922.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1730,229555,3,8,,103164353,3016,Unspecified,52000957.0,25451.0,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1731,229555,3,8,,103164353,3016,Unspecified,81902501.0,,,,Relative binding to GABA-A receptor in the presence and absence of GABA,Other,8388472.0,
1732,229769,4,9,,103164353,3016,Unspecified,120758.0,289606.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1733,229769,4,9,,103164353,3016,Unspecified,120761.0,24947.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1734,229769,4,9,,103164353,3016,Unspecified,120763.0,140675.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1735,229769,4,9,,103164353,3016,Unspecified,120764.0,29707.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1736,229769,4,9,,103164353,3016,Unspecified,120769.0,25450.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1737,229769,4,9,,103164353,3016,Unspecified,120782.0,140674.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1738,229769,4,9,,103164353,3016,Unspecified,120788.0,29709.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1739,229769,4,9,,103164353,3016,Unspecified,120790.0,79211.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1740,229769,4,9,,103164353,3016,Unspecified,232127.0,29708.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1741,229769,4,9,,103164353,3016,Unspecified,544363.0,29689.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1742,229769,4,9,,103164353,3016,Unspecified,3023821.0,81658.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1743,229769,4,9,,103164353,3016,Unspecified,13959374.0,65191.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1744,229769,4,9,,103164353,3016,Unspecified,51317298.0,29705.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1745,229769,4,9,,103164353,3016,Unspecified,52000955.0,24922.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1746,229769,4,9,,103164353,3016,Unspecified,52000957.0,25451.0,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1747,229769,4,9,,103164353,3016,Unspecified,81902501.0,,,,GABA ratio (IC50/IC50 in the presence of 10e-4 GABA).,Other,2836588.0,
1748,229770,3,9,,103164353,3016,Unspecified,120758.0,289606.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1749,229770,3,9,,103164353,3016,Unspecified,120761.0,24947.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1750,229770,3,9,,103164353,3016,Unspecified,120763.0,140675.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1751,229770,3,9,,103164353,3016,Unspecified,120764.0,29707.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1752,229770,3,9,,103164353,3016,Unspecified,120769.0,25450.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1753,229770,3,9,,103164353,3016,Unspecified,120782.0,140674.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1754,229770,3,9,,103164353,3016,Unspecified,120788.0,29709.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1755,229770,3,9,,103164353,3016,Unspecified,120790.0,79211.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1756,229770,3,9,,103164353,3016,Unspecified,232127.0,29708.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1757,229770,3,9,,103164353,3016,Unspecified,544363.0,29689.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1758,229770,3,9,,103164353,3016,Unspecified,3023821.0,81658.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1759,229770,3,9,,103164353,3016,Unspecified,13959374.0,65191.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1760,229770,3,9,,103164353,3016,Unspecified,51317298.0,29705.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1761,229770,3,9,,103164353,3016,Unspecified,52000955.0,24922.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1762,229770,3,9,,103164353,3016,Unspecified,52000957.0,25451.0,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1763,229770,3,9,,103164353,3016,Unspecified,81902501.0,,,,Relative inhibition of [3H]diazepam binding to GABA-A receptor of rat forebrain in the presence and absence of GABA(10e-4M),Other,2836588.0,
1764,230747,3,3,,103164353,3016,Unspecified,,,,,Ratio of the antifighting effect to muscle relaxant action,Other,6131132.0,
1765,231293,3,6,,103164353,3016,Inconclusive,,,,,Ratio of binding affinity of 5-HT1A receptor to that of 5-HT1D receptor; NT means not tested,Other,,
1766,231333,3,3,,103164353,3016,Unspecified,,,,,Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer),Other,11384238.0,
1767,232380,3,6,,103164353,3016,Inconclusive,,,,,Ratio of EC50 of 5-HT1A receptor to that of 5-HT1D receptor; NT means not tested,Other,,
1768,232605,4,3,,103164353,3016,Unspecified,,,,,Ratio of IC50 CCK(pancreas)/ IC50BZD (brain),Other,2848124.0,
1769,232720,3,5,,103164353,3016,Unspecified,,,,,Selectivity ratio of alpha1 beta-3 gamma2 GABA A / BzR and alpha5 beta-3 gamma2 GABA A / BzR,Other,10633039.0,
1770,233756,3,7,,103164353,3016,Unspecified,,,,,"GABA ratio, relative binding in the presence and absence of 10 uM GABA (IC50-GABA/IC50+GABA)",Other,12477354.0,
1771,235586,3,3,,103164353,3016,Unspecified,,,,,Ratio of ED50 (ethanol) to that of ED50 (fighting),Other,1977910.0,
1772,235587,3,3,,103164353,3016,Unspecified,,,,,Ratio of ED50 (hexobarbital) to that of ED50 (fighting),Other,1977910.0,
1773,235588,3,3,,103164353,3016,Unspecified,,,,,Ratio of ED50 (rotarod) to that of ED50 (fighting),Other,1977910.0,
1774,237585,5,2,,103164353,3016,Unspecified,,,,,Tested for fraction of oral dose absorbed orally in humans,Other,15857133.0,
1775,239299,7,1,,103164353,3016,Active,,,0.01,Ki,Displacement of [3H]flumazenil from bovine benzodiazepine receptor GABA-A channel of brain membranes,Confirmatory,15828832.0,
1776,239563,8,5,,103164353,3016,Active,120773.0,2562.0,0.0066,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric acid A receptor alpha-2-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1777,239563,8,5,,103164353,3016,Active,116242488.0,2566.0,0.0066,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric acid A receptor alpha-2-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1778,239563,8,5,,103164353,3016,Active,126302547.0,2555.0,0.0066,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric acid A receptor alpha-2-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1779,239564,8,5,,103164353,3016,Active,120773.0,2562.0,0.013000000000000001,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-1-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1780,239564,8,5,,103164353,3016,Active,27808653.0,2554.0,0.013000000000000001,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-1-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1781,239564,8,5,,103164353,3016,Active,116242488.0,2566.0,0.013000000000000001,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-1-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1782,239565,8,5,,103164353,3016,Active,120773.0,2562.0,0.033,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-3-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1783,239565,8,5,,103164353,3016,Active,462149.0,2556.0,0.033,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-3-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1784,239565,8,5,,103164353,3016,Active,116242488.0,2566.0,0.033,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-3-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1785,239566,8,5,,103164353,3016,Active,120773.0,2562.0,0.011000000000000001,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-5-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1786,239566,8,5,,103164353,3016,Active,399519.0,2558.0,0.011000000000000001,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-5-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1787,239566,8,5,,103164353,3016,Active,116242488.0,2566.0,0.011000000000000001,Ki,Inhibition of [3H]Ro-151788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-5-beta-3-gamma-2 subtype expressed in L (tk-) cells,Confirmatory,15743180.0,
1788,240426,6,2,,103164353,3016,Unspecified,,,,,Ability of the compound to protect mice against pentylenetetrazole induced convulsion in the presence of 10 mg/kg flumazenil; Ranges 60.1-135.9,Other,15876530.0,
1789,240427,6,2,,103164353,3016,Unspecified,,,,,Ability of the compound to protect mice against maximal electric shock (MES) induced convulsion in the presence of 10 mg/kg flumazenil; Range 54.9-102.9,Other,15876530.0,
1790,242870,6,2,,103164353,3016,Unspecified,,,,,Lethal dose of in mice,Other,15876530.0,
1791,243413,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-1-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1792,243413,3,10,,103164353,3016,Unspecified,27808653.0,2554.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-1-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1793,243413,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-1-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1794,243414,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-2-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1795,243414,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-2-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1796,243414,3,10,,103164353,3016,Unspecified,126302547.0,2555.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-2-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1797,243415,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-3-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1798,243415,3,10,,103164353,3016,Unspecified,462149.0,2556.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-3-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1799,243415,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-3-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1800,243416,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-5-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1801,243416,3,10,,103164353,3016,Unspecified,399519.0,2558.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-5-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1802,243416,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy was measured as modulation of the current in response to GABA at hGABA alpha-5-beta-3-gamma-2 receptor expressed in Xenopus oocytes,Other,15743180.0,
1803,246891,6,2,,103164353,3016,Unspecified,,,,,Effective dose against maximal electroshock (MES) induced convulsants in mice,Other,15780622.0,
1804,246933,6,2,,103164353,3016,Unspecified,,,,,Effective dose against pentylenetetrazole (PTZ) induced anticonvulsant activity in mice,Other,15780622.0,
1805,247022,6,2,,103164353,3016,Unspecified,,,,,Effective dose required to protect mice against convulsion induced by a lethal dose of PTZ (100 mg/kg) was determined,Other,15546729.0,
1806,247046,6,2,,103164353,3016,Unspecified,,,,,Effective dose against maximal electroshock (MES) induced convulsions in presence of flumazenil at 10 mg/kg in mice; Range: 1.1-2.6,Other,15780622.0,
1807,247063,6,2,,103164353,3016,Unspecified,,,,,Effective dose against pentylenetetrazole (PTZ) induced anticonvulsant activity in presence of flumazenil at 10 mg/kg in mice; Range: 1.1-2,Other,15780622.0,
1808,247081,6,2,,103164353,3016,Unspecified,,,,,Effective dose required to protect mice against convulsion induced electroshock was determined by MES test in the presence of 10 mg/kg flumazenil,Other,15546729.0,
1809,252193,3,4,,103164353,3016,Unspecified,,,,,Time spent into the open arms of the maze for anxiolytic activity in ICR mouse through elevated plus maze test after intraperitoneal injection of 15 mg/kg,Other,15982883.0,
1810,252929,3,3,,103164353,3016,Unspecified,,,,,Number of entries into the closed arms of the maze for anxiolytic activity in ICR mouse through elevated plus test after intraperitoneal injection of 15 mg/kg,Other,15982883.0,
1811,252930,3,3,,103164353,3016,Unspecified,,,,,Number of entries into the open arms of the maze for anxiolytic activity in ICR mouse through elevated plus maze test after intraperitoneal injection of 15 mg/kg,Other,15982883.0,
1812,252931,3,3,,103164353,3016,Unspecified,,,,,Percentage number of entries into the open arms of the maze for anxiolytic activity in ICR mouse through elevated plus test after intraperitoneal injection of 15 mg/kg,Other,15982883.0,
1813,253162,3,3,,103164353,3016,Unspecified,,,,,Total number of entries into the open and closed arms of the maze for anxiolytic activity in ICR mouse through elevated plus test after intraperitoneal injection of 15 mg/kg,Other,15982883.0,
1814,253365,6,2,,103164353,3016,Unspecified,,,,,Lethal dose tested against mice,Other,15780622.0,
1815,253367,6,2,,103164353,3016,Unspecified,,,,,Lethal dose in mice,Other,15546729.0,
1816,254367,6,2,,103164353,3016,Active,,,0.013999999999999999,Ki,Binding affinity for rat alpha-1 beta2/3 gamma2 GABA A / BzR receptor,Confirmatory,16220991.0,
1817,254368,6,2,,103164353,3016,Active,,,0.02,Ki,Binding affinity for rat alpha2 beta2/3 gamma2 GABA-A/BzR receptor,Confirmatory,16220991.0,
1818,254369,6,2,,103164353,3016,Active,,,0.015,Ki,Binding affinity for rat alpha-3 beta2/3 gamma2 GABA-A/BzR receptor,Confirmatory,16220991.0,
1819,254370,6,2,,103164353,3016,Active,,,0.011000000000000001,Ki,Binding affinity for rat alpha-5 beta2/3 gamma2 GABA-A/BzR receptor,Confirmatory,16220991.0,
1820,255079,8,5,,103164353,3016,Active,803374855.0,140.0,0.012,IC50,Inhibitory concentration against human Adenosine A3 receptor expressed in HEK293 cells using 0.1 nM [3H]AB-MECA,Confirmatory,16250647.0,
1821,256039,3,3,,103164353,3016,Unspecified,,,,,Duration of loss of the righting reflex induced by ethanol at a dose of 1 mg/Kg when given per oral; n=12,Other,16220991.0,
1822,256040,3,3,,103164353,3016,Unspecified,,,,,Duration of loss of the righting reflex induced by ethanol at a dose of 3 mg/Kg when given per oral; n=14,Other,16220991.0,
1823,256042,3,3,,103164353,3016,Unspecified,,,,,Duration of loss of the righting reflex induced by ethanol at a dose of 0.3 mg/Kg when given per oral; n=8,Other,16220991.0,
1824,259129,8,5,,103164353,3016,Active,120773.0,2562.0,0.013000000000000001,Ki,Displacement of [3H]-Ro15-1788 from human recombinant GABAA alpha1 in combination with beta-3-gamma-2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1825,259129,8,5,,103164353,3016,Active,27808653.0,2554.0,0.013000000000000001,Ki,Displacement of [3H]-Ro15-1788 from human recombinant GABAA alpha1 in combination with beta-3-gamma-2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1826,259129,8,5,,103164353,3016,Active,116242488.0,2566.0,0.013000000000000001,Ki,Displacement of [3H]-Ro15-1788 from human recombinant GABAA alpha1 in combination with beta-3-gamma-2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1827,259130,8,5,,103164353,3016,Active,120773.0,2562.0,0.0066,Ki,Displacement of [3H]-Ro15-1788 from human recombinant GABAA alpha2 in combination with beta3gamma2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1828,259130,8,5,,103164353,3016,Active,116242488.0,2566.0,0.0066,Ki,Displacement of [3H]-Ro15-1788 from human recombinant GABAA alpha2 in combination with beta3gamma2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1829,259130,8,5,,103164353,3016,Active,126302547.0,2555.0,0.0066,Ki,Displacement of [3H]-Ro15-1788 from human recombinant GABAA alpha2 in combination with beta3gamma2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1830,259131,8,5,,103164353,3016,Active,120773.0,2562.0,0.033,Ki,Displacement of [3H]Ro-151788 from human recombinant GABAA alpha3 in combination with beta3gamma2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1831,259131,8,5,,103164353,3016,Active,462149.0,2556.0,0.033,Ki,Displacement of [3H]Ro-151788 from human recombinant GABAA alpha3 in combination with beta3gamma2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1832,259131,8,5,,103164353,3016,Active,116242488.0,2566.0,0.033,Ki,Displacement of [3H]Ro-151788 from human recombinant GABAA alpha3 in combination with beta3gamma2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1833,259132,8,5,,103164353,3016,Active,120773.0,2562.0,0.011000000000000001,Ki,Displacement of [3H]Ro-151788 from human recombinant GABAA alpha5 in combination with beta3gamma2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1834,259132,8,5,,103164353,3016,Active,399519.0,2558.0,0.011000000000000001,Ki,Displacement of [3H]Ro-151788 from human recombinant GABAA alpha5 in combination with beta3gamma2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1835,259132,8,5,,103164353,3016,Active,116242488.0,2566.0,0.011000000000000001,Ki,Displacement of [3H]Ro-151788 from human recombinant GABAA alpha5 in combination with beta3gamma2 expressed in L(tk-) cells,Confirmatory,16392789.0,
1836,259133,3,11,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy against human recombinant GABAA alpha-1 in combination with beta3gamma2 expressed in L(tk-) cells by whole cell patch clamp method,Other,16392789.0,
1837,259133,3,11,,103164353,3016,Unspecified,27808653.0,2554.0,,,Efficacy against human recombinant GABAA alpha-1 in combination with beta3gamma2 expressed in L(tk-) cells by whole cell patch clamp method,Other,16392789.0,
1838,259133,3,11,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy against human recombinant GABAA alpha-1 in combination with beta3gamma2 expressed in L(tk-) cells by whole cell patch clamp method,Other,16392789.0,
1839,259134,4,11,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy against human recombinant GABAA alpha3 in combination with beta-3-gamma-2 expressed in L(tk-) cells by whole cell patch clamp method,Other,16392789.0,
1840,259134,4,11,,103164353,3016,Unspecified,462149.0,2556.0,,,Efficacy against human recombinant GABAA alpha3 in combination with beta-3-gamma-2 expressed in L(tk-) cells by whole cell patch clamp method,Other,16392789.0,
1841,259134,4,11,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy against human recombinant GABAA alpha3 in combination with beta-3-gamma-2 expressed in L(tk-) cells by whole cell patch clamp method,Other,16392789.0,
1842,259135,4,11,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy against human recombinant GABAA alpha5 in combination with beta3gamma2 expressed in L(tk-) cells by whole cell patch clamp method,Other,16392789.0,
1843,259135,4,11,,103164353,3016,Unspecified,399519.0,2558.0,,,Efficacy against human recombinant GABAA alpha5 in combination with beta3gamma2 expressed in L(tk-) cells by whole cell patch clamp method,Other,16392789.0,
1844,259135,4,11,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy against human recombinant GABAA alpha5 in combination with beta3gamma2 expressed in L(tk-) cells by whole cell patch clamp method,Other,16392789.0,
1845,260334,8,5,,103164353,3016,Active,120773.0,2562.0,0.013000000000000001,Ki,Displacement of [3H]Ro 15-1788 from recombinant human GABAA alpha-1 receptor plus beta3gamma2 expressed in L(tk-) cells,Confirmatory,16480260.0,
1846,260334,8,5,,103164353,3016,Active,27808653.0,2554.0,0.013000000000000001,Ki,Displacement of [3H]Ro 15-1788 from recombinant human GABAA alpha-1 receptor plus beta3gamma2 expressed in L(tk-) cells,Confirmatory,16480260.0,
1847,260334,8,5,,103164353,3016,Active,116242488.0,2566.0,0.013000000000000001,Ki,Displacement of [3H]Ro 15-1788 from recombinant human GABAA alpha-1 receptor plus beta3gamma2 expressed in L(tk-) cells,Confirmatory,16480260.0,
1848,260336,8,5,,103164353,3016,Active,120773.0,2562.0,0.033,Ki,Displacement of [3H] Ro15-1788 from recombinant human GABAA alpha2 receptor plus beta-3-gamma-2 expressed in L(tk-) cells,Confirmatory,16480260.0,
1849,260336,8,5,,103164353,3016,Active,116242488.0,2566.0,0.033,Ki,Displacement of [3H] Ro15-1788 from recombinant human GABAA alpha2 receptor plus beta-3-gamma-2 expressed in L(tk-) cells,Confirmatory,16480260.0,
1850,260336,8,5,,103164353,3016,Active,126302547.0,2555.0,0.033,Ki,Displacement of [3H] Ro15-1788 from recombinant human GABAA alpha2 receptor plus beta-3-gamma-2 expressed in L(tk-) cells,Confirmatory,16480260.0,
1851,260339,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy against recombinant human GABAA alpha3 receptor plus beta-3-gamma-2 expressed in L(tk-) cells by whole cell patch clamp method relative to chlordiazepoxide,Other,16480260.0,
1852,260339,3,10,,103164353,3016,Unspecified,462149.0,2556.0,,,Efficacy against recombinant human GABAA alpha3 receptor plus beta-3-gamma-2 expressed in L(tk-) cells by whole cell patch clamp method relative to chlordiazepoxide,Other,16480260.0,
1853,260339,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy against recombinant human GABAA alpha3 receptor plus beta-3-gamma-2 expressed in L(tk-) cells by whole cell patch clamp method relative to chlordiazepoxide,Other,16480260.0,
1854,260364,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy against recombinant human GABAA alpha1 receptor plus beta3gamma2 expressed in L(tk-) cells by whole cell patch clamp method relative to chlordiazepoxide,Other,16480260.0,
1855,260364,3,10,,103164353,3016,Unspecified,27808653.0,2554.0,,,Efficacy against recombinant human GABAA alpha1 receptor plus beta3gamma2 expressed in L(tk-) cells by whole cell patch clamp method relative to chlordiazepoxide,Other,16480260.0,
1856,260364,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy against recombinant human GABAA alpha1 receptor plus beta3gamma2 expressed in L(tk-) cells by whole cell patch clamp method relative to chlordiazepoxide,Other,16480260.0,
1857,261133,9,5,,103164353,3016,Active,120758.0,289606.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1858,261133,9,5,,103164353,3016,Active,120761.0,24947.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1859,261133,9,5,,103164353,3016,Active,120763.0,140675.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1860,261133,9,5,,103164353,3016,Active,120764.0,29707.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1861,261133,9,5,,103164353,3016,Active,120769.0,25450.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1862,261133,9,5,,103164353,3016,Active,120782.0,140674.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1863,261133,9,5,,103164353,3016,Active,120788.0,29709.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1864,261133,9,5,,103164353,3016,Active,120790.0,79211.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1865,261133,9,5,,103164353,3016,Active,232127.0,29708.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1866,261133,9,5,,103164353,3016,Active,544363.0,29689.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1867,261133,9,5,,103164353,3016,Active,3023821.0,81658.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1868,261133,9,5,,103164353,3016,Active,13959374.0,65191.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1869,261133,9,5,,103164353,3016,Active,51317298.0,29705.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1870,261133,9,5,,103164353,3016,Active,52000955.0,24922.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1871,261133,9,5,,103164353,3016,Active,52000957.0,25451.0,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1872,261133,9,5,,103164353,3016,Active,81902501.0,,0.0068,Ki,Binding affinity to Wistar rat benzodiazepine receptor,Confirmatory,16539371.0,
1873,261135,7,2,,103164353,3016,Unspecified,,,,,Anxiolytic activity in NMRI BR mice after ip administration by PTZ test,Other,16539371.0,
1874,261136,4,3,,103164353,3016,Unspecified,,,,,Neurotoxicological activity in NMRI BR mice after ip administration by rotarod test,Other,16539371.0,
1875,261137,7,2,,103164353,3016,Unspecified,,,,,Anxiolytic activity in rat after oral administration by PTZ test,Other,16539371.0,
1876,261138,4,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in rat after oral administration by vogel conflict test,Other,16539371.0,
1877,261139,4,3,,103164353,3016,Unspecified,,,,,Neurotoxicological activity in rat after oral administration by rotarod test,Other,16539371.0,
1878,261140,3,3,,103164353,3016,Unspecified,,,,,Protective index (PI=TD50/ED50) in rat after oral administration,Other,16539371.0,
1879,262560,8,5,,103164353,3016,Active,27808653.0,2554.0,0.012,Ki,Displacement of [3H]Flumazenil from human GABA-Aalpha1 receptor plus beta-2-gamma-2 expressed in HEK293 cells,Confirmatory,16610795.0,
1880,262560,8,5,,103164353,3016,Active,116242488.0,2566.0,0.012,Ki,Displacement of [3H]Flumazenil from human GABA-Aalpha1 receptor plus beta-2-gamma-2 expressed in HEK293 cells,Confirmatory,16610795.0,
1881,262560,8,5,,103164353,3016,Active,292495010.0,2561.0,0.012,Ki,Displacement of [3H]Flumazenil from human GABA-Aalpha1 receptor plus beta-2-gamma-2 expressed in HEK293 cells,Confirmatory,16610795.0,
1882,262561,8,5,,103164353,3016,Active,462149.0,2556.0,0.013999999999999999,Ki,Displacement of [3H]Flumazenil from human GABA-Aalpha3 receptor plus beta-2-gamma-2 expressed in HEK293 cells,Confirmatory,16610795.0,
1883,262561,8,5,,103164353,3016,Active,116242488.0,2566.0,0.013999999999999999,Ki,Displacement of [3H]Flumazenil from human GABA-Aalpha3 receptor plus beta-2-gamma-2 expressed in HEK293 cells,Confirmatory,16610795.0,
1884,262561,8,5,,103164353,3016,Active,292495010.0,2561.0,0.013999999999999999,Ki,Displacement of [3H]Flumazenil from human GABA-Aalpha3 receptor plus beta-2-gamma-2 expressed in HEK293 cells,Confirmatory,16610795.0,
1885,262562,3,5,,103164353,3016,Unspecified,,,,,Selectivity for human GABA-Aalpha1 receptor plus beta-2-gamma-2 over GABA-Aalpha3 receptor plus beta2gamma2,Other,16610795.0,
1886,262962,7,5,,103164353,3016,Active,120752.0,780973.0,0.01,Ki,Displacement of [3H]flumazenil from GABA-A receptor in bovine brain membranes,Confirmatory,16610792.0,
1887,262962,7,5,,103164353,3016,Active,120756.0,282236.0,0.01,Ki,Displacement of [3H]flumazenil from GABA-A receptor in bovine brain membranes,Confirmatory,16610792.0,
1888,262962,7,5,,103164353,3016,Active,120759.0,282237.0,0.01,Ki,Displacement of [3H]flumazenil from GABA-A receptor in bovine brain membranes,Confirmatory,16610792.0,
1889,262962,7,5,,103164353,3016,Active,120766.0,282239.0,0.01,Ki,Displacement of [3H]flumazenil from GABA-A receptor in bovine brain membranes,Confirmatory,16610792.0,
1890,262962,7,5,,103164353,3016,Active,120784.0,282240.0,0.01,Ki,Displacement of [3H]flumazenil from GABA-A receptor in bovine brain membranes,Confirmatory,16610792.0,
1891,262962,7,5,,103164353,3016,Active,143811394.0,282238.0,0.01,Ki,Displacement of [3H]flumazenil from GABA-A receptor in bovine brain membranes,Confirmatory,16610792.0,
1892,275980,3,3,,103164353,3016,Unspecified,,,,,"Locomotor activity in Swiss mouse measured as number of crossings in the arena test at 2 mg/kg, ip",Other,17253849.0,
1893,275981,3,3,,103164353,3016,Unspecified,,,,,"Locomotor activity in Swiss mouse measured as number of rearings in the arena test at 2 mg/kg, ip",Other,17253849.0,
1894,275986,3,3,,103164353,3016,Active,,,,,"Antianxiolytic activity in Swiss mouse assessed as reduction of latency to leave the enclosed arm by elevated T maze test at 2 mg/kg, ip",Other,17253849.0,
1895,275987,3,3,,103164353,3016,Active,,,,,"Antianxiolytic activity in Swiss mouse assessed as reduction of latency to leave the enclosed arm by elevated T maze test at 10 mg/kg, po",Other,17253849.0,
1896,275989,3,3,,103164353,3016,Active,,,,,"Antianxiolytic activity in Swiss mouse assessed as impairment of inhibitory avoidance task by elevated T-maze test at 3 mg/kg, po",Other,17253849.0,
1897,275990,3,3,,103164353,3016,Active,,,,,"Antianxiolytic activity in Swiss mouse assessed as impairment of inhibitory avoidance task by elevated T-maze test at 10 mg/kg, po",Other,17253849.0,
1898,275992,3,3,,103164353,3016,Inactive,,,,,"Antianxiolytic activity in Swiss mouse assessed as effect on latency to leave the open arm by elevated T maze test at 2 mg/kg, ip",Other,17253849.0,
1899,280839,4,4,,103164353,3016,Active,,,0.01,Ki,Displacement of [3H]flumazenil from benzodiazepine receptor in bovine brain membranes,Confirmatory,17335185.0,
1900,280846,3,11,,103164353,3016,Unspecified,120788.0,29709.0,,,Agonist activity at rat GABAA alpha-1-beta-2-gamma-2 expressed in HEK293 cells assessed as chloride influx,Other,17335185.0,
1901,280846,3,11,,103164353,3016,Unspecified,51317298.0,29705.0,,,Agonist activity at rat GABAA alpha-1-beta-2-gamma-2 expressed in HEK293 cells assessed as chloride influx,Other,17335185.0,
1902,280846,3,11,,103164353,3016,Unspecified,52000957.0,25451.0,,,Agonist activity at rat GABAA alpha-1-beta-2-gamma-2 expressed in HEK293 cells assessed as chloride influx,Other,17335185.0,
1903,282665,8,5,,103164353,3016,Active,120773.0,2562.0,0.013999999999999999,Ki,Displacement of [3H]Ro 15-1788 from human recombinant GABAA alpha-1-beta-3-gamma-2 receptor expressed in L(tk-) cells,Confirmatory,16279764.0,
1904,282665,8,5,,103164353,3016,Active,27808653.0,2554.0,0.013999999999999999,Ki,Displacement of [3H]Ro 15-1788 from human recombinant GABAA alpha-1-beta-3-gamma-2 receptor expressed in L(tk-) cells,Confirmatory,16279764.0,
1905,282665,8,5,,103164353,3016,Active,116242488.0,2566.0,0.013999999999999999,Ki,Displacement of [3H]Ro 15-1788 from human recombinant GABAA alpha-1-beta-3-gamma-2 receptor expressed in L(tk-) cells,Confirmatory,16279764.0,
1906,282666,8,5,,103164353,3016,Active,120773.0,2562.0,0.02,Ki,Displacement of [3H]Ro 15-1788 from human recombinant GABAA alpha-2-beta-3-gamma-2 receptor expressed in L(tk-) cells,Confirmatory,16279764.0,
1907,282666,8,5,,103164353,3016,Active,116242488.0,2566.0,0.02,Ki,Displacement of [3H]Ro 15-1788 from human recombinant GABAA alpha-2-beta-3-gamma-2 receptor expressed in L(tk-) cells,Confirmatory,16279764.0,
1908,282666,8,5,,103164353,3016,Active,126302547.0,2555.0,0.02,Ki,Displacement of [3H]Ro 15-1788 from human recombinant GABAA alpha-2-beta-3-gamma-2 receptor expressed in L(tk-) cells,Confirmatory,16279764.0,
1909,282667,8,5,,103164353,3016,Active,120773.0,2562.0,0.015,Ki,Displacement of [3H]Ro 15-1788 from human recombinant GABAA alpha-3-beta-3-gamma-2 receptor expressed in L(tk-) cells,Confirmatory,16279764.0,
1910,282667,8,5,,103164353,3016,Active,462149.0,2556.0,0.015,Ki,Displacement of [3H]Ro 15-1788 from human recombinant GABAA alpha-3-beta-3-gamma-2 receptor expressed in L(tk-) cells,Confirmatory,16279764.0,
1911,282667,8,5,,103164353,3016,Active,116242488.0,2566.0,0.015,Ki,Displacement of [3H]Ro 15-1788 from human recombinant GABAA alpha-3-beta-3-gamma-2 receptor expressed in L(tk-) cells,Confirmatory,16279764.0,
1912,282668,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy at human recombinant GABAA alpha-1-beta-3-gamma-2 receptor expressed in Xenopus laevis oocytes by two electrode voltage clamp method relative to GABA,Other,16279764.0,
1913,282668,3,10,,103164353,3016,Unspecified,27808653.0,2554.0,,,Efficacy at human recombinant GABAA alpha-1-beta-3-gamma-2 receptor expressed in Xenopus laevis oocytes by two electrode voltage clamp method relative to GABA,Other,16279764.0,
1914,282668,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy at human recombinant GABAA alpha-1-beta-3-gamma-2 receptor expressed in Xenopus laevis oocytes by two electrode voltage clamp method relative to GABA,Other,16279764.0,
1915,282669,4,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy at human recombinant GABAA alpha-2-beta-3-gamma-2 receptor expressed in Xenopus laevis oocytes by two electrode voltage clamp method relative to GABA,Other,16279764.0,
1916,282669,4,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy at human recombinant GABAA alpha-2-beta-3-gamma-2 receptor expressed in Xenopus laevis oocytes by two electrode voltage clamp method relative to GABA,Other,16279764.0,
1917,282669,4,10,,103164353,3016,Unspecified,126302547.0,2555.0,,,Efficacy at human recombinant GABAA alpha-2-beta-3-gamma-2 receptor expressed in Xenopus laevis oocytes by two electrode voltage clamp method relative to GABA,Other,16279764.0,
1918,282670,3,10,,103164353,3016,Unspecified,120773.0,2562.0,,,Efficacy at human recombinant GABAA alpha-3-beta-3-gamma-2 receptor expressed in Xenopus laevis oocytes by two electrode voltage clamp method relative to GABA,Other,16279764.0,
1919,282670,3,10,,103164353,3016,Unspecified,462149.0,2556.0,,,Efficacy at human recombinant GABAA alpha-3-beta-3-gamma-2 receptor expressed in Xenopus laevis oocytes by two electrode voltage clamp method relative to GABA,Other,16279764.0,
1920,282670,3,10,,103164353,3016,Unspecified,116242488.0,2566.0,,,Efficacy at human recombinant GABAA alpha-3-beta-3-gamma-2 receptor expressed in Xenopus laevis oocytes by two electrode voltage clamp method relative to GABA,Other,16279764.0,
1921,283715,3,3,,103164353,3016,Active,,,,,"Anxiolytic activity of ICR mouse assessed as increase in time spent in open arms at 1.0 mg/kg, ip by EPM test relative to control",Other,17309299.0,
1922,283717,3,3,,103164353,3016,Active,,,,,"Anticonvulsant effect in ICR mouse assessed as mortality protection against pentylenetetrazole-induced seizures at 1.0 mg/kg, ip relative to control",Other,17309299.0,
1923,287755,4,3,,103164353,3016,Active,,,0.01,Ki,Displacement of [3H]flumazenil from bovine brain cortex GABAA/Bz receptor,Confirmatory,17306981.0,
1924,287756,8,5,,103164353,3016,Active,120788.0,29709.0,0.012,Ki,Displacement of [3H]Ro15-1788 from rat recombinant GABA alpha-1-beta-2-gamma-2 receptor expressed in HEK293 cells,Confirmatory,17306981.0,
1925,287756,8,5,,103164353,3016,Active,51317298.0,29705.0,0.012,Ki,Displacement of [3H]Ro15-1788 from rat recombinant GABA alpha-1-beta-2-gamma-2 receptor expressed in HEK293 cells,Confirmatory,17306981.0,
1926,287756,8,5,,103164353,3016,Active,52000957.0,25451.0,0.012,Ki,Displacement of [3H]Ro15-1788 from rat recombinant GABA alpha-1-beta-2-gamma-2 receptor expressed in HEK293 cells,Confirmatory,17306981.0,
1927,287757,8,5,,103164353,3016,Active,120761.0,24947.0,0.013999999999999999,Ki,Displacement of [3H]Ro15-1788 from rat recombinant GABA alpha-3-beta-2-gamma-2 receptor expressed in HEK293 cells,Confirmatory,17306981.0,
1928,287757,8,5,,103164353,3016,Active,120788.0,29709.0,0.013999999999999999,Ki,Displacement of [3H]Ro15-1788 from rat recombinant GABA alpha-3-beta-2-gamma-2 receptor expressed in HEK293 cells,Confirmatory,17306981.0,
1929,287757,8,5,,103164353,3016,Active,52000957.0,25451.0,0.013999999999999999,Ki,Displacement of [3H]Ro15-1788 from rat recombinant GABA alpha-3-beta-2-gamma-2 receptor expressed in HEK293 cells,Confirmatory,17306981.0,
1930,287758,6,2,,103164353,3016,Active,,,0.0098,Ki,Displacement of [3H]Ro-151788 from rat recombinant GABA alpha-5-beta-2-gamma-2 receptor expressed in HEK293 cells,Confirmatory,17306981.0,
1931,287759,3,4,,103164353,3016,Unspecified,,,,,"Effect on motor coordination in CD1 Albino mouse assessed as number of falls in 30 secs at 0.3 mg/kg, po after 30 mins by rotarod test relative to control",Other,17306981.0,
1932,287760,3,4,,103164353,3016,Unspecified,,,,,"Effect on motor coordination in CD1 Albino mouse assessed as number of falls in 30 secs at 1 mg/kg, po after 30 mins by rotarod test relative to control",Other,17306981.0,
1933,287761,3,4,,103164353,3016,Unspecified,,,,,"Effect on motor coordination in CD1 Albino mouse assessed as number of falls in 30 secs at 3 mg/kg, po after 30 mins by rotarod test relative to control",Other,17306981.0,
1934,287765,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizure in CD1 Albino at 0.3 mg/kg, po",Other,17306981.0,
1935,287766,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizure in CD1 Albino mouse at 1 mg/kg, po",Other,17306981.0,
1936,287767,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizure in CD1 Albino mouse at 3 mg/kg, po",Other,17306981.0,
1937,288809,7,1,,103164353,3016,Active,113576.0,213.0,,,Binding affinity to 15 uM human serum albumin at 15 uM,Other,17507228.0,
1938,288810,7,1,,103164353,3016,Active,112877.0,5004.0,,,Binding affinity to human alpha1-acid glycoprotein at 30 uM,Other,17507228.0,
1939,288812,7,1,,103164353,3016,Active,,,,,Binding affinity to human alpha1-acid glycoprotein F1-S variant at 30 uM,Other,17507228.0,
1940,288813,7,1,,103164353,3016,Active,,,,,Binding affinity to human alpha1-acid glycoprotein F1-S variant at 60 uM,Other,17507228.0,
1941,288814,7,1,,103164353,3016,Active,,,,,Binding affinity to human alpha1-acid glycoprotein A variant at 30 uM,Other,17507228.0,
1942,288815,7,1,,103164353,3016,Active,,,,,Binding affinity to human alpha1-acid glycoprotein A variant at 60 uM,Other,17507228.0,
1943,288890,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Swiss Albino mouse assessed as number of punished crossings for 60 secs at 1.25 mg/kg, ip administered 60 mins before the test in four-plate test",Other,17517514.0,
1944,288899,3,3,,103164353,3016,Inconclusive,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 1.25 mg/kg, ip administered 60 mins before the test",Other,17517514.0,
1945,288900,3,3,,103164353,3016,Inconclusive,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 2.5 mg/kg, ip administered 60 mins before the test",Other,17517514.0,
1946,288905,3,3,,103164353,3016,Unspecified,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 1.25 mg/kg, ip administered 60 mins before the test",Other,17517514.0,
1947,288906,3,3,,103164353,3016,Unspecified,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 2.5 mg/kg, ip administered 60 mins before the test",Other,17517514.0,
1948,288911,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Swiss Albino mouse assessed as number of punished crossings for 60 secs at 2.5 mg/kg, ip administered 60 mins before the test in four-plate test",Other,17517514.0,
1949,288912,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Swiss Albino mouse assessed as number of punished crossings for 60 secs at 5 mg/kg, ip administered 60 mins before the test in four-plate test",Other,17517514.0,
1950,288913,3,3,,103164353,3016,Inconclusive,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 5 mg/kg, ip administered 60 mins before the test",Other,17517514.0,
1951,288914,3,3,,103164353,3016,Unspecified,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 5 mg/kg, ip administered 60 mins before the test",Other,17517514.0,
1952,293418,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Swiss Albino mouse assessed as latency at 2 mg/kg, po by PTZ induced seizure test",Other,17189665.0,
1953,293420,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Swiss Albino mouse assessed as mortality at 2 mg/kg, po by PTZ induced seizure test",Other,17189665.0,
1954,293422,3,3,,103164353,3016,Active,,,,,"Anticonvulsant activity in Swiss Albino mouse assessed as latency period at 50 mg/kg, po by PTZ induced seizure test",Other,17189665.0,
1955,293424,3,3,,103164353,3016,Unspecified,,,,,Antianxiety study in Swiss Albino mouse assessed as ratio of number of entreis in open arm to total entries at 2 mg/kg by elevated plus maze test,Other,17189665.0,
1956,293426,3,3,,103164353,3016,Unspecified,,,,,Antianxiety study in Swiss Albino mouse assessed as time spent in open arm at 2 mg/kg by elevated plus maze model,Other,17189665.0,
1957,293428,3,3,,103164353,3016,Unspecified,,,,,Antianxiety study in Swiss Albino mouse assessed as number of rares in close arm at 2 mg/kg by elevated plus maze model,Other,17189665.0,
1958,293430,3,4,,103164353,3016,Unspecified,,,,,Effect on coordination in Swiss Albino mouse at 2 mg/kg by rotarod accelorod test,Other,17189665.0,
1959,293434,3,3,,103164353,3016,Unspecified,,,,,Antianxiety study in Swiss Albino mouse assessed as time spent in close arm at 2 mg/kg by elevated plus maze model,Other,17189665.0,
1960,294268,4,4,,103164353,3016,Active,,,0.0068,Ki,Displacement of [3H]flunitrazepam from benzodiazepine receptor in rat neuronal membranes at 10 uM,Confirmatory,17303289.0,
1961,294270,3,3,,103164353,3016,Unspecified,,,,,Potentiation of GABA-induced current in rat cortical neurons at 10 uM by whole-cell patch clamp technique,Other,17303289.0,
1962,294276,4,3,,103164353,3016,Inconclusive,,,,,Inhibition of voltage dependent sodium current in rat cortical neurons by whole-cell patch clamp technique,Other,17303289.0,
1963,294611,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic-like activity in Swiss Albino mouse at 1.25 mg/kg by four plate test,Other,17321139.0,
1964,294612,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic-like activity in Swiss Albino mouse at 2.5 mg/kg by four plate test,Other,17321139.0,
1965,294613,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic-like activity in Swiss Albino mouse at 5 mg/kg by four plate test,Other,17321139.0,
1966,298031,3,5,,103164353,3016,Unspecified,,,,,"Lipophilicity, log D at pH7.4",Other,17725338.0,
1967,298032,3,3,,103164353,3016,Unspecified,,,,,"Acid dissociation constant, pKa of the compound",Other,17725338.0,
1968,306149,6,2,,103164353,3016,Unspecified,,,300.0,EC50,Inhibition of F1F0-ATPase hydrolysis activity in bovine submitochondrial particles,Confirmatory,17251020.0,
1969,306150,6,2,,103164353,3016,Unspecified,,,210.0,EC50,Inhibition of F1F0-ATPase synthesis activity in bovine submitochondrial particles,Confirmatory,17251020.0,
1970,306151,6,2,,103164353,3016,Unspecified,,,170.0,EC50,Induction of reactive oxygen species response in Ramos cells after 1 hr,Confirmatory,17251020.0,
1971,306152,6,2,,103164353,3016,Unspecified,,,200.0,EC50,Induction of reactive oxygen species response in Jurkat cells after 1 hr,Confirmatory,17251020.0,
1972,306153,6,2,,103164353,3016,Unspecified,,,250.0,EC50,Induction of cell death in Ramos cells after 24 hrs,Confirmatory,17251020.0,
1973,306154,6,2,,103164353,3016,Unspecified,,,170.0,EC50,Induction of cell death in Jurkat cells after 24 hrs,Confirmatory,17251020.0,
1974,308065,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic effect in Albino ICR mouse assessed as time spent on open arms of elevated plus-maze test at 1 mg/ kg, ip",Other,17507222.0,
1975,308067,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic effect in Albino ICR mouse assessed as number of entries in open arms of elevated plus-maze test at 1 mg/kg, ip",Other,17507222.0,
1976,309507,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Swiss Albino mouse assessed as number of punished crossings for 60 secs at 2.5 mg/kg administered 30 mins before the test by four-plate test,Other,17825569.0,
1977,309508,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Swiss Albino mouse assessed as number of punished crossings for 60 secs at 5 mg/kg administered 30 mins before the test by four-plate test,Other,17825569.0,
1978,309510,3,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Swiss Albino mouse assessed as number of punished crossings for 60 secs at 1.25 mg/kg administered 30 mins before the test by four-plate test,Other,17825569.0,
1979,310931,3,4,,103164353,3016,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17300161.0,
1980,310933,3,4,,103164353,3016,Unspecified,,,,,Permeability across PAMPA membrane after 7 hrs,Other,17300161.0,
1981,311367,3,6,,103164353,3016,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
1982,311524,4,3,,103164353,3016,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
1983,318309,5,3,,103164353,3016,Unspecified,,,,,Metabolic stability assessed as half life in rat liver microsomes,Other,18324762.0,
1984,318310,5,4,,103164353,3016,Unspecified,,,,,Metabolic stability assessed as intrinsic body clearance in rat liver microsomes,Other,18324762.0,
1985,327169,3,3,,103164353,3016,Unspecified,,,,,Apparent permeability across parallel artificial membrane,Other,18348514.0,
1986,327170,4,6,,103164353,3016,Active,113576.0,213.0,24.5471,Kd,Binding affinity to human serum albumin by PAMPA method,Confirmatory,18348514.0,
1987,327589,4,4,,103164353,3016,Active,,,0.01,Ki,Displacement of [3H]flumazenil from GABAA/BzR complex in bovine cerebral cortex membrane,Confirmatory,18325771.0,
1988,327591,3,3,,103164353,3016,Unspecified,,,,,"Effect on motor coordination in CD1 Albino mouse assessed as number of falls in 30 secs at 1 mg/kg, ip after 20 mins by rotarod test",Other,18325771.0,
1989,327595,3,3,,103164353,3016,Inactive,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizure in CD1 Albino mouse assessed as shock latency at 1 mg/kg, ip after 20 mins",Other,18325771.0,
1990,327599,3,3,,103164353,3016,Active,,,,,"Sedative activity in CD1 albino mouse assessed as reduction of spontaneous motility at 3 mg/kg, ip after 20 mins by hole-board test",Other,18325771.0,
1991,327600,3,3,,103164353,3016,Active,,,,,"Sedative activity in CD1 albino mouse assessed as reduction of curiosity at 3 mg/kg, ip after 20 mins by hole-board test",Other,18325771.0,
1992,327619,3,3,,103164353,3016,Inactive,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizure in CD1 Albino mouse assessed as convulsant latency at 1 mg/kg, ip after 20 mins",Other,18325771.0,
1993,327623,3,3,,103164353,3016,Active,,,,,"Amnesic activity in CD1 albino mouse at 1 mg/kg, ip",Other,18325771.0,
1994,330911,9,1,,103164353,3016,Unspecified,113576.0,213.0,,,Binding affinity to human serum albumin on sepharose column by affinity chromatography,Other,18289858.0,
1995,340238,4,3,,103164353,3016,Active,,,0.011000000000000001,IC50,Inhibition of central benzodiazepine receptor,Confirmatory,18588282.0,
1996,343089,7,3,,103164353,3016,Active,,,0.036000000000000004,Kd,Binding affinity to GABAA alpha-1-beta-2-gamma-2 receptor,Confirmatory,18537233.0,
1997,343090,7,3,,103164353,3016,Active,,,,Ki,Binding affinity to GABAA alpha-5-beta-2-gamma-2 receptor,Confirmatory,18537233.0,
1998,346025,3,3,,103164353,3016,Unspecified,,,,,Binding affinity to beta cyclodextrin,Other,19056282.0,
1999,346404,6,2,,103164353,3016,Active,,,0.012,IC50,Displacement of radiolabeled Diazepam from central-type benzodiazepine receptor,Confirmatory,18983139.0,
2000,352385,3,4,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in Swiss albino mouse assessed as protection against pentylenetetrazole-induced seizures at 4 mg/kg administered 1 hr before PTZ challenge relative to control,Other,18672315.0,
2001,352387,3,4,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in Swiss albino mouse assessed as duration of pentylenetetrazole-induced seizures at 4 mg/kg administered 1 hr before PTZ challenge,Other,18672315.0,
2002,356502,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 1 mg/kg, po administered 10 mins before test by elevated plus-maze test",Other,14575433.0,
2003,356503,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 1 mg/kg, po administered 10 mins before test assessed per 5 mins by tilting type ambulometer test",Other,14575433.0,
2004,356504,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 1 mg/kg, po for 7 days measured 24 hrs after final drug administration by elevated plus-maze test",Other,14575433.0,
2005,356505,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 1 mg/kg, po for 7 days measured 24 hrs after final drug administration assessed per 5 mins by tilting type ambulometer test",Other,14575433.0,
2006,356530,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in ddY mouse assessed as pentobarbital-induced sleep time at 1 mg/kg, po administered 10 mins before pentobarbital challenge",Other,14575433.0,
2007,356537,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in ddY mouse assessed as number of shuttle per hour at 1 mg/kg, po by discrete shuttle avoidance test",Other,14575433.0,
2008,356538,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in ddY mouse assessed as number of shocks per hour at 1 mg/kg, po by discrete shuttle avoidance test",Other,14575433.0,
2009,365612,3,3,,103164353,3016,Unspecified,,,,,"Toxic myorelaxant activity in CD1 albino mouse assessed as number of falls in 30 secs at 1 mg/kg, ip after 30 mins by rotarod test",Other,18637672.0,
2010,365618,3,3,,103164353,3016,Inactive,,,,,"Anticonvulsant activity in CD1 albino mouse assessed as pentylenetetrazole-induced convulsion latency time at 1 mg/kg, ip",Other,18637672.0,
2011,365619,3,3,,103164353,3016,Inactive,,,,,"Anticonvulsant activity in CD1 albino mouse assessed as pentylenetetrazole-induced death latency time at 1 mg/kg, ip",Other,18637672.0,
2012,365626,3,3,,103164353,3016,Unspecified,,,,,"Antianxiety activity in CD1 albino mouse assessed as number of crosses at 1 mg/kg, ip by light-dark box method",Other,18637672.0,
2013,365627,3,3,,103164353,3016,Unspecified,,,,,"Antianxiety activity in CD1 albino mouse assessed as time spent in light at 1 mg/kg, ip by light-dark box method",Other,18637672.0,
2014,365644,3,3,,103164353,3016,Unspecified,,,,,"Effect on ethanol-induced sleep in CD1 albino mouse assessed as induction time 1 mg/kg, ip",Other,18637672.0,
2015,365645,3,3,,103164353,3016,Unspecified,,,,,"Effect on ethanol-induced sleep in CD1 albino mouse time assessed as endurance time 1 mg/kg, ip",Other,18637672.0,
2016,365922,3,3,,103164353,3016,Unspecified,,,,,"Effect on learning and memory performance in CD1 albino mouse assessed as training session latency at 1 mg/kg, ip by passive avoidance test",Other,18637672.0,
2017,365923,3,3,,103164353,3016,Unspecified,,,,,"Effect on learning and memory performance in CD1 albino mouse assessed as retention session latency at 1 mg/kg, ip by passive avoidance test",Other,18637672.0,
2018,366630,6,2,,103164353,3016,Active,,,0.7,EC50,Displacement of [3H]flunitrazepam from benzodiazepine receptor in rat brain cortex by scintillation counting,Confirmatory,18640843.0,
2019,368136,3,10,,103164353,3016,Active,130253.0,24230.0,,,Displacement of [3H]diazepam from TSPO in Wistar rat brain by scintillation counting,Other,19133775.0,
2020,368137,3,10,,103164353,3016,Active,130253.0,24230.0,,,Displacement of [3H]diazepam from TSPO in Wistar rat kidney by scintillation counting,Other,19133775.0,
2021,368138,3,3,,103164353,3016,Active,,,,,Displacement of [3H]diazepam from central benzodiazepine receptor in Wistar rat brain by scintillation counting,Other,19133775.0,
2022,368139,3,3,,103164353,3016,Active,,,,,Displacement of [3H]diazepam from central benzodiazepine receptor in Wistar rat kidney by scintillation counting,Other,19133775.0,
2023,371496,3,3,,103164353,3016,Unspecified,,,,,"Sedative activity in Swiss mouse assessed as inhibition on spontaneous locomotor activity at 10 mg/kg, po measured for every 5 mins during 60 to 90 mins",Other,18045747.0,
2024,371915,4,3,,103164353,3016,Active,,,0.01,Ki,Displacement of [3H]flumazenil from Benzodiazepine receptor in bovine cerebral cortex membrane,Confirmatory,19469479.0,
2025,371917,8,5,,103164353,3016,Active,51317298.0,29705.0,0.011000000000000001,Ki,Displacement of [3H]flumazenil from rat GABA-A alpha-1-beta-2-gamma-2 receptor expressed in HEK293 cells,Confirmatory,19469479.0,
2026,371918,8,5,,103164353,3016,Active,120758.0,289606.0,0.015,Ki,Displacement of [3H]flumazenil from rat GABA-A alpha-2-beta-2-gamma-2 receptor expressed in HEK293 cells,Confirmatory,19469479.0,
2027,371920,8,5,,103164353,3016,Active,120764.0,29707.0,0.0098,Ki,Displacement of [3H]flumazenil from rat GABA-A alpha-5-beta-3-gamma-2 receptor expressed in HEK293 cells,Confirmatory,19469479.0,
2028,371922,3,10,,103164353,3016,Unspecified,51317298.0,29705.0,,,Agonist activity at rat GABA-A alpha-1-beta-2-gamma-2 receptor expressed in HEK293 cells assessed as increase in 36Cl- influx,Other,19469479.0,
2029,371923,3,10,,103164353,3016,Unspecified,120758.0,289606.0,,,Agonist activity at rat GABA-A alpha-2-beta-2-gamma-2 receptor expressed in HEK293 cells assessed as increase in 36Cl- influx,Other,19469479.0,
2030,371924,3,3,,103164353,3016,Active,,,,,"Anxiolytic effect in CD1 mouse assessed as increase in time spent in white compartment at 1.25 mg/kg, ip by light/dark box test",Other,19469479.0,
2031,371925,3,3,,103164353,3016,Active,,,,,"Anxiolytic effect in CD1 mouse assessed as increase in number of transfers from lit to the dark area at 1.25 mg/kg, ip by light/dark box test",Other,19469479.0,
2032,372157,3,3,,103164353,3016,Unspecified,,,,,"Toxicity in CD1 mouse assessed as sedative effect at 1.25 mg/kg, ip by light/dark box test",Other,19469479.0,
2033,373867,6,3,,103164353,3016,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
2034,377464,3,3,,103164353,3016,Inactive,,,,,Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 0.75 mg/kg after 30 mins in presence of picrotoxin by hole-board assay,Other,15787439.0,
2035,377465,3,3,,103164353,3016,Inactive,,,,,Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 0.75 mg/kg after 30 mins in presence of picrotoxin by hole-board assay,Other,15787439.0,
2036,377469,3,3,,103164353,3016,Active,,,,,Anxiolytic activity against CF1 mouse assessed as increase in time spent in light compartment at 0.85 mg/kg for 5 mins,Other,15787439.0,
2037,377470,3,3,,103164353,3016,Active,,,,,Anxiolytic activity against CF1 mouse assessed as increase in latency to enter in the dark compartment 0.85 mg/kg for 5 mins,Other,15787439.0,
2038,377473,3,3,,103164353,3016,Inactive,,,,,Anxiolytic activity against CF1 mouse assessed as increase in time spent in light compartment at 0.85 mg/kg in presence of picrotoxin for 5 mins,Other,15787439.0,
2039,377474,3,3,,103164353,3016,Inactive,,,,,Anxiolytic activity against CF1 mouse assessed as increase in latency to enter in the dark compartment 0.85 mg/kg in presence of picrotoxin for 5 mins,Other,15787439.0,
2040,377479,3,3,,103164353,3016,Inactive,,,,,Effect on locomotory activity in CF1 mouse assessed as change in spontaneous activity at 3 to 30 mg/kg,Other,15787439.0,
2041,377480,3,3,,103164353,3016,Inactive,,,,,Effect on locomotory activity in CF1 mouse assessed as change in spontaneous activity at 0.75 and 0.85 mg/kg,Other,15787439.0,
2042,377482,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity against CF1 mouse assessed as protection against PTZ-induced convulsions at 0.8 mg/kg, ip for 60 mins",Other,15787439.0,
2043,377483,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity against CF1 mouse assessed as protection against PTZ-induced convulsions at 20 mg/kg, ip for 60 mins",Other,15787439.0,
2044,377496,3,3,,103164353,3016,Unspecified,,,,,Effect on short term memory of CF1 mouse assessed as reduction in latency during aquisition at 0.85 mg/kg by by passive avoidance test,Other,15787439.0,
2045,377504,3,3,,103164353,3016,Unspecified,,,,,Effect on long term memory of CF1 mouse assessed as reduction in latency during aquisition at 0.85 mg/kg by by passive avoidance test,Other,15787439.0,
2046,377508,3,3,,103164353,3016,Unspecified,,,,,Effect on long term memory of CF1 mouse assessed as reduction in step down latency at 0.85 mg/kg by by passive avoidance test,Other,15787439.0,
2047,378496,3,3,,103164353,3016,Inactive,,,,,Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 0.75 mg/kg after 30 mins in presence of picrotoxin by hole-board assay,Other,15787439.0,
2048,378502,3,3,,103164353,3016,Active,,,,,Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 0.75 mg/kg after 30 mins by hole-board assay,Other,15787439.0,
2049,378503,3,3,,103164353,3016,Active,,,,,Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 0.75 mg/kg after 30 mins by hole-board assay,Other,15787439.0,
2050,378504,3,3,,103164353,3016,Active,,,,,Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 0.75 mg/kg after 30 mins by hole-board assay,Other,15787439.0,
2051,378971,3,3,,103164353,3016,Active,,,,,"Anxiolytic effect in ICR mouse assessed as increase in time spent on open arm at 1.0 mg/kg, ip administered 1 hr before by elevated plus-maze test",Other,16441069.0,
2052,378974,3,3,,103164353,3016,Active,,,,,"Anxiolytic effect in ICR mouse assessed as increase in entries of open arm at 1.0 mg/kg, ip administered 1 hr before by elevated plus-maze test",Other,16441069.0,
2053,380160,3,3,,103164353,3016,Inactive,,,,,"Protective effect against amphetamine-induced lethality in mouse at 4 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs",Other,16562831.0,
2054,385606,3,3,,103164353,3016,Unspecified,,,,,Activity of human GABA alpha-1-beta-2-gamma-2S327 receptor in wild type mouse assessed as ethanol induced GABA current,Other,17875639.0,
2055,386623,4,8,,103164353,3016,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
2056,389440,4,4,,103164353,3016,Active,,,0.0212,IC50,Displacement of [3H]flunitrazepam from GABAA benzodiazepine receptor in rat brain membrane,Confirmatory,18829330.0,
2057,389959,5,3,,103164353,3016,Unspecified,,,,,Metabolic stability in Sprague-Dawley rat liver microsomes assessed as half life at 1 uM,Other,18855374.0,
2058,389960,6,2,,103164353,3016,Unspecified,,,,,Metabolic stability in Sprague-Dawley rat liver microsomes assessed as intrinsic clearance per mg of protein at 1 uM,Other,18855374.0,
2059,393947,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Wistar rat assessed as time spent into open arms at 1 mg/kg, ip administered 60 mins before evaluation and measured during 5 mins by elevated plus-maze test",Other,19223188.0,
2060,393950,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Wistar rat assessed as number of entries into open arms at 1 mg/kg, ip administered 60 mins before evaluation and measured during 5 mins by elevated plus-maze test",Other,19223188.0,
2061,393953,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Wistar rat assessed as number of entries into closed arms at 1 mg/kg, ip administered 60 mins before evaluation and measured during 5 mins by elevated plus-maze test",Other,19223188.0,
2062,393956,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Wistar rat assessed as total number of entries at 1 mg/kg, ip administered 60 mins before evaluation and measured during 5 mins by elevated plus-maze test",Other,19223188.0,
2063,395324,3,4,,103164353,3016,Unspecified,,,,,"Lipophilicity, log D at pH 7.4 by liquid chromatography",Other,19256501.0,
2064,395325,3,3,,103164353,3016,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
2065,395327,3,3,,103164353,3016,Unspecified,,,,,"Dissociation constant, pKa by capillary electrophoresis",Other,19256501.0,
2066,399385,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in ddY mouse assessed as time spent in open-sided arms at 1 mg/kg, po administered once daily for 1 day by elevated plus-maze test",Other,9461663.0,
2067,401477,10,1,,103164353,3016,Active,,,0.005,IC50,Displacement of [3H]diazepam from benzodiazepine receptor in rat cerebral cortex membrane,Confirmatory,6330305.0,
2068,407366,9,5,,103164353,3016,Active,119810.0,24360.0,0.531,Ki,Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay,Confirmatory,18533710.0,
2069,407369,9,5,,103164353,3016,Unspecified,119810.0,24360.0,115.0,Ki,Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP low binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay,Confirmatory,18533710.0,
2070,408747,7,7,,103164353,3016,Active,130253.0,24230.0,,IC50,Displacement of [3H]PK11195 from PBR in rat kidney mitochondrial membrane,Confirmatory,18472268.0,
2071,418109,3,8,,103164353,3016,Unspecified,,,,,Activity at GABAA alpha-1-beta-3-gamma-2 receptor expressed in oocytes assessed as stimulation of GABA-induced current at 1 uM relative to control,Other,19275170.0,
2072,418110,3,8,,103164353,3016,Unspecified,,,,,Activity at GABAA alpha-2-beta-3-gamma-2 receptor expressed in oocytes assessed as stimulation of GABA-induced current at 1 uM relative to control,Other,19275170.0,
2073,418111,3,8,,103164353,3016,Unspecified,,,,,Activity at GABAA alpha-3-beta-3-gamma-2 receptor expressed in oocytes assessed as stimulation of GABA-induced current at 1 uM relative to control,Other,19275170.0,
2074,418112,3,8,,103164353,3016,Unspecified,,,,,Activity at GABAA alpha-5-beta-3-gamma-2 receptor expressed in oocytes assessed as stimulation of GABA-induced current at 1 uM relative to control,Other,19275170.0,
2075,419264,3,3,,103164353,3016,Active,,,,,"Anticonvulsant activity against pentylenetetrazole-induced shock in CD1 albino mouse assessed as absence of shocks at 1 mg/kg, ip preincubated for 30 mins before pentylenetetrazole challenge measured for 30 mins",Other,19591485.0,
2076,419268,3,3,,103164353,3016,Active,,,,,"Anticonvulsant activity against pentylenetetrazole-induced convulsions in CD1 albino mouse assessed as absence of convulsions at 1 mg/kg, ip preincubated for 30 mins before pentylenetetrazole challenge measured for 30 mins",Other,19591485.0,
2077,419272,3,3,,103164353,3016,Unspecified,,,,,"Effect on spontaneous motility in CD1 albino mouse assessed as number of movement on plane board at 3 mg/kg, ip after 20 mins by hole-board test",Other,19591485.0,
2078,419278,3,3,,103164353,3016,Unspecified,,,,,"Effect on explorative capacity in CD1 albino mouse assessed as curiosity-related number of head plugging activity on hole at 3 mg/kg, ip after 20 mins by hole-board test",Other,19591485.0,
2079,419293,3,3,,103164353,3016,Inactive,,,,,"Anxiolytic activity in CD1 albino mouse at 1 mg/kg, ip after 20 mins by light/dark box test in presence of flumazenil",Other,19591485.0,
2080,419305,3,3,,103164353,3016,Active,,,,,"Effect on ethanol-induced sleeping time in CD1 albino mouse assessed as increase in duration of loss of righting reflex at 1 mg/kg, ip preincubated 30 mins before ethanol challenge",Other,19591485.0,
2081,421594,3,3,,103164353,3016,Unspecified,,,,,"Effect on motor coordination in CD1 albino mouse assessed as number of falls form rotarod at 1 mg/kg, ip administered 60 mins before test measured for 30 seconds after 30 mins of drug infusion by rotarod test",Other,19591485.0,
2082,425652,7,2,,103164353,3016,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
2083,425653,7,2,,103164353,3016,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
2084,434959,1,1,,85788516,3016,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
2085,444050,7,1,,103164353,3016,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
2086,444051,6,2,,103164353,3016,Unspecified,,,,,Total clearance in human,Other,20070106.0,
2087,444052,6,2,,103164353,3016,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
2088,444053,6,2,,103164353,3016,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
2089,444054,6,1,,103164353,3016,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
2090,444055,3,3,,103164353,3016,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
2091,444056,3,3,,103164353,3016,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
2092,444057,3,3,,103164353,3016,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
2093,444058,6,2,,103164353,3016,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
2094,444876,3,3,,103164353,3016,Unspecified,,,,,"Sedative activity in Swiss mouse assessed as inhibition of spontaneous locomotor activity at 10 mg/kg, po dose measured for every 5 mins upto 90 mins",Other,19913952.0,
2095,448080,3,3,,103164353,3016,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse at 5 mg/kg, ip after 30 mins by photoactometer method",Other,19564060.0,
2096,448081,3,3,,103164353,3016,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse at 5 mg/kg, ip after 60 mins by photoactometer method",Other,19564060.0,
2097,448242,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as protection against PTZ-induced clonic convulsions at 0.5 mg/kg, ip administered after 30 mins PTZ challenge measured for 20 mins",Other,19564060.0,
2098,448243,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as protection against PTZ-induced clonic convulsions at 1 mg/kg, ip administered after 30 mins PTZ challenge measured for 20 mins",Other,19564060.0,
2099,448244,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as protection against PTZ-induced clonic convulsions at 2 mg/kg, ip administered after 30 mins PTZ challenge measured for 20 mins",Other,19564060.0,
2100,448245,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as protection against PTZ-induced clonic convulsions at 2.5 mg/kg, ip administered after 30 mins PTZ challenge measured for 20 mins",Other,19564060.0,
2101,448246,6,2,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in Swiss albino mouse assessed as protection against PTZ-induced clonic convulsions administered after 30 mins PTZ challenge measured for 20 mins,Other,19564060.0,
2102,449467,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Swiss albino mouse assessed as number of punished crossings at 1.25 mg/kg, ip administered 60 mins before test measured for 60s by four plate test",Other,19679379.0,
2103,449468,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Swiss albino mouse assessed as number of punished crossings at 2.5 mg/kg, ip administered 60 mins before test measured for 60s by four plate test",Other,19679379.0,
2104,449469,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Swiss albino mouse assessed as number of punished crossings at 5 mg/kg, ip administered 60 mins before test measured for 60s by four plate test",Other,19679379.0,
2105,449477,3,3,,103164353,3016,Inconclusive,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 1.25 mg/kg, ip administered 60 mins before test measured for 6 mins",Other,19679379.0,
2106,449478,3,3,,103164353,3016,Unspecified,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 1.25 mg/kg, ip administered 60 mins before test measured for 30 mins",Other,19679379.0,
2107,449479,3,3,,103164353,3016,Inconclusive,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 2.5 mg/kg, ip administered 60 mins before test measured for 6 mins",Other,19679379.0,
2108,449539,3,3,,103164353,3016,Unspecified,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 2.5 mg/kg, ip administered 60 mins before test measured for 30 mins",Other,19679379.0,
2109,449540,3,3,,103164353,3016,Inconclusive,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 5 mg/kg, ip administered 60 mins before test measured for 6 mins",Other,19679379.0,
2110,449541,3,3,,103164353,3016,Unspecified,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 5 mg/kg, ip administered 60 mins before test measured for 30 mins",Other,19679379.0,
2111,455986,3,5,,103164353,3016,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
2112,463254,1,1,,26719642,3016,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
2113,463963,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as reduction of supramaximal electroshock-induced hind limb tonic extension response at 5 mg/kg, ip administered 30 mins before SME challenge measured after 1 hr",Other,20034707.0,
2114,463966,3,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as inhibition of isoniazide hydrazone-induced seizure at 5 mg/kg, ip administered 30 mins before isoniazide hydrazone challenge measured after 1 hr",Other,20034707.0,
2115,463967,3,3,,103164353,3016,Unspecified,,,,,Toxicity in ip dosed Swiss albino mouse assessed as decrease in locomotor activity after 30 mins by actophotometer,Other,20034707.0,
2116,463968,3,3,,103164353,3016,Unspecified,,,,,Toxicity in ip dosed Swiss albino mouse assessed as assessed as decrease in fall of time after 30 mins by rotarod test,Other,20034707.0,
2117,467612,3,6,,103164353,3016,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
2118,467613,5,3,,103164353,3016,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
2119,476929,3,3,,103164353,3016,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
2120,476981,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing at 1.25 mg/kg, ip after 60 mins by four-plate test (RVb = 3.5 +/- 0.4)",Other,20060623.0,
2121,476982,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing at 2.5 mg/kg, ip after 60 mins by four-plate test (RVb = 3.5 +/- 0.4)",Other,20060623.0,
2122,476983,3,3,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing at 5 mg/kg, ip after 60 mins by four-plate test (RVb = 3.5 +/- 0.4)",Other,20060623.0,
2123,481439,3,4,,103164353,3016,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
2124,481442,3,6,,103164353,3016,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
2125,485281,1,1,,26719642,3016,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
2126,485290,1,1,,26719642,3016,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2127,485294,1,1,,26719642,3016,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
2128,485297,1,1,,26719642,3016,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
2129,485298,1,1,,26719642,3016,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
2130,485313,1,2,,26719642,3016,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
2131,485314,1,1,,26719642,3016,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
2132,485341,1,1,,26719642,3016,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
2133,485344,1,1,,26719642,3016,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
2134,485347,1,2,,26719642,3016,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
2135,485353,2,1,,26719642,3016,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
2136,485358,1,1,,26719642,3016,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
2137,485364,1,1,,26719642,3016,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
2138,485367,1,2,,26719642,3016,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
2139,488837,1,1,,26719642,3016,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
2140,492947,1,1,,26719642,3016,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
2141,492967,1,2,,99302055,3016,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
2142,493014,1,1,,26719642,3016,Inconclusive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
2143,493017,1,1,,103856624,3016,Active,,2554.0,,,Wombat Data for BeliefDocking,Other,8388472.0,
2144,493056,1,1,,26719642,3016,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
2145,493084,1,1,,26719642,3016,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
2146,493162,1,2,,99302055,3016,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
2147,494430,2,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizure in Wistar rat assessed as shock latency time at 2 mg/kg, ip administered 45 mins before pentylenetetrazole challenge (Rvb = 118 seconds)",Other,20510483.0,
2148,494431,2,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizure in Wistar rat assessed as duration of seizure at 2 mg/kg, ip administered 45 mins before pentylenetetrazole challenge (Rvb = 312 seconds)",Other,20510483.0,
2149,494432,2,3,,103164353,3016,Active,,,,,"Anticonvulsant activity in Wistar rat assessed as protection against pentylenetetrazole-induced seizure at 2 mg/kg, ip administered 45 mins before pentylenetetrazole challenge",Other,20510483.0,
2150,494435,2,4,,103164353,3016,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as reaction time at 2 mg/kg, ip after 0.5 hrs by hotplate method (Rvb = 7.4 seconds)",Other,20510483.0,
2151,494436,2,4,,103164353,3016,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as reaction time at 2 mg/kg, ip after 1 hr by hotplate method (Rvb = 7.5 seconds)",Other,20510483.0,
2152,496764,3,4,,103164353,3016,Active,,,,,Anxiolytic activity in zebrafish assessed as decrease in high intensity light-induced motor behavior at 10 to 100 uM by photomotor response assay,Other,20081854.0,
2153,496768,3,4,,103164353,3016,Inactive,,,,,Anxiolytic activity in zebrafish assessed as decrease in high intensity light-induced motor behavior at <10 uM by photomotor response assay,Other,20081854.0,
2154,496772,2,4,,103164353,3016,Active,,,,,Modulation of neurological behavior in zebrafish assessed as effect on touch response by high-throughput screening,Other,20081854.0,
2155,496817,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
2156,496818,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
2157,496819,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
2158,496820,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
2159,496821,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
2160,496823,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
2161,496824,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
2162,496825,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
2163,496826,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
2164,496827,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
2165,496828,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
2166,496829,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
2167,496830,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
2168,496831,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
2169,496832,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
2170,497005,4,2,,103164353,3016,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
2171,504327,1,1,,26719642,3016,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2172,504332,1,1,,26719642,3016,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2173,504333,1,1,,26719642,3016,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
2174,504651,1,1,,26719642,3016,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
2175,504652,1,1,,26719642,3016,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
2176,504660,1,1,,26719642,3016,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
2177,504810,1,2,,26719642,3016,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2178,504812,1,2,,26719642,3016,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2179,504842,1,1,,26719642,3016,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
2180,537201,2,4,,103164353,3016,Active,,,0.01,Ki,Displacement of [3H]Ro15-1788 from GABA(A) receptor benzodiazepine site in bovine brain membrane,Confirmatory,20939501.0,
2181,537203,2,5,,103164353,3016,Unspecified,,,,,"Toxicity in CD1 albino mouse assessed as number of falls from rod over 30 seconds at 1 mg/kg, ip after 25 mins of drug administration by rotarod test",Other,20939501.0,
2182,537204,2,5,,103164353,3016,Unspecified,,,,,"Toxicity in CD1 albino mouse assessed as number of falls from rod over 30 seconds at 3 mg/kg, ip after 25 mins of drug administration by rotarod test",Other,20939501.0,
2183,537207,2,4,,103164353,3016,Unspecified,,,,,"Toxicity in CD1 albino mouse assessed as myorelaxant activity over 35 mins at 1 mg/kg, ip by grip-strength meter assay",Other,20939501.0,
2184,537208,2,4,,103164353,3016,Unspecified,,,,,"Toxicity in CD1 albino mouse assessed as myorelaxant activity over 35 mins at 3 mg/kg, ip by grip-strength meter assay",Other,20939501.0,
2185,537211,2,4,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in CD1 albino mouse assessed as protection against pentylenetetrazole-induced shock and convulsion at 0.3 mg/kg, ip treated after 30 mins of pentylenetetrazole measured for 30 mins",Other,20939501.0,
2186,537212,2,4,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in CD1 albino mouse assessed as protection against pentylenetetrazole-induced shock and convulsion at 1 mg/kg, ip treated after 30 mins of pentylenetetrazole measured for 30 mins",Other,20939501.0,
2187,537220,2,4,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in CD1 albino mouse assessed as sleeping time at 0.3 mg/kg, ip pretreated 20 mins before test",Other,20939501.0,
2188,537221,2,4,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in CD1 albino mouse assessed as sleeping time at 1 mg/kg, ip pretreated 20 mins before test",Other,20939501.0,
2189,539464,4,2,,103164353,3016,Unspecified,,,,,Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis,Other,21055935.0,
2190,539470,6,1,,103164353,3016,Unspecified,,,,,Solubility of the compound in water,Other,21055935.0,
2191,540209,4,3,,103164353,3016,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2192,540210,4,3,,103164353,3016,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2193,540211,2,5,,103164353,3016,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2194,540212,4,3,,103164353,3016,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2195,540213,4,3,,103164353,3016,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2196,540275,1,1,,26719642,3016,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2197,540277,1,1,,26719642,3016,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2198,545726,2,4,,103164353,3016,Unspecified,,,,,Antianxiety activity in ip dosed Albino mouse assessed as increase in locomotor activity after 30 mins relative to Diazepam,Other,20950897.0,
2199,545727,4,2,,103164353,3016,Unspecified,,,,,Acute toxicity in rat,Other,20950897.0,
2200,548170,2,11,,103164353,3016,Unspecified,27808653.0,2554.0,,,Positive allosteric modulation of human alpha1beta2gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2201,548170,2,11,,103164353,3016,Unspecified,116242488.0,2566.0,,,Positive allosteric modulation of human alpha1beta2gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2202,548170,2,11,,103164353,3016,Unspecified,292495010.0,2561.0,,,Positive allosteric modulation of human alpha1beta2gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2203,548171,2,11,,103164353,3016,Unspecified,120773.0,2562.0,,,Positive allosteric modulation of human alpha2beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2204,548171,2,11,,103164353,3016,Unspecified,116242488.0,2566.0,,,Positive allosteric modulation of human alpha2beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2205,548171,2,11,,103164353,3016,Unspecified,126302547.0,2555.0,,,Positive allosteric modulation of human alpha2beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2206,548172,2,11,,103164353,3016,Unspecified,120773.0,2562.0,,,Positive allosteric modulation of human alpha3beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2207,548172,2,11,,103164353,3016,Unspecified,462149.0,2556.0,,,Positive allosteric modulation of human alpha3beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2208,548172,2,11,,103164353,3016,Unspecified,116242488.0,2566.0,,,Positive allosteric modulation of human alpha3beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2209,548173,2,11,,103164353,3016,Unspecified,120773.0,2562.0,,,Positive allosteric modulation of human alpha5beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2210,548173,2,11,,103164353,3016,Unspecified,399519.0,2558.0,,,Positive allosteric modulation of human alpha5beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2211,548173,2,11,,103164353,3016,Unspecified,116242488.0,2566.0,,,Positive allosteric modulation of human alpha5beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes at 1 uM,Other,20980155.0,
2212,548175,6,5,,103164353,3016,Active,27808653.0,2554.0,0.085,EC50,Binding affinity to human alpha1beta2gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2213,548175,6,5,,103164353,3016,Active,116242488.0,2566.0,0.085,EC50,Binding affinity to human alpha1beta2gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2214,548175,6,5,,103164353,3016,Active,292495010.0,2561.0,0.085,EC50,Binding affinity to human alpha1beta2gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2215,548176,6,5,,103164353,3016,Active,120773.0,2562.0,0.035,EC50,Binding affinity to human alpha2beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2216,548176,6,5,,103164353,3016,Active,116242488.0,2566.0,0.035,EC50,Binding affinity to human alpha2beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2217,548176,6,5,,103164353,3016,Active,126302547.0,2555.0,0.035,EC50,Binding affinity to human alpha2beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2218,548177,6,5,,103164353,3016,Active,120773.0,2562.0,0.131,EC50,Binding affinity to human alpha3beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2219,548177,6,5,,103164353,3016,Active,462149.0,2556.0,0.131,EC50,Binding affinity to human alpha3beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2220,548177,6,5,,103164353,3016,Active,116242488.0,2566.0,0.131,EC50,Binding affinity to human alpha3beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2221,548178,6,5,,103164353,3016,Active,120773.0,2562.0,0.045,EC50,Binding affinity to human alpha5beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2222,548178,6,5,,103164353,3016,Active,399519.0,2558.0,0.045,EC50,Binding affinity to human alpha5beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2223,548178,6,5,,103164353,3016,Active,116242488.0,2566.0,0.045,EC50,Binding affinity to human alpha5beta3gamma2 GABA receptor expressed in Xenopus laevis oocytes,Confirmatory,20980155.0,
2224,566246,2,4,,103164353,3016,Active,,,0.015,IC50,Inhibition of rat central benzodiazepine receptor,Confirmatory,20875743.0,
2225,566783,5,1,,103164353,3016,Unspecified,,,,,Half life in Sprague-Dawley rat liver microsomes by LC-MS/MS analysis,Other,21189020.0,
2226,566784,5,1,,103164353,3016,Unspecified,,,,,Intrinsic clearance in Sprague-Dawley rat liver microsomes after 60 mins by LC-MS/MS analysis,Other,21189020.0,
2227,566785,4,1,,103164353,3016,Inconclusive,,,,,Apparent permeability across human Caco2 cells after 180 mins by LC-MS/MS analysis,Other,21189020.0,
2228,577020,1,3,,103164353,3016,Unspecified,,,,,"Antidepressant activity against Mongolian gerbil assessed as increase in social interaction time at 0.5 mg/kg, ip",Other,21229983.0,
2229,588208,2,3,,103164353,3016,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
2230,588211,2,3,,103164353,3016,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2231,588212,2,3,,103164353,3016,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2232,588213,2,3,,103164353,3016,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2233,588214,2,3,,103164353,3016,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2234,588215,2,3,,103164353,3016,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2235,588216,2,3,,103164353,3016,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2236,588217,2,3,,103164353,3016,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2237,588218,2,3,,103164353,3016,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2238,588219,2,3,,103164353,3016,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2239,588220,2,3,,103164353,3016,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
2240,588342,1,1,,26719642,3016,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2241,592681,1,4,,103164353,3016,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
2242,599144,1,3,,103164353,3016,Unspecified,,,,,"Intrinsic solubility, log 1/S0 of the compound",Other,17574307.0,
2243,602332,1,1,,124893574,3016,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2244,603953,1,3,,103164353,3016,Unspecified,,,,,"In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
2245,604020,1,4,,103164353,3016,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
2246,604021,3,1,,103164353,3016,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
2247,604022,1,4,,103164353,3016,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
2248,604023,1,3,,103164353,3016,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
2249,604024,1,3,,103164353,3016,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
2250,604025,1,4,,103164353,3016,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
2251,604026,1,4,,103164353,3016,Unspecified,,,,,Unbound CSF to plasma concentration ratio in human,Other,19764786.0,
2252,604738,1,9,,103164353,3016,Inactive,113576.0,213.0,,,Displacement of radiolabeled warfarin from human serum albumin site 1 in phosphate buffer at pH 7.4 upto 12 uM by fluorescence spectroscopy,Other,20869876.0,
2253,604739,1,9,,103164353,3016,Active,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from human serum albumin site 2 in phosphate buffer at pH 7.4 upto 12 uM by fluorescence spectroscopy,Other,20869876.0,
2254,604741,1,9,,103164353,3016,Unspecified,113576.0,213.0,,,Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
2255,604742,1,9,,103164353,3016,Unspecified,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
2256,604743,1,9,,103164353,3016,Unspecified,113576.0,213.0,,,Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
2257,604744,1,9,,103164353,3016,Unspecified,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
2258,611348,1,5,,103164353,3016,Unspecified,,,,,Modulation of GABA alpha1beta2gamma2s receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV at 300 nM by two-microelectrode voltage clamp technique relative to GABA,Other,21699169.0,
2259,623669,1,4,,103164353,3016,Unspecified,,,,,"Neurotoxicity in mouse assessed as effect on motor coordination by measuring reduced latency at 10 mg/kg, ip after 40 mins by rotarod test",Other,21939182.0,
2260,623671,1,4,,103164353,3016,Unspecified,,,,,"Neurotoxicity in mouse assessed as effect on motor coordination at 10 mg/kg, ip after 40 mins by open field test",Other,21939182.0,
2261,624030,1,2,,124893574,3016,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2262,624101,1,2,,85788516,3016,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2263,624136,1,1,,85788516,3016,Inactive,208342286.0,7157.0,,,mutant P53 Measured in Biochemical System Using Small Molecule MicroArray - 2077-01_Other_SinglePoint_HTS_Activity,Screening,,
2264,624137,1,1,,85788516,3016,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
2265,624138,1,1,,85788516,3016,Inactive,21618340.0,6774.0,,,SMM STAT-3 Measured in Biochemical System Using Small Molecule MicroArray - 2076-01_Other_SinglePoint_HTS_Activity_Set2,Screening,,
2266,624139,1,1,,85788516,3016,Inactive,34577122.0,4790.0,,,NF-KappaB Measured in Biochemical System Using Small Molecule MicroArray - 2080-01_Other_SinglePoint_HTS_Activity,Screening,,
2267,624141,1,1,,85788516,3016,Inactive,71774083.0,4609.0,,,SMM c-myc Measured in Biochemical System Using Small Molecule MicroArray - 2081-01_Other_SinglePoint_HTS_Activity,Screening,,
2268,624151,1,1,,85788516,3016,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
2269,624156,1,1,,85788516,3016,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
2270,624170,1,1,,124893574,3016,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2271,624172,1,1,,124893574,3016,Inconclusive,1724069.0,2740.0,22.3872,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2272,624173,1,3,,124893574,3016,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2273,624260,1,1,,85788516,3016,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2274,624349,1,2,,92308494,3016,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2275,624647,3,4,,103164353,3016,Unspecified,,,300.0,Ki,Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes,Confirmatory,15781124.0,
2276,624652,3,4,,103164353,3016,Active,,,40.0,Ki,Inhibition of ciramadol glucuronidation by human UGT enzymes from liver microsomes,Confirmatory,15781124.0,
2277,624654,3,4,,103164353,3016,Unspecified,,,180.0,Ki,Inhibition of codeine glucuronidation by human UGT enzymes from liver microsomes,Confirmatory,15781124.0,
2278,624657,3,4,,103164353,3016,Unspecified,,,120.0,Ki,Inhibition of morphine glucuronidation by human UGT enzymes from liver microsomes,Confirmatory,15781124.0,
2279,625144,5,5,,103164353,3016,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2280,625145,4,7,,103164353,3016,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2281,625146,5,5,,103164353,3016,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2282,625147,4,7,,103164353,3016,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2283,625148,4,7,,103164353,3016,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2284,625149,4,7,,103164353,3016,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2285,625150,5,5,,103164353,3016,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2286,625151,4,7,,103164353,3016,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2287,625152,4,7,,103164353,3016,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2288,625153,4,7,,103164353,3016,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2289,625154,4,7,,103164353,3016,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2290,625155,4,7,,103164353,3016,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2291,625156,1,9,,103164353,3016,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
2292,625157,6,2,,103164353,3016,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
2293,625158,3,4,,103164353,3016,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
2294,625159,5,5,,103164353,3016,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
2295,625160,1,9,,103164353,3016,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
2296,625161,4,7,,103164353,3016,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
2297,625162,4,7,,103164353,3016,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2298,625163,4,7,,103164353,3016,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2299,625164,1,6,,103164353,3016,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
2300,625165,3,4,,103164353,3016,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2301,625166,3,4,,103164353,3016,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2302,625167,5,5,,103164353,3016,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
2303,625168,4,7,,103164353,3016,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
2304,625169,1,6,,103164353,3016,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
2305,625170,3,4,,103164353,3016,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
2306,625171,4,7,,103164353,3016,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
2307,625172,4,7,,103164353,3016,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
2308,625173,5,5,,103164353,3016,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
2309,625174,5,5,,103164353,3016,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
2310,625175,5,5,,103164353,3016,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
2311,625176,1,9,,103164353,3016,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
2312,625177,5,5,,103164353,3016,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2313,625178,5,5,,103164353,3016,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2314,625179,1,9,,103164353,3016,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
2315,625180,5,5,,103164353,3016,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2316,625181,5,5,,103164353,3016,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2317,625182,5,5,,103164353,3016,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2318,625183,5,5,,103164353,3016,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
2319,625184,5,5,,103164353,3016,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2320,625185,5,5,,103164353,3016,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2321,625186,5,5,,103164353,3016,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2322,625187,5,5,,103164353,3016,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2323,625188,1,9,,103164353,3016,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
2324,625189,1,7,,103164353,3016,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
2325,625190,4,5,,103164353,3016,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
2326,625191,4,7,,103164353,3016,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2327,625192,4,7,,103164353,3016,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
2328,625193,5,5,,103164353,3016,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
2329,625194,4,7,,103164353,3016,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
2330,625195,4,7,,103164353,3016,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
2331,625196,5,6,,103164353,3016,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
2332,625197,3,4,,103164353,3016,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
2333,625198,4,7,,103164353,3016,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2334,625199,4,7,,103164353,3016,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2335,625200,4,7,,103164353,3016,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2336,625201,4,7,,103164353,3016,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
2337,625202,4,7,,103164353,3016,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
2338,625203,4,7,,103164353,3016,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
2339,625204,4,7,,103164353,3016,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2340,625205,4,7,,103164353,3016,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
2341,625206,4,7,,103164353,3016,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2342,625207,4,7,,103164353,3016,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2343,625208,5,5,,103164353,3016,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2344,625209,4,7,,103164353,3016,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2345,625210,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2346,625211,1,6,,103164353,3016,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2347,625212,3,4,,103164353,3016,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2348,625213,4,7,,103164353,3016,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2349,625214,1,9,,103164353,3016,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2350,625215,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2351,625216,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2352,625217,4,7,,103164353,3016,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2353,625218,4,7,,103164353,3016,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2354,625219,3,4,,103164353,3016,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2355,625220,4,7,,103164353,3016,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2356,625221,4,7,,103164353,3016,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2357,625222,4,7,,103164353,3016,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2358,625223,4,7,,103164353,3016,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2359,625224,3,4,,103164353,3016,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2360,625225,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2361,625226,4,7,,103164353,3016,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2362,625227,4,7,,103164353,3016,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2363,625228,4,7,,103164353,3016,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2364,625229,5,5,,103164353,3016,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2365,625230,1,6,,103164353,3016,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2366,625231,4,7,,103164353,3016,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2367,625232,1,9,,103164353,3016,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2368,625233,4,7,,103164353,3016,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2369,625234,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2370,625235,4,7,,103164353,3016,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2371,625236,5,5,,103164353,3016,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2372,625237,4,7,,103164353,3016,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2373,625238,4,7,,103164353,3016,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2374,625239,4,7,,103164353,3016,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2375,625240,1,9,,103164353,3016,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2376,625241,4,7,,103164353,3016,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2377,625242,4,7,,103164353,3016,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2378,625243,5,5,,103164353,3016,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2379,625244,5,5,,103164353,3016,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2380,625245,5,5,,103164353,3016,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2381,625246,1,9,,103164353,3016,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2382,625247,5,5,,103164353,3016,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2383,625248,5,5,,103164353,3016,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2384,625249,5,5,,103164353,3016,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2385,625250,5,5,,103164353,3016,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2386,625251,5,5,,103164353,3016,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2387,625252,4,7,,103164353,3016,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2388,625253,4,7,,103164353,3016,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2389,625254,4,7,,103164353,3016,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2390,625255,4,7,,103164353,3016,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2391,625256,4,7,,103164353,3016,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2392,625257,4,7,,103164353,3016,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2393,625258,4,7,,103164353,3016,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2394,625259,4,7,,103164353,3016,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2395,625260,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2396,625261,3,4,,103164353,3016,Active,,,0.0288,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2397,625262,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2398,625263,4,7,,103164353,3016,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2399,625264,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2400,625265,1,6,,103164353,3016,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2401,625266,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2402,625267,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2403,625268,4,2,,103164353,3016,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2404,625268,4,2,,103164353,3016,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2405,625268,4,2,,103164353,3016,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2406,625268,4,2,,103164353,3016,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2407,625269,4,7,,103164353,3016,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2408,625270,4,7,,103164353,3016,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2409,625271,5,5,,103164353,3016,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2410,625272,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2411,625273,4,6,,103164353,3016,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2412,625274,1,6,,103164353,3016,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2413,625275,3,4,,103164353,3016,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2414,625279,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2415,625280,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2416,625281,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2417,625282,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2418,625283,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2419,625284,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2420,625285,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2421,625286,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2422,625287,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2423,625288,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2424,625289,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2425,625290,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2426,625291,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2427,625292,1,3,,103164353,3016,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2428,625819,1,3,,103164353,3016,Unspecified,,,,,"Neurotoxicity in Swiss albino CF1 mouse assessed as decrease in locomotor activity at 4 mg/kg, ip after 4 hrs postdose",Other,21930331.0,
2429,625820,1,3,,103164353,3016,Unspecified,,,,,"Neurotoxicity in Swiss albino CF1 mouse assessed as decrease in locomotor activity at 4 mg/kg, ip after 0.5 hrs postdose",Other,21930331.0,
2430,626991,1,3,,103164353,3016,Unspecified,,,,,"Antianxiety activity in mouse assessed as increase in time spent in illuminated area at 1 mg/kg, po by light/dark box test (Rvb = 116.4 +/- 7.5 sec)",Other,21916402.0,
2431,643207,1,4,,103164353,3016,Active,,,,,"Antistress activity in Swiss albino mouse assessed as reversal of immobilization stress-induced decrease in frequency of head dip at 2 mg/kg, ip administered 60 mins before stress induction measured after 10 mins by hole board test",Other,22178092.0,
2432,643210,1,4,,103164353,3016,Active,,,,,"Antistress activity in Swiss albino mouse assessed as reversal of immobilization stress-induced decrease in rearing at 2 mg/kg, ip administered 60 mins before stress induction measured after 10 mins by hole board test",Other,22178092.0,
2433,643215,1,4,,103164353,3016,Active,,,,,"Antistress activity in Swiss albino mouse assessed as reversal of immobilization stress-induced decrease in number of line crossing at 2 mg/kg, ip administered 60 mins before stress induction measured after 10 mins by open field test",Other,22178092.0,
2434,643249,1,4,,103164353,3016,Active,,,,,"Antistress activity in Swiss albino mouse assessed as reversal of immobilization stress-induced decrease in frequency of rearing at 2 mg/kg, ip administered 60 mins before stress induction measured after 10 mins by open field test",Other,22178092.0,
2435,643252,1,4,,103164353,3016,Active,,,,,"Antistress activity in Swiss albino mouse assessed as increase in immobilization stress-induced decrease in non-social behavior at 2 mg/kg, ip administered 60 mins before stress induction measured after 10 mins by open field test",Other,22178092.0,
2436,643255,1,4,,103164353,3016,Active,,,,,"Antistress activity in Swiss albino mouse assessed as reversal of immobilization stress-induced decrease in locomotor activity at 2 mg/kg, ip administered 60 mins before stress induction measured every 5 mins by actophotometer test",Other,22178092.0,
2437,643383,1,6,,103164353,3016,Unspecified,,,,,Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy,Other,22122484.0,
2438,646285,1,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Wistar rat assessed as increase in open arm entries at 5 mg/kg after 5 mins by plus-maze test (Rvb = 26.3 +/- 2.1 %),Other,22277589.0,
2439,646286,1,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Wistar rat assessed as increase in open arm entries at 2.5 mg/kg after 5 mins by plus-maze test (Rvb = 26.3 +/- 2.1 %),Other,22277589.0,
2440,646287,1,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Wistar rat assessed as increase in open arm entries at 1.25 mg/kg after 5 mins by plus-maze test (Rvb = 26.3 +/- 2.1 %),Other,22277589.0,
2441,646295,1,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Wistar rat assessed as increase in time spent in open arms at 5 mg/kg after 5 mins by plus-maze test (Rvb = 13 +/- 2.3 %),Other,22277589.0,
2442,646423,1,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Wistar rat assessed as increase in time spent in open arms at 2.5 mg/kg after 5 mins by plus-maze test (Rvb = 13 +/- 2.3 %),Other,22277589.0,
2443,646424,1,3,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Wistar rat assessed as increase in time spent in open arms at 1.25 mg/kg after 5 mins by plus-maze test (Rvb = 13 +/- 2.3 %),Other,22277589.0,
2444,651548,1,1,,85788516,3016,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2445,651631,4,1,,144206622,3016,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2446,651631,4,1,,144209656,3016,Inconclusive,269849759.0,7157.0,0.1963,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2447,651632,4,1,,144206622,3016,Inconclusive,296439460.0,79915.0,23.7101,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2448,651632,4,1,,144209656,3016,Inconclusive,296439460.0,79915.0,31.1058,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2449,651633,4,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2450,651633,4,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2451,651634,4,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2452,651634,4,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2453,651828,1,2,,92308494,3016,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2454,652048,1,2,,144206622,3016,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2455,652051,1,1,,144206622,3016,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2456,663662,1,2,,103164353,3016,Unspecified,,,,,Neurotoxicity in Swiss albino mouse by rotarod test,Other,22534186.0,
2457,663981,1,2,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss albino mouse assessed as decrease in time of subcutaneous PTZ-induced clonic hind leg extension administered 30 mins before subcutaneous PTZ challenge measured after 0.5 hrs (Rvb = 76.80 +/- 2.41 sec),Other,22534186.0,
2458,667598,1,3,,103164353,3016,Unspecified,,,,,Displacement of [3H]flunitrazepam from benzodiazepine receptor in bovine brain membrane at 1 uM by liquid scintillation counting,Other,22795832.0,
2459,668118,1,3,,103164353,3016,Active,,,,,"Hypnotic activity in po dosed fasted C57BL/6N mouse assessed as decrease in latency of pentobarbital-induced sleep at 2 mg/kg, po administered 45 mins prior to pentobarbital-induction by polysomnographic analysis",Other,22543233.0,
2460,668119,1,3,,103164353,3016,Active,,,,,"Hypnotic activity in po dosed fasted C57BL/6N mouse assessed as decrease in pentobarbital-induced non-rapid eye movement sleep duration at 2 mg/kg, po administered 45 mins prior to pentobarbital-induction by polysomnographic analysis",Other,22543233.0,
2461,668120,1,3,,103164353,3016,Inactive,,,,,"Hypnotic activity in po dosed fasted C57BL/6N mouse assessed as effect on pentobarbital-induced rapid eye movement sleep duration at 2 mg/kg, po administered 45 mins prior to pentobarbital-induction by polysomnographic analysis",Other,22543233.0,
2462,668121,1,3,,103164353,3016,Active,,,,,"Hypnotic activity in po dosed fasted C57BL/6N mouse assessed as increase in pentobarbital-induced non-rapid eye movement sleep duration at 2 mg/kg, po administered 45 mins prior to pentobarbital-induction measured up to 2 hrs by polysomnographic analysis",Other,22543233.0,
2463,668122,1,3,,103164353,3016,Unspecified,,,,,"Hypnotic activity in po dosed fasted C57BL/6N mouse assessed as decrease in mean duration of wakefulness at 2 mg/kg, po administered 45 mins prior to pentobarbital-induction measured up to 3 hrs by polysomnographic analysis relative to vehicle treated control",Other,22543233.0,
2464,668123,1,3,,103164353,3016,Inactive,,,,,"Hypnotic activity in po dosed fasted C57BL/6N mouse assessed as change in pentobarbital-induced non-rapid eye movement sleep duration at 2 mg/kg, po administered 45 mins prior to pentobarbital-induction measured up to 3 hrs by polysomnographic analysis",Other,22543233.0,
2465,668124,1,3,,103164353,3016,Inactive,,,,,"Hypnotic activity in po dosed fasted C57BL/6N mouse assessed as change in pentobarbital-induced rapid eye movement sleep duration at 2 mg/kg, po administered 45 mins prior to pentobarbital-induction measured up to 3 hrs by polysomnographic analysis",Other,22543233.0,
2466,668125,1,3,,103164353,3016,Active,,,,,"Hypnotic activity in po dosed fasted C57BL/6N mouse assessed as decrease in pentobarbital-induced non-rapid eye movement sleep EEG delta activity at 2 mg/kg, po administered 45 mins prior to pentobarbital-induction by polysomnographic analysis",Other,22543233.0,
2467,668126,1,3,,103164353,3016,Inactive,,,,,"Hypnotic activity in fasted C57BL/6N mouse assessed as increase in pentobarbital-induced sleep duration at 0.5 mg/kg, po administered 45 mins prior to pentobarbital-induction coadministered with flumazenil by polysomnographic analysis",Other,22543233.0,
2468,668130,1,3,,103164353,3016,Inactive,,,,,"Hypnotic activity in fasted C57BL/6N mouse assessed as increase in pentobarbital-induced sleep duration at 2 mg/kg, po administered 45 mins prior to pentobarbital-induction coadministered with flumazenil by polysomnographic analysis",Other,22543233.0,
2469,668132,1,3,,103164353,3016,Inactive,,,,,"Hypnotic activity in fasted C57BL/6N mouse assessed as decrease in pentobarbital-induced sleep latency at 2 mg/kg, po administered 45 mins prior to pentobarbital-induction coadministered with flumazenil by polysomnographic analysis",Other,22543233.0,
2470,670591,1,2,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as protection from PTZ-induced seizures at 1 mg/kg, po administered 30 mins before PTZ challenge measured after 30 mins",Other,22704999.0,
2471,678730,1,8,,103164353,3016,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: no change in plasma concentration in mdr1a(-/-) mouse,Other,11181899.0,
2472,678731,1,8,,103164353,3016,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: no change in brain concentration in mdr1a(-/-) mouse,Other,11181899.0,
2473,679279,1,9,,103164353,3016,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (apical to basal ) of Diazepam at 12.1 nM in MDR1-expressing LLC-PK1 cells,Other,11785684.0,
2474,681154,1,8,,103164353,3016,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: cell accumulation in KB-3-1 and KB-V1 cells,Other,11181899.0,
2475,681164,2,8,,103164353,3016,Unspecified,238054374.0,5243.0,72.4,Km,TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells,Confirmatory,11785684.0,
2476,681165,1,8,,103164353,3016,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in mdr1a-expressing LLC-PK1 cell,Other,11181899.0,
2477,681355,1,8,,103164353,3016,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells,Other,11181899.0,
2478,686978,1,1,,144206622,3016,Inconclusive,79154014.0,55775.0,33.4983,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2479,686979,1,1,,144206622,3016,Inconclusive,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2480,699539,1,7,,103164353,3016,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2481,699540,1,7,,103164353,3016,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2482,699541,1,7,,103164353,3016,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2483,701025,1,2,,103164353,3016,Active,,,,,"Anxiolytic effect in mouse assessed as increase in time spent in light compartment at 1 mg/kg, ip by light/dark box test",Other,21751815.0,
2484,701032,1,2,,103164353,3016,Active,,,,,"Myorelaxant activity in mouse assessed as motor coordination measuring number of falls at 1 mg/kg, ip measured for 30 seconds after 45 mins of compound administration by rotarod test",Other,21751815.0,
2485,705095,1,2,,103164353,3016,Active,,,,,Anxiolytic activity in ip dosed Swiss albino mouse pain model after 30 mins by light/dark box test,Other,22094278.0,
2486,705105,1,2,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Swiss albino mouse pain model assessed as protection against intraperitoneally administered pentylenetetrazol-induced seizures at 1 mg/kg, ip after 30 mins",Other,22094278.0,
2487,708769,1,2,,103164353,3016,Inactive,,,,,Anxiolytic activity in ip dosed Swiss albino mouse pain model after 30 mins by light/dark box test in presence of flumazenil,Other,22094278.0,
2488,720516,2,1,,144206622,3016,Active,296439460.0,79915.0,24.6377,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2489,720516,2,1,,144209656,3016,Active,296439460.0,79915.0,53.2322,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2490,720532,1,1,,144206622,3016,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2491,720533,1,1,,144206622,3016,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2492,720552,2,1,,144206622,3016,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2493,720552,2,1,,144209656,3016,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2494,720554,1,3,,92308494,3016,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2495,720634,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2496,720634,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2497,720635,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2498,720635,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2499,720637,2,1,,144206622,3016,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2500,720637,2,1,,144209656,3016,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2501,720641,1,2,,92308494,3016,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2502,720674,2,2,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2503,720674,2,2,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2504,720675,2,2,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2505,720675,2,2,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2506,720678,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2507,720678,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2508,720679,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2509,720679,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2510,720680,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2511,720680,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2512,720681,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2513,720681,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2514,720682,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2515,720682,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2516,720683,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2517,720683,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2518,720684,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2519,720684,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2520,720685,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2521,720685,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2522,720686,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2523,720686,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2524,720687,2,2,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2525,720687,2,2,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2526,720691,4,1,,144206622,3016,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2527,720691,4,1,,144209656,3016,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2528,720692,3,1,,144206622,3016,Active,311348376.0,2908.0,13.4481,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2529,720692,3,1,,144209656,3016,Active,311348376.0,2908.0,27.954,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2530,720693,3,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2531,720693,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2532,720717,1,3,,92308494,3016,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2533,720719,2,1,,144206622,3016,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2534,720719,2,1,,144209656,3016,Inconclusive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2535,720725,2,1,,144206622,3016,Active,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2536,720725,2,1,,144209656,3016,Active,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2537,726252,2,5,,103164353,3016,Active,120773.0,2562.0,0.017,IC50,Binding affinity to human recombinant GABAA alpha5beta3gamma2 expressed in Xenopus laevis oocytes by patch clamp technique,Confirmatory,23121096.0,
2538,726252,2,5,,103164353,3016,Active,399519.0,2558.0,0.017,IC50,Binding affinity to human recombinant GABAA alpha5beta3gamma2 expressed in Xenopus laevis oocytes by patch clamp technique,Confirmatory,23121096.0,
2539,726252,2,5,,103164353,3016,Active,116242488.0,2566.0,0.017,IC50,Binding affinity to human recombinant GABAA alpha5beta3gamma2 expressed in Xenopus laevis oocytes by patch clamp technique,Confirmatory,23121096.0,
2540,733582,1,2,,103164353,3016,Unspecified,,,,,Neurotoxicity in ip dosed mouse assessed as minimum effective dose required to induce motor impairment measured after 4 hrs by Rotarod test,Other,23352511.0,
2541,733583,1,2,,103164353,3016,Unspecified,,,,,Neurotoxicity in ip dosed mouse assessed as minimum effective dose required to induce motor impairment measured after 0.5 hrs by Rotarod test,Other,23352511.0,
2542,733586,1,2,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity against maximal electroshock-induced seizures in NMRI mouse assessed as latency period for the onset of clonus at 10 mg/kg, ip measured after 0.5 hrs by maximal electroshock test (Rvb = 2.18 +/-0.47 secs)",Other,23352511.0,
2543,733945,1,2,,103164353,3016,Active,,,,,"Sedative activity in rat assessed as reduction of D-amphetamine sulfate-induced locomotion at 3 mg/kg, ip administered 20 mins prior to testing measured for 90 mins relative to vehicle-treated control",Other,23218469.0,
2544,733947,1,2,,103164353,3016,Active,,,,,"Anxiolytic activity in rat assessed as increase in time spent in lighted area at 3 mg/kg, ip administered 20 mins prior to testing measured for 30 mins by light/dark cycle test relative to vehicle-treated control",Other,23218469.0,
2545,735821,1,2,,103164353,3016,Unspecified,,,,,"Toxicity in Swiss webster mouse assessed as decrease in time stayed on rotarod at 10 mg/kg, ip measured after 30 mins by rotarod test",Other,23437926.0,
2546,739951,1,2,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in CD1 albino mouse assessed as protection against pentylenetetrazole-induced convulsions at 10 mg/kg, po administered 30 mins prior to pentylenetetrazole challenge measured over 30 mins (Rvb = 7.1%)",Other,23490154.0,
2547,739953,1,2,,103164353,3016,Unspecified,,,,,"Neurotoxicity in CD1 albino mouse assessed as decrease in number of falls from rotating rod at 10 mg/kg, po by rota-rod test relative to control",Other,23490154.0,
2548,739956,1,2,,103164353,3016,Inactive,,,,,"Anxiolytic activity in CD1 albino mouse assessed as increase in time spent in illuminated side at 10 mg/kg, po administered 30 mins prior to testing measured for 5 mins by light-dark box test in presence of flumazenil",Other,23490154.0,
2549,739957,1,2,,103164353,3016,Active,,,,,"Anxiolytic activity in CD1 albino mouse assessed as increase in time spent in illuminated side at 10 mg/kg, po administered 30 mins prior to testing measured for 5 mins by light-dark box test",Other,23490154.0,
2550,743012,3,1,,144206622,3016,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2551,743012,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2552,743014,3,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2553,743014,3,1,,144209656,3016,Inconclusive,,,69.6372,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2554,743015,3,1,,144206622,3016,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2555,743015,3,1,,144209656,3016,Inconclusive,,,69.6372,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2556,743033,3,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2557,743033,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2558,743035,2,1,,144206622,3016,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2559,743035,2,1,,144209656,3016,Active,124375976.0,367.0,15.7197,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2560,743036,2,1,,144206622,3016,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2561,743036,2,1,,144209656,3016,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2562,743040,3,1,,144206622,3016,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2563,743040,3,1,,144209656,3016,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2564,743041,3,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2565,743041,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2566,743042,3,1,,144206622,3016,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2567,743042,3,1,,144209656,3016,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2568,743053,2,1,,144206622,3016,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2569,743053,2,1,,144209656,3016,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2570,743054,2,1,,144206622,3016,Inconclusive,124375976.0,367.0,22.3838,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2571,743054,2,1,,144209656,3016,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2572,743063,2,1,,144206622,3016,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2573,743063,2,1,,144209656,3016,Active,124375976.0,367.0,23.0734,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2574,743064,3,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2575,743064,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2576,743065,3,1,,144206622,3016,Inconclusive,399498506.0,24831.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2577,743065,3,1,,144209656,3016,Inconclusive,399498506.0,24831.0,69.6372,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2578,743066,3,1,,144206622,3016,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2579,743066,3,1,,144209656,3016,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2580,743067,2,1,,144206622,3016,Inconclusive,399498506.0,24831.0,25.1151,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2581,743067,2,1,,144209656,3016,Active,399498506.0,24831.0,69.6372,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2582,743069,2,1,,144206622,3016,Inactive,348019627.0,2099.0,15.089,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2583,743069,2,1,,144209656,3016,Inconclusive,348019627.0,2099.0,4.4304,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2584,743074,2,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2585,743074,2,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2586,743075,2,1,,144206622,3016,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2587,743075,2,1,,144209656,3016,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2588,743077,2,1,,144206622,3016,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2589,743077,2,1,,144209656,3016,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2590,743078,2,1,,144206622,3016,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2591,743078,2,1,,144209656,3016,Inconclusive,348019627.0,2099.0,4.43041,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2592,743079,3,1,,144206622,3016,Inconclusive,348019627.0,2099.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2593,743079,3,1,,144209656,3016,Inconclusive,348019627.0,2099.0,27.7231,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2594,743080,3,1,,144206622,3016,Active,348019627.0,2099.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2595,743080,3,1,,144209656,3016,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2596,743081,3,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2597,743081,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2598,743083,3,1,,144206622,3016,Inactive,119597822.0,1588.0,21.1317,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2599,743083,3,1,,144209656,3016,Inactive,119597822.0,1588.0,6.9637,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2600,743084,3,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2601,743084,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2602,743085,3,1,,144206622,3016,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2603,743085,3,1,,144209656,3016,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2604,743086,3,1,,144206622,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2605,743086,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2606,743091,2,1,,144206622,3016,Active,348019627.0,2099.0,23.7101,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2607,743091,2,1,,144209656,3016,Inconclusive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2608,743094,3,1,,144206622,3016,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2609,743094,3,1,,144209656,3016,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2610,743122,2,1,,144206622,3016,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2611,743122,2,1,,144209656,3016,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2612,743139,2,1,,144206622,3016,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2613,743139,2,1,,144209656,3016,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2614,743140,2,1,,144206622,3016,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2615,743140,2,1,,144209656,3016,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2616,743191,3,1,,144209656,3016,Inconclusive,216409692.0,5468.0,55.7756,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2617,743191,3,1,,170464626,3016,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2618,743194,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2619,743194,3,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2620,743199,2,1,,144209656,3016,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2621,743199,2,1,,170464626,3016,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2622,743202,4,1,,144209656,3016,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2623,743202,4,1,,170464626,3016,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2624,743203,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2625,743203,3,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2626,743209,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2627,743209,3,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2628,743210,4,1,,144209656,3016,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2629,743210,4,1,,170464626,3016,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2630,743211,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2631,743211,3,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2632,743212,3,1,,144209656,3016,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2633,743212,3,1,,170464626,3016,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2634,743213,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2635,743213,3,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2636,743215,3,1,,144209656,3016,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2637,743215,3,1,,170464626,3016,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2638,743217,3,1,,144209656,3016,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2639,743217,3,1,,170464626,3016,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2640,743218,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2641,743218,3,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2642,743219,3,1,,144209656,3016,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2643,743219,3,1,,170464626,3016,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2644,743220,3,1,,144209656,3016,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2645,743220,3,1,,170464626,3016,Inconclusive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2646,743221,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2647,743221,3,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2648,743222,3,1,,144209656,3016,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2649,743222,3,1,,170464626,3016,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2650,743223,3,1,,144209656,3016,Inconclusive,216409708.0,7421.0,7.8785,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2651,743223,3,1,,170464626,3016,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2652,743224,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2653,743224,3,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2654,743225,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2655,743225,3,1,,170464626,3016,Inconclusive,,,0.0952,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2656,743226,2,1,,144209656,3016,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2657,743226,2,1,,170464626,3016,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2658,743227,2,1,,144209656,3016,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2659,743227,2,1,,170464626,3016,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2660,743228,3,1,,144209656,3016,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2661,743228,3,1,,170464626,3016,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2662,743239,2,1,,144209656,3016,Inconclusive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2663,743239,2,1,,170464626,3016,Inconclusive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2664,743240,2,1,,144209656,3016,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2665,743240,2,1,,170464626,3016,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2666,743241,2,1,,144209656,3016,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2667,743241,2,1,,170464626,3016,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2668,743242,2,1,,144209656,3016,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2669,743242,2,1,,170464626,3016,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2670,743244,1,1,,144206622,3016,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2671,743262,1,1,,144206622,3016,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: Hit Validation,Confirmatory,,
2672,743268,1,1,,172080370,3016,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2673,743270,1,1,,172080370,3016,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2674,743271,1,1,,172080370,3016,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2675,743272,1,1,,172080370,3016,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2676,743281,1,1,,46386554,3016,Inactive,1778357.0,22341.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
2677,743281,1,1,,46386554,3016,Inactive,219520294.0,8828.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
2678,749877,1,1,,103164353,3016,Unspecified,,,,,"Neurotoxicity in NMRI mouse assessed as minimal motor impairment at 20 to 100 mg/kg, ip after 4 hrs by rotarod test",Other,23623419.0,
2679,749878,1,1,,103164353,3016,Unspecified,,,,,"Neurotoxicity in NMRI mouse assessed as minimal motor impairment at 20 to 100 mg/kg, ip after 0.5 hrs by rotarod test",Other,23623419.0,
2680,749885,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed NMRI mouse assessed as dose required to cause protection against subcutaneous pentylene tetrazole-induced seizure after 4 hrs,Other,23623419.0,
2681,749886,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed NMRI mouse assessed as dose required to cause protection against subcutaneous pentylene tetrazole-induced seizure after 0.5 hrs,Other,23623419.0,
2682,749887,1,1,,103164353,3016,Inconclusive,,,,,Anticonvulsant activity in ip dosed NMRI mouse assessed as dose required to cause protection against maximal electroshock-induced seizures after 4 hrs,Other,23623419.0,
2683,749888,1,1,,103164353,3016,Inconclusive,,,,,Anticonvulsant activity in ip dosed NMRI mouse assessed as dose required to cause protection against maximal electroshock-induced seizures after 0.5 hrs,Other,23623419.0,
2684,751091,1,1,,103164353,3016,Unspecified,,,,,"Neurotoxicity in Swiss mouse assessed as motor impairment at 5 mg/kg, ip administered 60 mins measured for 1 min by rotarod test",Other,23734744.0,
2685,751680,1,1,,103164353,3016,Active,,,0.016,IC50,Displacement of [3H]Flunitrazepam from central-type GABAA receptor flunitrazepam binding site in Wistar rat brain after 60 mins,Confirmatory,23403082.0,
2686,751745,1,1,,103164353,3016,Unspecified,,,,,Displacement of [3H]Flunitrazepam from central-type GABAA receptor flunitrazepam binding site in Wistar rat brain at 10 uM after 60 mins relative to control,Other,23403082.0,
2687,751896,1,1,,103164353,3016,Active,,,0.0095,IC50,Binding affinity to central BZD receptor (unknown origin) by radioligand displacement assay,Confirmatory,23466604.0,
2688,752257,1,1,,103164353,3016,Active,,,0.11,IC50,Binding affinity to central-type BZD receptor (unknown origin) by radioligand displacement assay,Confirmatory,23582449.0,
2689,764469,1,1,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Wistar albino rat assessed as protection against subcutaneous pentylenetetrazole-induced mortality at 5 mg/kg, ip administered 1 hr prior to pentylenetetrazole challenge measured for 300 secs relative to control",Other,23831812.0,
2690,764472,1,1,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Wistar albino rat assessed as time of onset of subcutaneous pentylenetetrazole-induced clonic convulsion at 5 mg/kg, ip administered 1 hr prior to pentylenetetrazole challenge measured for 300 secs (Rvb = 83 +/- 4 secs)",Other,23831812.0,
2691,772064,1,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in albino mouse assessed as protection against against subcutaneous pentylenetetrazole-induced death measured as mortality at 30 mg/kg, ip after 0.5 hr",Other,,
2692,772065,1,3,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in albino mouse assessed as seizure at 100 mg/kg, ip after 0.5 hr",Other,,
2693,772074,1,3,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed albino mouse assessed as protection against maximal electroshock-induced seizures after 0.5 hr,Other,,
2694,779429,1,1,,103164353,3016,Unspecified,,,,,"Neurotoxicity in ddY mouse assessed as elongation of hexobarbital-induced sleep at 0.3 to 3 mg/kg, po after 1 hr",Other,24050790.0,
2695,779440,1,1,,103164353,3016,Unspecified,,,,,"Neurotoxicity in ddY mouse assessed as reduction in locomotor activity at 3 to 30 mg/kg, po after 1 hr",Other,24050790.0,
2696,779441,1,1,,103164353,3016,Unspecified,,,,,"Neurotoxicity in Wistar rat assessed as memory impairment at 1 to 30 mg/kg, po after 1 hr by passive avoidance test",Other,24050790.0,
2697,779442,1,1,,103164353,3016,Unspecified,,,,,"Neurotoxicity in ddY mouse assessed as motor impairment at 3 to 30 mg/kg, po after 1 hr by horizontal rotarod test",Other,24050790.0,
2698,836334,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/8,Other,,
2699,836335,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/8,Other,,
2700,836336,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/8,Other,,
2701,836337,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/8,Other,,
2702,836338,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/8,Other,,
2703,836339,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/9,Other,,
2704,836340,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/9,Other,,
2705,837018,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/9,Other,,
2706,837019,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/9,Other,,
2707,837020,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/9,Other,,
2708,837021,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/9,Other,,
2709,837022,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/9,Other,,
2710,837023,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/9,Other,,
2711,837024,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/9,Other,,
2712,837025,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/9,Other,,
2713,837026,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/9,Other,,
2714,837027,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/9,Other,,
2715,837028,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/9,Other,,
2716,837029,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/9,Other,,
2717,837030,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/9,Other,,
2718,837031,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/9,Other,,
2719,837032,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/9,Other,,
2720,837033,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/10,Other,,
2721,837034,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/10,Other,,
2722,837035,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/10,Other,,
2723,837036,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/10,Other,,
2724,837037,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/10,Other,,
2725,837038,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/10,Other,,
2726,837039,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/10,Other,,
2727,837040,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/10,Other,,
2728,837041,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/10,Other,,
2729,837042,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/10,Other,,
2730,837043,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/10,Other,,
2731,837044,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/10,Other,,
2732,837045,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/10,Other,,
2733,837046,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/10,Other,,
2734,837047,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/10,Other,,
2735,837048,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/10,Other,,
2736,837049,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/10,Other,,
2737,837050,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/11,Other,,
2738,837051,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/11,Other,,
2739,837052,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/11,Other,,
2740,837053,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/11,Other,,
2741,837054,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/11,Other,,
2742,837055,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/11,Other,,
2743,837056,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/11,Other,,
2744,837057,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/11,Other,,
2745,837058,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/11,Other,,
2746,837092,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/7,Other,,
2747,837093,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/7,Other,,
2748,837094,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/8,Other,,
2749,837095,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/8,Other,,
2750,837096,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/8,Other,,
2751,837097,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/8,Other,,
2752,837098,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/8,Other,,
2753,837099,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/8,Other,,
2754,837100,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/8,Other,,
2755,837101,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/8,Other,,
2756,837102,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/8,Other,,
2757,837103,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/8,Other,,
2758,837104,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/8,Other,,
2759,837105,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/8,Other,,
2760,837106,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/8,Other,,
2761,837782,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/8,Other,,
2762,837783,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/8,Other,,
2763,837784,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/8,Other,,
2764,837785,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/8,Other,,
2765,837786,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/9,Other,,
2766,837787,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/9,Other,,
2767,837788,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/9,Other,,
2768,837789,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/9,Other,,
2769,837790,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/9,Other,,
2770,837791,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/9,Other,,
2771,837792,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/9,Other,,
2772,837793,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/9,Other,,
2773,837794,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/9,Other,,
2774,837795,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/9,Other,,
2775,837796,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/9,Other,,
2776,837797,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/9,Other,,
2777,837798,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/9,Other,,
2778,837799,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/9,Other,,
2779,837800,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/9,Other,,
2780,837801,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/9,Other,,
2781,837802,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/9,Other,,
2782,837803,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/10,Other,,
2783,837804,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/10,Other,,
2784,837805,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/10,Other,,
2785,837806,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/10,Other,,
2786,837807,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/10,Other,,
2787,837808,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/10,Other,,
2788,837809,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/10,Other,,
2789,837810,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/10,Other,,
2790,837811,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/10,Other,,
2791,837812,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/10,Other,,
2792,837813,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/10,Other,,
2793,838985,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/5,Other,,
2794,838986,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/5,Other,,
2795,838987,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/5,Other,,
2796,838988,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/5,Other,,
2797,838989,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/5,Other,,
2798,838990,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/5,Other,,
2799,838991,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/5,Other,,
2800,838992,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/5,Other,,
2801,838993,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/5,Other,,
2802,838994,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/5,Other,,
2803,839669,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/5,Other,,
2804,839670,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/5,Other,,
2805,839671,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/5,Other,,
2806,839672,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/5,Other,,
2807,839673,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/5,Other,,
2808,839895,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/11,Other,,
2809,839896,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/11,Other,,
2810,839897,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/11,Other,,
2811,839898,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/11,Other,,
2812,839899,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/11,Other,,
2813,839900,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/11,Other,,
2814,839901,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/11,Other,,
2815,839902,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/11,Other,,
2816,839903,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/12,Other,,
2817,839904,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/12,Other,,
2818,839905,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/12,Other,,
2819,839906,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/12,Other,,
2820,839907,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/12,Other,,
2821,839908,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/12,Other,,
2822,839909,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/12,Other,,
2823,839910,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/12,Other,,
2824,839911,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/12,Other,,
2825,839912,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/12,Other,,
2826,839913,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/12,Other,,
2827,839914,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/12,Other,,
2828,839915,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/12,Other,,
2829,839916,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/12,Other,,
2830,839917,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/12,Other,,
2831,839918,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/12,Other,,
2832,839919,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/12,Other,,
2833,839920,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/13,Other,,
2834,839921,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/13,Other,,
2835,839922,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/13,Other,,
2836,839923,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/13,Other,,
2837,839924,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/13,Other,,
2838,839925,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/13,Other,,
2839,839926,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/13,Other,,
2840,839927,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/13,Other,,
2841,839928,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/13,Other,,
2842,839929,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/13,Other,,
2843,839930,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/13,Other,,
2844,839931,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/13,Other,,
2845,839932,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/13,Other,,
2846,839933,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/13,Other,,
2847,839934,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/13,Other,,
2848,839935,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/13,Other,,
2849,839936,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/13,Other,,
2850,839976,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/10,Other,,
2851,839977,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/10,Other,,
2852,839978,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/10,Other,,
2853,839979,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/10,Other,,
2854,839980,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/10,Other,,
2855,840608,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/14,Other,,
2856,840609,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/14,Other,,
2857,840610,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/14,Other,,
2858,840611,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/14,Other,,
2859,840612,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/14,Other,,
2860,840653,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/10,Other,,
2861,840654,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/11,Other,,
2862,840655,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/11,Other,,
2863,840656,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/11,Other,,
2864,840657,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/11,Other,,
2865,840658,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/11,Other,,
2866,840659,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/11,Other,,
2867,840660,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/11,Other,,
2868,840661,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/11,Other,,
2869,840662,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/11,Other,,
2870,840663,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/11,Other,,
2871,840664,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/11,Other,,
2872,840665,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/11,Other,,
2873,840666,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/11,Other,,
2874,840667,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/11,Other,,
2875,840668,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/11,Other,,
2876,840669,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/11,Other,,
2877,840670,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/11,Other,,
2878,840671,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/12,Other,,
2879,840672,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/12,Other,,
2880,840673,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/12,Other,,
2881,840674,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/12,Other,,
2882,840675,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/12,Other,,
2883,840676,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/12,Other,,
2884,840677,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/12,Other,,
2885,840678,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/12,Other,,
2886,840679,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/12,Other,,
2887,840680,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/12,Other,,
2888,840681,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/12,Other,,
2889,840682,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/12,Other,,
2890,840683,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/12,Other,,
2891,840684,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/12,Other,,
2892,840685,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/12,Other,,
2893,840686,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/12,Other,,
2894,840687,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/12,Other,,
2895,840688,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/13,Other,,
2896,840689,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/13,Other,,
2897,840690,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/13,Other,,
2898,840691,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/13,Other,,
2899,840692,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/13,Other,,
2900,840693,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/13,Other,,
2901,841223,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/13,Other,,
2902,841224,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/13,Other,,
2903,841225,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/13,Other,,
2904,841226,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/13,Other,,
2905,841227,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/13,Other,,
2906,841228,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/13,Other,,
2907,841229,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/13,Other,,
2908,841230,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/13,Other,,
2909,841231,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/13,Other,,
2910,841232,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/13,Other,,
2911,841908,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/13,Other,,
2912,841909,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/14,Other,,
2913,841910,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/14,Other,,
2914,841911,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/14,Other,,
2915,841912,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/14,Other,,
2916,841913,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/14,Other,,
2917,841914,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/14,Other,,
2918,841915,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/14,Other,,
2919,841916,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/14,Other,,
2920,841917,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/14,Other,,
2921,841918,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/14,Other,,
2922,841919,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/14,Other,,
2923,841920,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/14,Other,,
2924,841921,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/14,Other,,
2925,841922,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/14,Other,,
2926,841923,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/14,Other,,
2927,841924,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/14,Other,,
2928,841925,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/14,Other,,
2929,841926,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/15,Other,,
2930,841927,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/15,Other,,
2931,841928,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/15,Other,,
2932,841929,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/15,Other,,
2933,841930,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/15,Other,,
2934,841931,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/15,Other,,
2935,841932,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/15,Other,,
2936,841933,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/15,Other,,
2937,841934,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/15,Other,,
2938,841935,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/15,Other,,
2939,841936,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/15,Other,,
2940,841937,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/15,Other,,
2941,841938,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/15,Other,,
2942,841939,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/15,Other,,
2943,841940,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/15,Other,,
2944,841941,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/15,Other,,
2945,841942,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/15,Other,,
2946,841943,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/16,Other,,
2947,841944,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/16,Other,,
2948,842774,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/14,Other,,
2949,842775,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/14,Other,,
2950,842776,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/14,Other,,
2951,842777,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/14,Other,,
2952,842778,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/14,Other,,
2953,842779,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/14,Other,,
2954,842780,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/14,Other,,
2955,842781,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/14,Other,,
2956,842782,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/14,Other,,
2957,842783,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/14,Other,,
2958,842784,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/14,Other,,
2959,842785,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/14,Other,,
2960,842786,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/15,Other,,
2961,842787,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/15,Other,,
2962,842788,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/15,Other,,
2963,842789,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/15,Other,,
2964,842790,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/15,Other,,
2965,842791,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/15,Other,,
2966,842792,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/15,Other,,
2967,842793,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/15,Other,,
2968,842794,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/15,Other,,
2969,842795,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/15,Other,,
2970,842796,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/15,Other,,
2971,842797,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/15,Other,,
2972,842798,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/15,Other,,
2973,842799,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/15,Other,,
2974,842800,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/15,Other,,
2975,842801,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/15,Other,,
2976,842802,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/15,Other,,
2977,842803,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/16,Other,,
2978,842804,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/16,Other,,
2979,842805,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/16,Other,,
2980,842806,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/16,Other,,
2981,842807,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/16,Other,,
2982,843482,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/16,Other,,
2983,843483,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/16,Other,,
2984,843484,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/16,Other,,
2985,843485,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/16,Other,,
2986,843486,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/16,Other,,
2987,843487,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/16,Other,,
2988,843488,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/16,Other,,
2989,843489,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/16,Other,,
2990,843490,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/16,Other,,
2991,843491,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/16,Other,,
2992,843492,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/16,Other,,
2993,843493,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/16,Other,,
2994,843494,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/5,Other,,
2995,843495,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/5,Other,,
2996,843959,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/5,Other,,
2997,843960,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/5,Other,,
2998,843961,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/6,Other,,
2999,843962,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/6,Other,,
3000,843963,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/6,Other,,
3001,843964,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/6,Other,,
3002,843965,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/6,Other,,
3003,843966,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/6,Other,,
3004,843967,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/6,Other,,
3005,843968,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/6,Other,,
3006,843969,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/6,Other,,
3007,843970,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/6,Other,,
3008,843971,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/6,Other,,
3009,843972,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/6,Other,,
3010,843973,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/6,Other,,
3011,843974,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/6,Other,,
3012,844646,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/6,Other,,
3013,844647,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/6,Other,,
3014,844648,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/6,Other,,
3015,844649,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/7,Other,,
3016,844650,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/7,Other,,
3017,844651,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/7,Other,,
3018,844652,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/7,Other,,
3019,844653,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/7,Other,,
3020,844654,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/7,Other,,
3021,844655,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/7,Other,,
3022,844656,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/7,Other,,
3023,844657,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/7,Other,,
3024,844658,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/7,Other,,
3025,844659,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/7,Other,,
3026,844660,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/7,Other,,
3027,844661,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 158/7,Other,,
3028,844662,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 158/7,Other,,
3029,844663,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 158/7,Other,,
3030,844664,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 158/7,Other,,
3031,844665,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 158/7,Other,,
3032,844666,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 158/8,Other,,
3033,844667,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 158/8,Other,,
3034,844668,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 158/8,Other,,
3035,844669,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 158/8,Other,,
3036,844670,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 158/8,Other,,
3037,844671,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 158/8,Other,,
3038,844672,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 158/8,Other,,
3039,844673,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 158/8,Other,,
3040,844674,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 158/8,Other,,
3041,844675,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 158/8,Other,,
3042,844676,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 158/8,Other,,
3043,844677,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 158/8,Other,,
3044,844780,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/16,Other,,
3045,844781,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/16,Other,,
3046,844782,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/16,Other,,
3047,844783,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/16,Other,,
3048,844784,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/16,Other,,
3049,844785,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/16,Other,,
3050,844786,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/16,Other,,
3051,844787,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/16,Other,,
3052,844788,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/16,Other,,
3053,844789,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/16,Other,,
3054,844790,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/16,Other,,
3055,844791,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/16,Other,,
3056,844792,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/16,Other,,
3057,844793,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/16,Other,,
3058,844794,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/16,Other,,
3059,845655,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/5,Other,,
3060,845656,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/5,Other,,
3061,845657,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/5,Other,,
3062,845658,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/5,Other,,
3063,845659,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/5,Other,,
3064,845660,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/5,Other,,
3065,845661,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/5,Other,,
3066,845662,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/5,Other,,
3067,845663,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/5,Other,,
3068,845664,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/5,Other,,
3069,845665,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/5,Other,,
3070,845666,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/5,Other,,
3071,845667,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/5,Other,,
3072,845668,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/5,Other,,
3073,845669,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/5,Other,,
3074,845670,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/6,Other,,
3075,845671,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/6,Other,,
3076,845672,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/6,Other,,
3077,845673,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/6,Other,,
3078,845674,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/6,Other,,
3079,845675,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/6,Other,,
3080,845676,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/6,Other,,
3081,845677,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/6,Other,,
3082,846347,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/6,Other,,
3083,846348,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/6,Other,,
3084,846349,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/6,Other,,
3085,846350,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/6,Other,,
3086,846351,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/6,Other,,
3087,846352,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/6,Other,,
3088,846353,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/6,Other,,
3089,846354,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 159/6,Other,,
3090,846355,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 159/6,Other,,
3091,846356,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 159/7,Other,,
3092,846357,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 159/7,Other,,
3093,846358,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 159/7,Other,,
3094,846359,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 159/7,Other,,
3095,846360,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 159/7,Other,,
3096,846361,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 159/7,Other,,
3097,846362,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 159/7,Other,,
3098,846363,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 159/7,Other,,
3099,846364,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 159/7,Other,,
3100,846365,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 159/7,Other,,
3101,846366,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 159/7,Other,,
3102,846367,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 159/7,Other,,
3103,846368,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 159/7,Other,,
3104,846369,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 159/7,Other,,
3105,846370,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 159/7,Other,,
3106,871975,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/12,Other,,
3107,871976,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/12,Other,,
3108,871977,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/13,Other,,
3109,871978,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/13,Other,,
3110,871979,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/13,Other,,
3111,871980,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/13,Other,,
3112,871981,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/13,Other,,
3113,871982,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/13,Other,,
3114,871983,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/13,Other,,
3115,871984,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/13,Other,,
3116,871985,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/13,Other,,
3117,871986,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/13,Other,,
3118,871987,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/13,Other,,
3119,871988,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/13,Other,,
3120,871989,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/13,Other,,
3121,871990,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/13,Other,,
3122,871991,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/13,Other,,
3123,871992,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/13,Other,,
3124,871993,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/13,Other,,
3125,871994,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/13,Other,,
3126,871995,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/13,Other,,
3127,871996,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/13,Other,,
3128,871997,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/13,Other,,
3129,871998,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/14,Other,,
3130,871999,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/14,Other,,
3131,872000,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/14,Other,,
3132,872001,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/14,Other,,
3133,872002,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/14,Other,,
3134,872003,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/14,Other,,
3135,872004,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/14,Other,,
3136,872005,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/14,Other,,
3137,872006,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/14,Other,,
3138,872007,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/14,Other,,
3139,872008,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/14,Other,,
3140,872009,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/14,Other,,
3141,872010,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/14,Other,,
3142,872041,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/9,Other,,
3143,872042,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/9,Other,,
3144,872043,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/9,Other,,
3145,872044,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/9,Other,,
3146,872045,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/9,Other,,
3147,872046,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/9,Other,,
3148,872047,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/9,Other,,
3149,872048,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/9,Other,,
3150,872049,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/9,Other,,
3151,872050,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/9,Other,,
3152,872051,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/9,Other,,
3153,872052,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/9,Other,,
3154,872053,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/9,Other,,
3155,872054,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/10,Other,,
3156,872055,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/10,Other,,
3157,872056,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/10,Other,,
3158,872057,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/10,Other,,
3159,872058,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/10,Other,,
3160,872059,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/10,Other,,
3161,872060,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/10,Other,,
3162,872061,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/10,Other,,
3163,872062,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/10,Other,,
3164,872063,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/10,Other,,
3165,872064,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/10,Other,,
3166,872065,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/10,Other,,
3167,872748,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/10,Other,,
3168,872749,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/10,Other,,
3169,872750,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/10,Other,,
3170,872751,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/10,Other,,
3171,872752,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/10,Other,,
3172,872753,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/10,Other,,
3173,872754,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/10,Other,,
3174,872755,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/10,Other,,
3175,872756,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/10,Other,,
3176,872757,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/11,Other,,
3177,872758,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/11,Other,,
3178,872759,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/11,Other,,
3179,872760,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/11,Other,,
3180,872761,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/11,Other,,
3181,872762,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/11,Other,,
3182,872763,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/11,Other,,
3183,872764,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/11,Other,,
3184,872765,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/11,Other,,
3185,872766,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/11,Other,,
3186,872767,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/11,Other,,
3187,872768,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/11,Other,,
3188,872769,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/11,Other,,
3189,874121,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/5,Other,,
3190,874122,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/5,Other,,
3191,874123,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/5,Other,,
3192,874124,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/5,Other,,
3193,874125,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/5,Other,,
3194,874126,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/5,Other,,
3195,874127,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/5,Other,,
3196,874128,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/5,Other,,
3197,874129,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/5,Other,,
3198,874130,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/5,Other,,
3199,874131,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/5,Other,,
3200,874132,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/5,Other,,
3201,874133,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/6,Other,,
3202,874134,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/6,Other,,
3203,874135,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/6,Other,,
3204,874136,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/6,Other,,
3205,874137,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/6,Other,,
3206,874138,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/6,Other,,
3207,874139,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/6,Other,,
3208,874140,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/6,Other,,
3209,874141,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/6,Other,,
3210,874142,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/6,Other,,
3211,874143,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/6,Other,,
3212,874144,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/6,Other,,
3213,874145,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/6,Other,,
3214,874146,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/6,Other,,
3215,874147,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/6,Other,,
3216,874148,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/6,Other,,
3217,874149,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/6,Other,,
3218,874150,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/6,Other,,
3219,874151,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/6,Other,,
3220,874152,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/6,Other,,
3221,874153,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/6,Other,,
3222,874154,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/7,Other,,
3223,874155,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/7,Other,,
3224,874156,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/7,Other,,
3225,874157,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/7,Other,,
3226,874158,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/7,Other,,
3227,874159,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/7,Other,,
3228,874160,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/7,Other,,
3229,874203,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/14,Other,,
3230,874204,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/14,Other,,
3231,874205,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/14,Other,,
3232,874206,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/14,Other,,
3233,874840,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/7,Other,,
3234,874841,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/7,Other,,
3235,874842,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/7,Other,,
3236,874843,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/7,Other,,
3237,874844,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/7,Other,,
3238,874845,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/7,Other,,
3239,874846,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/7,Other,,
3240,874847,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/7,Other,,
3241,874848,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/7,Other,,
3242,874885,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/14,Other,,
3243,874886,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/14,Other,,
3244,874887,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/14,Other,,
3245,874888,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/14,Other,,
3246,874889,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/15,Other,,
3247,874890,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/15,Other,,
3248,874891,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/15,Other,,
3249,874892,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/15,Other,,
3250,874893,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/15,Other,,
3251,874894,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/15,Other,,
3252,874895,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/15,Other,,
3253,874896,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/15,Other,,
3254,874897,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/15,Other,,
3255,874898,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/15,Other,,
3256,874899,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/15,Other,,
3257,874900,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/15,Other,,
3258,874901,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/15,Other,,
3259,874902,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/15,Other,,
3260,874903,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/15,Other,,
3261,874904,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/15,Other,,
3262,874905,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/15,Other,,
3263,874906,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/15,Other,,
3264,874907,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/15,Other,,
3265,874908,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/15,Other,,
3266,874909,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/15,Other,,
3267,874910,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/16,Other,,
3268,874911,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/16,Other,,
3269,874912,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/16,Other,,
3270,874913,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/16,Other,,
3271,874914,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/16,Other,,
3272,874915,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/16,Other,,
3273,874916,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/16,Other,,
3274,874917,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/16,Other,,
3275,874918,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/16,Other,,
3276,874919,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/16,Other,,
3277,874920,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/16,Other,,
3278,874921,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/16,Other,,
3279,874922,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/16,Other,,
3280,874923,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/16,Other,,
3281,874924,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/16,Other,,
3282,874925,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/16,Other,,
3283,874926,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/16,Other,,
3284,874927,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/16,Other,,
3285,874928,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/16,Other,,
3286,874960,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/11,Other,,
3287,874961,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/11,Other,,
3288,874962,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/11,Other,,
3289,874963,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/11,Other,,
3290,874964,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/11,Other,,
3291,874965,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/11,Other,,
3292,874966,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/11,Other,,
3293,874967,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/11,Other,,
3294,874968,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/12,Other,,
3295,874969,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/12,Other,,
3296,874970,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/12,Other,,
3297,874971,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/12,Other,,
3298,874972,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/12,Other,,
3299,874973,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/12,Other,,
3300,874974,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/12,Other,,
3301,874975,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/12,Other,,
3302,875659,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/12,Other,,
3303,875660,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/12,Other,,
3304,875661,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/12,Other,,
3305,875662,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/12,Other,,
3306,875663,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/12,Other,,
3307,875664,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/12,Other,,
3308,875665,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/12,Other,,
3309,875666,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/12,Other,,
3310,875667,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/12,Other,,
3311,875668,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/12,Other,,
3312,875669,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/12,Other,,
3313,875670,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/12,Other,,
3314,875671,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/12,Other,,
3315,875672,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/13,Other,,
3316,875673,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/13,Other,,
3317,875674,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/13,Other,,
3318,875675,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/13,Other,,
3319,875676,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/13,Other,,
3320,875677,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/13,Other,,
3321,875678,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/13,Other,,
3322,875679,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/13,Other,,
3323,875680,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/13,Other,,
3324,875681,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/13,Other,,
3325,875682,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/13,Other,,
3326,875683,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/13,Other,,
3327,875684,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/13,Other,,
3328,875685,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/13,Other,,
3329,875686,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/13,Other,,
3330,875687,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/13,Other,,
3331,875688,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/13,Other,,
3332,875689,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/13,Other,,
3333,877040,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/7,Other,,
3334,877041,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/7,Other,,
3335,877042,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/7,Other,,
3336,877043,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/7,Other,,
3337,877044,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/7,Other,,
3338,877045,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/8,Other,,
3339,877046,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/8,Other,,
3340,877047,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/8,Other,,
3341,877048,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/8,Other,,
3342,877049,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/8,Other,,
3343,877050,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/8,Other,,
3344,877051,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/8,Other,,
3345,877052,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/8,Other,,
3346,877053,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/8,Other,,
3347,877054,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/8,Other,,
3348,877055,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/8,Other,,
3349,877056,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/8,Other,,
3350,877057,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/8,Other,,
3351,877058,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/8,Other,,
3352,877059,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/8,Other,,
3353,877060,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/8,Other,,
3354,877061,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/8,Other,,
3355,877062,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/8,Other,,
3356,877063,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/8,Other,,
3357,877064,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/8,Other,,
3358,877065,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/8,Other,,
3359,877066,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/9,Other,,
3360,877067,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/9,Other,,
3361,877068,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/9,Other,,
3362,877069,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/9,Other,,
3363,877070,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/9,Other,,
3364,877750,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/9,Other,,
3365,877751,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/9,Other,,
3366,877752,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/9,Other,,
3367,877753,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/9,Other,,
3368,877754,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/9,Other,,
3369,877755,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/9,Other,,
3370,877756,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/9,Other,,
3371,877757,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/9,Other,,
3372,877758,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/9,Other,,
3373,877759,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/9,Other,,
3374,877760,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/9,Other,,
3375,877761,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/9,Other,,
3376,877762,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/9,Other,,
3377,877763,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/9,Other,,
3378,877764,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/9,Other,,
3379,877765,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/9,Other,,
3380,877766,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/10,Other,,
3381,877799,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/16,Other,,
3382,877800,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/16,Other,,
3383,877801,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/5,Other,,
3384,877802,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/5,Other,,
3385,877803,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/5,Other,,
3386,877804,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/5,Other,,
3387,877805,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/5,Other,,
3388,877806,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/5,Other,,
3389,877807,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/5,Other,,
3390,877808,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/5,Other,,
3391,877809,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/5,Other,,
3392,877810,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/5,Other,,
3393,877811,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/5,Other,,
3394,877812,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/5,Other,,
3395,877813,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/5,Other,,
3396,877814,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/5,Other,,
3397,877815,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/5,Other,,
3398,877816,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/5,Other,,
3399,877817,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/5,Other,,
3400,877818,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/5,Other,,
3401,877819,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/5,Other,,
3402,877820,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/5,Other,,
3403,877821,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/5,Other,,
3404,877822,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/6,Other,,
3405,877823,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/6,Other,,
3406,877824,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/6,Other,,
3407,877825,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/6,Other,,
3408,877826,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/6,Other,,
3409,877827,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/6,Other,,
3410,877828,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/6,Other,,
3411,877829,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/6,Other,,
3412,877830,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/6,Other,,
3413,877831,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/6,Other,,
3414,877832,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/6,Other,,
3415,877833,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/6,Other,,
3416,877834,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/6,Other,,
3417,877835,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/6,Other,,
3418,877836,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/6,Other,,
3419,877837,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/6,Other,,
3420,877838,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/6,Other,,
3421,877839,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/6,Other,,
3422,877878,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/13,Other,,
3423,877879,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/13,Other,,
3424,877880,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/13,Other,,
3425,877881,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/14,Other,,
3426,877882,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/14,Other,,
3427,877883,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/14,Other,,
3428,877884,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/14,Other,,
3429,878523,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/6,Other,,
3430,878524,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/6,Other,,
3431,878525,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/6,Other,,
3432,878526,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/7,Other,,
3433,878527,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/7,Other,,
3434,878528,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/7,Other,,
3435,878569,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/14,Other,,
3436,878570,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/14,Other,,
3437,878571,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/14,Other,,
3438,878572,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/14,Other,,
3439,878573,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/14,Other,,
3440,878574,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/14,Other,,
3441,878575,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/14,Other,,
3442,878576,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/14,Other,,
3443,878577,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/14,Other,,
3444,878578,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/14,Other,,
3445,878579,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/14,Other,,
3446,878580,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/14,Other,,
3447,878581,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/14,Other,,
3448,878582,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/14,Other,,
3449,878583,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/14,Other,,
3450,878584,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/14,Other,,
3451,878585,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/14,Other,,
3452,878586,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/15,Other,,
3453,878587,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/15,Other,,
3454,878588,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/15,Other,,
3455,878589,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/15,Other,,
3456,878590,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/15,Other,,
3457,878591,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/15,Other,,
3458,878592,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/15,Other,,
3459,878593,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/15,Other,,
3460,878594,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/15,Other,,
3461,878595,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/15,Other,,
3462,878596,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/15,Other,,
3463,878597,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/15,Other,,
3464,878598,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/15,Other,,
3465,878599,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/15,Other,,
3466,878600,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/15,Other,,
3467,878601,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/15,Other,,
3468,878602,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/15,Other,,
3469,878603,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/15,Other,,
3470,878604,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/15,Other,,
3471,878605,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/15,Other,,
3472,878606,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/15,Other,,
3473,878607,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/16,Other,,
3474,878608,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/16,Other,,
3475,879959,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/10,Other,,
3476,879960,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/10,Other,,
3477,879961,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/10,Other,,
3478,879962,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/10,Other,,
3479,879963,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/10,Other,,
3480,879964,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/10,Other,,
3481,879965,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/10,Other,,
3482,879966,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/10,Other,,
3483,879967,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/10,Other,,
3484,879968,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/10,Other,,
3485,879969,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/10,Other,,
3486,879970,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/10,Other,,
3487,879971,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/10,Other,,
3488,879972,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/10,Other,,
3489,879973,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/10,Other,,
3490,879974,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/10,Other,,
3491,879975,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/10,Other,,
3492,879976,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/10,Other,,
3493,879977,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/10,Other,,
3494,879978,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/10,Other,,
3495,879979,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/11,Other,,
3496,879980,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/11,Other,,
3497,880661,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/11,Other,,
3498,880662,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/11,Other,,
3499,880663,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/11,Other,,
3500,880664,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/11,Other,,
3501,880665,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/11,Other,,
3502,880666,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/11,Other,,
3503,880667,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/11,Other,,
3504,880668,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/11,Other,,
3505,880669,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/11,Other,,
3506,880670,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/11,Other,,
3507,880671,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/11,Other,,
3508,880672,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/11,Other,,
3509,880673,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/11,Other,,
3510,880674,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/11,Other,,
3511,880675,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/11,Other,,
3512,880676,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/11,Other,,
3513,880677,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/11,Other,,
3514,880678,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 158/11,Other,,
3515,880679,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 158/11,Other,,
3516,880680,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/12,Other,,
3517,880681,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/12,Other,,
3518,880682,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/12,Other,,
3519,880683,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/12,Other,,
3520,880684,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/12,Other,,
3521,880685,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/12,Other,,
3522,880686,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/12,Other,,
3523,880718,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/7,Other,,
3524,880719,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/7,Other,,
3525,880720,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/7,Other,,
3526,880721,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/7,Other,,
3527,880722,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/7,Other,,
3528,880723,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/7,Other,,
3529,880724,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/7,Other,,
3530,880725,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/7,Other,,
3531,880726,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/7,Other,,
3532,880727,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/7,Other,,
3533,880728,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/7,Other,,
3534,880729,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/7,Other,,
3535,880730,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/7,Other,,
3536,880731,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/7,Other,,
3537,880732,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/7,Other,,
3538,880733,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/7,Other,,
3539,880734,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/7,Other,,
3540,880735,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/7,Other,,
3541,880736,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/8,Other,,
3542,880737,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/8,Other,,
3543,880738,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/8,Other,,
3544,880739,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/8,Other,,
3545,880740,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/8,Other,,
3546,880741,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/8,Other,,
3547,880742,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/8,Other,,
3548,880743,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/8,Other,,
3549,880744,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/8,Other,,
3550,880745,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/8,Other,,
3551,880746,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/8,Other,,
3552,880747,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/8,Other,,
3553,880748,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/8,Other,,
3554,880749,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/8,Other,,
3555,880750,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/8,Other,,
3556,881433,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/8,Other,,
3557,881434,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/8,Other,,
3558,881435,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/8,Other,,
3559,881436,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/8,Other,,
3560,881437,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/8,Other,,
3561,881438,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/8,Other,,
3562,881439,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 159/9,Other,,
3563,881440,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 159/9,Other,,
3564,881441,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/9,Other,,
3565,881442,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/9,Other,,
3566,881443,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/9,Other,,
3567,881444,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/9,Other,,
3568,881445,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/9,Other,,
3569,881446,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/9,Other,,
3570,881480,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 159/16,Other,,
3571,881481,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 159/16,Other,,
3572,881482,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 159/16,Other,,
3573,881483,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 159/16,Other,,
3574,881484,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 159/16,Other,,
3575,881485,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 159/16,Other,,
3576,881486,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 159/16,Other,,
3577,881487,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 159/16,Other,,
3578,881488,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 159/16,Other,,
3579,881489,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 159/16,Other,,
3580,881490,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 159/16,Other,,
3581,881491,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 159/16,Other,,
3582,881492,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 159/16,Other,,
3583,881493,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 159/16,Other,,
3584,881494,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 159/16,Other,,
3585,881495,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 159/16,Other,,
3586,881496,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 159/16,Other,,
3587,881497,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 159/16,Other,,
3588,881498,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 159/16,Other,,
3589,882837,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 158/5,Other,,
3590,882838,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 158/5,Other,,
3591,882839,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 158/5,Other,,
3592,882840,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 158/5,Other,,
3593,882841,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 158/5,Other,,
3594,882842,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 158/5,Other,,
3595,882843,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 158/5,Other,,
3596,882844,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/5,Other,,
3597,882845,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/5,Other,,
3598,882880,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 158/12,Other,,
3599,882881,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 158/12,Other,,
3600,882882,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 158/12,Other,,
3601,882883,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 158/12,Other,,
3602,882884,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 158/12,Other,,
3603,882885,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 158/12,Other,,
3604,882886,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 158/12,Other,,
3605,882887,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 158/12,Other,,
3606,882888,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 158/12,Other,,
3607,882889,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 158/12,Other,,
3608,882890,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 158/12,Other,,
3609,882891,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 158/12,Other,,
3610,925632,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020617,Other,,
3611,925633,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020617,Other,,
3612,925634,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020617,Other,,
3613,925635,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020617,Other,,
3614,925636,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020617,Other,,
3615,925637,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020617,Other,,
3616,925638,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020617,Other,,
3617,926790,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020617",Other,,
3618,926791,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020617,Other,,
3619,926792,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020617,Other,,
3620,926793,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020617,Other,,
3621,926794,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020617,Other,,
3622,926795,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020617,Other,,
3623,926796,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020617,Other,,
3624,926797,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020617,Other,,
3625,926798,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020617,Other,,
3626,926799,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020617,Other,,
3627,926800,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020617,Other,,
3628,926801,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020617,Other,,
3629,926802,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020617,Other,,
3630,926803,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020617,Other,,
3631,926804,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020617,Other,,
3632,926805,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020617,Other,,
3633,926806,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020617,Other,,
3634,926807,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020617,Other,,
3635,926808,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020617,Other,,
3636,926809,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020617",Other,,
3637,926810,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020617,Other,,
3638,926811,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020617,Other,,
3639,926812,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020617,Other,,
3640,926813,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020617,Other,,
3641,926814,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020617,Other,,
3642,926815,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020617,Other,,
3643,926816,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020617,Other,,
3644,926817,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020617,Other,,
3645,926818,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020617,Other,,
3646,926819,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020617,Other,,
3647,926820,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020617,Other,,
3648,960953,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020617,Other,,
3649,960954,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020617,Other,,
3650,960955,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020617,Other,,
3651,961320,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020617,Other,,
3652,961321,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020617,Other,,
3653,961322,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020617,Other,,
3654,961323,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020617,Other,,
3655,961324,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020617,Other,,
3656,961325,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020617,Other,,
3657,961326,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020617,Other,,
3658,961327,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020617,Other,,
3659,961328,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020617,Other,,
3660,961329,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020617,Other,,
3661,961330,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020617,Other,,
3662,961331,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020617,Other,,
3663,961332,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020617,Other,,
3664,961333,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020617,Other,,
3665,961334,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020617,Other,,
3666,961335,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020617,Other,,
3667,961336,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020617,Other,,
3668,961337,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020617,Other,,
3669,961338,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020617,Other,,
3670,961339,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020617,Other,,
3671,962654,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020617,Other,,
3672,962655,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020617,Other,,
3673,962656,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020617,Other,,
3674,962657,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020617,Other,,
3675,962658,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020617,Other,,
3676,962659,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020617,Other,,
3677,962660,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020617,Other,,
3678,962661,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020617,Other,,
3679,962662,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020617,Other,,
3680,962663,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020617,Other,,
3681,962664,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020617,Other,,
3682,962665,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020617,Other,,
3683,962666,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020617,Other,,
3684,962667,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020617,Other,,
3685,962668,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020617,Other,,
3686,1007192,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S020617,Other,,
3687,1007193,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020617",Other,,
3688,1007194,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020617",Other,,
3689,1007195,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020617",Other,,
3690,1007196,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020617",Other,,
3691,1009063,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020617",Other,,
3692,1009064,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020617",Other,,
3693,1009065,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020617",Other,,
3694,1009066,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S020617",Other,,
3695,1009067,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S020617",Other,,
3696,1009068,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S020617",Other,,
3697,1009069,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S020617",Other,,
3698,1009070,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020617,Other,,
3699,1009651,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020617",Other,,
3700,1009652,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020617,Other,,
3701,1009653,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020617",Other,,
3702,1009654,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020617",Other,,
3703,1009655,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020617",Other,,
3704,1009656,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020617",Other,,
3705,1009657,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020617",Other,,
3706,1009658,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020617",Other,,
3707,1009659,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020617",Other,,
3708,1009660,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020617",Other,,
3709,1009661,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020617",Other,,
3710,1009662,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S020617",Other,,
3711,1009663,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S020617,Other,,
3712,1009664,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020617",Other,,
3713,1009665,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020617",Other,,
3714,1009666,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020617",Other,,
3715,1009667,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020617",Other,,
3716,1009668,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020617",Other,,
3717,1009669,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020617",Other,,
3718,1009670,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020617",Other,,
3719,1009671,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020617",Other,,
3720,1009672,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020617",Other,,
3721,1009673,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020617",Other,,
3722,1009674,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020617",Other,,
3723,1009675,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S020617",Other,,
3724,1009676,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S020617",Other,,
3725,1009677,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S020617",Other,,
3726,1009678,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020617,Other,,
3727,1009679,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020617,Other,,
3728,1009680,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020617",Other,,
3729,1009681,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020617",Other,,
3730,1009682,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020617",Other,,
3731,1011548,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020617",Other,,
3732,1011549,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S020617",Other,,
3733,1011550,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S020617",Other,,
3734,1011551,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S020617",Other,,
3735,1012135,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S020617",Other,,
3736,1012136,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020617,Other,,
3737,1012137,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S020617",Other,,
3738,1012138,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020617",Other,,
3739,1012139,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020617",Other,,
3740,1012140,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020617",Other,,
3741,1012141,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020617",Other,,
3742,1012142,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020617,Other,,
3743,1012143,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020617",Other,,
3744,1012144,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020617",Other,,
3745,1012145,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S020617",Other,,
3746,1012146,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S020617",Other,,
3747,1012147,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020617",Other,,
3748,1012148,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020617",Other,,
3749,1012149,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020617",Other,,
3750,1012150,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020617",Other,,
3751,1012151,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S020617",Other,,
3752,1012152,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S020617",Other,,
3753,1012153,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S020617",Other,,
3754,1012154,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S020617",Other,,
3755,1012155,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S020617",Other,,
3756,1012156,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020617",Other,,
3757,1012157,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020617,Other,,
3758,1012158,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020617",Other,,
3759,1012159,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020617",Other,,
3760,1012160,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S020617",Other,,
3761,1012161,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S020617",Other,,
3762,1012162,1,3,,103164353,3016,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020617,Other,,
3763,1012163,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020617",Other,,
3764,1012164,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020617",Other,,
3765,1012165,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020617",Other,,
3766,1012166,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020617",Other,,
3767,1012167,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020617",Other,,
3768,1012168,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020617",Other,,
3769,1012169,1,3,,103164353,3016,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S020617",Other,,
3770,1049594,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/11,Other,,
3771,1049595,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/11,Other,,
3772,1049875,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/11,Other,,
3773,1049876,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/11,Other,,
3774,1049877,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/11,Other,,
3775,1049878,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/12,Other,,
3776,1049879,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/12,Other,,
3777,1049880,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/12,Other,,
3778,1049881,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/12,Other,,
3779,1049882,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/12,Other,,
3780,1049883,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/13,Other,,
3781,1049884,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/13,Other,,
3782,1049885,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/13,Other,,
3783,1049886,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/13,Other,,
3784,1049887,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/13,Other,,
3785,1049888,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/14,Other,,
3786,1049889,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/14,Other,,
3787,1049890,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/14,Other,,
3788,1049891,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/14,Other,,
3789,1049892,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/14,Other,,
3790,1049893,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/15,Other,,
3791,1049894,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/15,Other,,
3792,1049895,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/15,Other,,
3793,1049896,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/15,Other,,
3794,1049897,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/15,Other,,
3795,1049898,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/16,Other,,
3796,1049899,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/16,Other,,
3797,1049900,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/16,Other,,
3798,1049901,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/16,Other,,
3799,1049902,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/16,Other,,
3800,1051606,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/5,Other,,
3801,1051607,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/5,Other,,
3802,1051608,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/5,Other,,
3803,1051609,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/5,Other,,
3804,1051610,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/5,Other,,
3805,1051611,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/6,Other,,
3806,1051612,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/6,Other,,
3807,1051613,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/6,Other,,
3808,1051614,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/6,Other,,
3809,1051615,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/6,Other,,
3810,1051616,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/7,Other,,
3811,1051617,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/7,Other,,
3812,1051618,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/7,Other,,
3813,1051619,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/7,Other,,
3814,1051870,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/7,Other,,
3815,1051871,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/8,Other,,
3816,1051872,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/8,Other,,
3817,1051873,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/8,Other,,
3818,1051874,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/8,Other,,
3819,1051875,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/8,Other,,
3820,1051876,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/9,Other,,
3821,1051877,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/9,Other,,
3822,1051878,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/9,Other,,
3823,1051879,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/9,Other,,
3824,1051880,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/9,Other,,
3825,1051881,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/10,Other,,
3826,1051882,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/10,Other,,
3827,1051883,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/10,Other,,
3828,1051884,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/10,Other,,
3829,1051885,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/10,Other,,
3830,1051886,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/11,Other,,
3831,1051887,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/11,Other,,
3832,1051888,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/11,Other,,
3833,1051889,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/11,Other,,
3834,1051890,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/11,Other,,
3835,1051891,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/12,Other,,
3836,1051892,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/12,Other,,
3837,1051893,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/12,Other,,
3838,1051894,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/12,Other,,
3839,1051895,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/12,Other,,
3840,1051896,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/13,Other,,
3841,1051897,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/13,Other,,
3842,1051898,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/13,Other,,
3843,1052639,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/13,Other,,
3844,1052640,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/13,Other,,
3845,1052641,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/14,Other,,
3846,1052642,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/14,Other,,
3847,1052643,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/14,Other,,
3848,1052644,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/14,Other,,
3849,1052645,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/14,Other,,
3850,1052646,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/15,Other,,
3851,1052647,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/15,Other,,
3852,1052648,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/15,Other,,
3853,1052926,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/15,Other,,
3854,1052927,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/15,Other,,
3855,1052928,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 158/16,Other,,
3856,1052929,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 158/16,Other,,
3857,1052930,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 158/16,Other,,
3858,1052931,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 158/16,Other,,
3859,1052932,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 158/16,Other,,
3860,1052933,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/5,Other,,
3861,1052934,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/5,Other,,
3862,1052935,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/5,Other,,
3863,1052936,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/5,Other,,
3864,1052937,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/5,Other,,
3865,1052938,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/6,Other,,
3866,1052939,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/6,Other,,
3867,1052940,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/6,Other,,
3868,1052941,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/6,Other,,
3869,1052942,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/6,Other,,
3870,1052943,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/7,Other,,
3871,1052944,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/7,Other,,
3872,1052945,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/7,Other,,
3873,1052946,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/7,Other,,
3874,1052947,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/7,Other,,
3875,1052948,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/8,Other,,
3876,1052949,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/8,Other,,
3877,1052950,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/8,Other,,
3878,1052951,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/8,Other,,
3879,1052952,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/8,Other,,
3880,1052953,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/9,Other,,
3881,1052954,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/9,Other,,
3882,1052955,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/9,Other,,
3883,1052956,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/9,Other,,
3884,1052957,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/9,Other,,
3885,1052958,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 159/10,Other,,
3886,1052959,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 159/10,Other,,
3887,1052960,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 159/10,Other,,
3888,1052961,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 159/10,Other,,
3889,1052962,1,2,,103164353,3016,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 159/10,Other,,
3890,1068425,1,1,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Wistar albino rat assessed as protection against subcutaneous pentylenetetrazole-induced mortality at 5 mg/kg, ip pretreated for 1 hr followed by pentylenetetrazole challenge measured over 300 secs relative to control",Other,24384550.0,
3891,1068427,1,1,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Wistar albino rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures by measuring latency period at 5 mg/kg, ip pretreated for 1 hr followed by pentylenetetrazole challenge measured over 300 secs (Rvb = 72 +/- 2 secs)",Other,24384550.0,
3892,1070095,1,1,,103164353,3016,Unspecified,,,,,Modulation of rat GABAA alpha1beta2gamma2S receptor expressed in Xenopus laevis oocytes assessed as potentiation of EC5 to 10 GABA-induced chloride ion current at holding potential -70 mV at 1 uM by two-microelectrode voltage clamp assay relative to GABA-treated control,Other,24462176.0,
3893,1070525,1,1,,103164353,3016,Unspecified,,,,,Positive allosteric modulation of rat alpha1beta2gamma2S GABAA receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at 1 uM by two-microelectrode voltage clamp electrophysiology relative to control,Other,24571311.0,
3894,1072083,1,1,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in NMRI mouse assessed as pentylenetetrazole-induced clonic seizure threshold at 0.1 mg/kg, ip administered 60 mins before pentylenetetrazole challenge",Other,24530225.0,
3895,1072084,1,1,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in NMRI mouse assessed as pentylenetetrazole-induced clonic seizure threshold at 0.05 mg/kg, ip administered 60 mins before pentylenetetrazole challenge",Other,24530225.0,
3896,1072088,1,1,,103164353,3016,Active,,,,IC50,Displacement of [3H]flumazenil from GABAA/BZD receptor in Sprague-Dawley rat cortical membrane after 35 mins by competition binding assay,Confirmatory,24530225.0,
3897,1079931,1,1,,103164353,3016,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3898,1079932,1,1,,103164353,3016,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3899,1079933,1,1,,103164353,3016,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3900,1079934,1,1,,103164353,3016,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3901,1079935,1,1,,103164353,3016,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3902,1079936,1,1,,103164353,3016,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3903,1079937,1,1,,103164353,3016,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3904,1079938,1,1,,103164353,3016,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3905,1079939,1,1,,103164353,3016,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3906,1079940,1,1,,103164353,3016,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3907,1079941,1,1,,103164353,3016,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3908,1079942,1,1,,103164353,3016,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3909,1079943,1,1,,103164353,3016,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3910,1079944,1,1,,103164353,3016,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3911,1079945,1,1,,103164353,3016,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3912,1079946,1,1,,103164353,3016,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3913,1079947,1,1,,103164353,3016,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3914,1079948,1,1,,103164353,3016,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3915,1079949,1,1,,103164353,3016,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3916,1083853,2,1,,103164353,3016,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,,
3917,1083854,1,2,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures administered 1 hr before pentylenetetrazole challenge measured after 30 min,Other,,
3918,1083856,1,2,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures at 3 mg/kg, ip administered 1 hr before pentylenetetrazole challenge measured after 30 min",Other,,
3919,1083859,1,2,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures at 2 mg/kg, ip administered 1 hr before pentylenetetrazole challenge measured after 30 min",Other,,
3920,1083862,1,2,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures at 1 mg/kg, ip administered 1 hr before pentylenetetrazole challenge measured after 30 min",Other,,
3921,1085323,1,2,,103164353,3016,Unspecified,,,,,"Neurotoxicity in Mus musculus Swiss albino (mouse) assessed as motor impairment at 600 mg/kg, ip measured for 1 min by rotarod test",Other,,
3922,1085324,1,2,,103164353,3016,Unspecified,,,,,"Neurotoxicity in Mus musculus Swiss albino (mouse) assessed as motor impairment at 100 mg/kg, ip measured for 1 min by rotarod test",Other,,
3923,1085330,1,2,,103164353,3016,Active,,,,,"Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced clonic spasms at 30 mg/kg, ip after 4 hr post compound treatment",Other,,
3924,1085331,1,2,,103164353,3016,Active,,,,,"Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced clonic spasms at 30 mg/kg, ip after 0.5 hr post compound treatment",Other,,
3925,1086726,1,2,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Mus musculus Swiss albino (mouse) assessed as increase in time spent in light zone at 2 mg/kg, po administered 1 hr prior to testing measured for 5 min by light-dark test (Rvb = 64 +/- 4.02 secs)",Other,,
3926,1086730,1,2,,103164353,3016,Active,,,,,"Anxiolytic activity in Mus musculus Swiss albino (mouse) assessed as increase in ambulation at 2 mg/kg, po administered 45 min prior to testing measured for 5 min by open-field test relative to control",Other,,
3927,1086734,1,2,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Mus musculus Swiss albino (mouse) assessed as time spent in neutral zone at 2 mg/kg, po administered 1 hr prior to testing measured for 5 min by plus-maze test (Rvb = 70 +/- 5.63 secs)",Other,,
3928,1086737,1,2,,103164353,3016,Unspecified,,,,,"Anxiolytic activity in Mus musculus Swiss albino (mouse) assessed as increase in time spent in open arms at 2 mg/kg, po administered 1 hr prior to testing measured for 5 min by plus-maze test (Rvb = 23 +/- 1.63 secs)",Other,,
3929,1093609,1,4,,103164353,3016,Active,21362409.0,100033901.0,,,Reversible mixed-type inhibition of Equus caballus (horse) serum butyrylcholinesterase (BChE) assessed as inhibition of BTCh hydrolysis by Ellman method,Other,,
3930,1093610,1,4,,103164353,3016,Active,14916521.0,,,,Reversible mixed-type inhibition of Electrophorus electricus (electric eel) acetylcholinesterase (AChE) assessed as inhibition of ATCh hydrolysis by Ellman method,Other,,
3931,1093611,4,2,,103164353,3016,Active,21362409.0,100033901.0,0.043,Ki,Inhibition of Equus caballus (horse) serum butyrylcholinesterase (BChE) assessed as inhibition of BTCh hydrolysis by Ellman method,Confirmatory,,
3932,1093612,4,2,,103164353,3016,Active,14916521.0,,13.0,Ki,Inhibition of Electrophorus electricus (electric eel) acetylcholinesterase (AChE) assessed as inhibition of ATCh hydrolysis by Ellman method,Confirmatory,,
3933,1094547,1,2,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Mus musculus Swiss albino (mouse) assessed as time spent in light chamber at 2 mg/kg by light-dark box test,Other,,
3934,1094549,1,2,,103164353,3016,Unspecified,,,,,Anxiolytic activity in Mus musculus Swiss albino (mouse) assessed as time spent in open arm by elevated plus maze test,Other,,
3935,1094550,1,2,,103164353,3016,Unspecified,,,,,"Toxicity in Mus musculus Swiss albino (mouse) assessed as mortality at 4 mg/kg, po",Other,,
3936,1094552,1,2,,103164353,3016,Active,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizures in Mus musculus Swiss albino (mouse) assessed as onset of seizures at 4 mg/kg, po administered 1 hr prior challenge",Other,,
3937,1095455,1,2,,103164353,3016,Active,,,,,"Anticonvulsant activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of pentyleneterazole-induced colonic convulsion measured as onset of convulsion at 4 mg/kg, ip pretreated 30 min prior to pentylenetetrazole challenge",Other,,
3938,1095457,1,2,,103164353,3016,Active,,,,,"Anticonvulsant activity in Rattus norvegicus Wistar albino (rat) assessed as reduction in pentyleneterazole-induced mortality at 4 mg/kg, ip pretreated 30 min prior to pentylenetetrazole challenge",Other,,
3939,1095467,1,2,,103164353,3016,Unspecified,,,,,"Analgesic activity in Mus musculus Swiss (mouse) assessed as time spent in light chamber at 2 mg/kg, ip measured after 30 min by light and dark model test (Rvb = 130.2 +/- 0.01 sec)",Other,,
3940,1097336,1,3,,103164353,3016,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
3941,1106495,1,2,,103164353,3016,Unspecified,,,,,"Anticonvulsant activity in Mus musculus albino (mouse) assessed as protection against PTZ-induced clonic convulsion at 2 mg/kg, ip administered 30 min prior to PTZ-challenge relative to control",Other,,
3942,1117298,1,2,,170464626,3016,Inactive,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3943,1117304,1,2,,170464626,3016,Active,,,25.1189,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3944,1117305,1,2,,170464626,3016,Inactive,,,35.4813,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3945,1117310,1,1,,170464626,3016,Inactive,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3946,1117312,1,1,,170464626,3016,Active,,,35.4813,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3947,1117314,1,1,,170464626,3016,Inactive,,,25.1189,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3948,1117319,1,2,,26719642,3016,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3949,1117319,1,2,,26719642,3016,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3950,1123418,1,1,,103164353,3016,Unspecified,,,,,Induction of muscle relaxation/sedation in po dosed mouse by inclined screen test,Other,34039.0,
3951,1123419,1,1,,103164353,3016,Unspecified,,,,,Induction of taming effect in po dosed mouse by foot shock method,Other,34039.0,
3952,1123420,1,1,,103164353,3016,Unspecified,,,,,Muscle relaxing activity in po dosed cat,Other,34039.0,
3953,1123421,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as reduction of pentylenetetrazole-induced seizures,Other,34039.0,
3954,1123422,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as reduction of maximal electroshock-induced seizures,Other,34039.0,
3955,1123423,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as reduction of minimal electroshock-induced seizures,Other,34039.0,
3956,1128799,1,3,,103164353,3016,Unspecified,113576.0,213.0,,,Binding affinity to human serum albumin at 30 uM by HPLC analysis,Other,24568674.0,
3957,1128800,1,3,,103164353,3016,Unspecified,124028612.0,24186.0,,,Binding affinity to rat serum albumin at 30 uM by HPLC analysis,Other,24568674.0,
3958,1128801,1,3,,103164353,3016,Unspecified,113576.0,213.0,,,Binding affinity to human serum albumin,Other,24568674.0,
3959,1129361,1,1,,103164353,3016,Unspecified,,,,,Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis,Other,24601604.0,
3960,1130718,1,1,,103164353,3016,Unspecified,,,,,"Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for anticonvulsant activity in po dosed albino Swiss-Webster mouse assessed as reduction of pentylenetetrazole-induced seizure",Other,490555.0,
3961,1130720,1,1,,103164353,3016,Unspecified,,,,,"Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for anticonvulsant activity in po dosed albino Swiss-Webster mouse assessed as reduction of maximum electro shock-induced seizure",Other,490555.0,
3962,1130721,1,1,,103164353,3016,Unspecified,,,,,"Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for anticonvulsant activity in po dosed albino Swiss-Webster mouse assessed as reduction of minimum electro shock-induced seizure",Other,490555.0,
3963,1130724,1,1,,103164353,3016,Unspecified,,,,,"Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for muscle relaxing activity in po dosed albino Swiss-Webster mouse",Other,490555.0,
3964,1130726,1,1,,103164353,3016,Unspecified,,,,,"Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for behavioral activity in po dosed albino Swiss-Webster mouse by fighting test",Other,490555.0,
3965,1130727,1,1,,103164353,3016,Unspecified,,,,,"Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for hypnotic activity in po dosed albino Swiss-Webster mouse",Other,490555.0,
3966,1130728,1,1,,103164353,3016,Unspecified,,,,,Toxicity in po dosed albino Swiss-Webster mouse,Other,490555.0,
3967,1130729,2,1,,103164353,3016,Unspecified,,,,,"1-Octanol-aqueous phosphate buffer partition coefficient, log P of the compound at pH 7.35",Other,490555.0,
3968,1132355,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed ddY mouse assessed as reduction of pentylenetetrazole-induced seizure,Other,628001.0,
3969,1132356,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed ddY mouse assessed as reduction of maximal electroshock-induced seizure,Other,628001.0,
3970,1132357,1,1,,103164353,3016,Unspecified,,,,,Taming activity in po dosed electrofootshock-induced fighting ddY mouse,Other,628001.0,
3971,1132358,1,1,,103164353,3016,Unspecified,,,,,Muscle relaxant activity in po dosed ddY mouse,Other,628001.0,
3972,1132359,1,1,,103164353,3016,Unspecified,,,,,Toxicity in po dosed ddY mouse assessed as motor incoordination by rotarod test,Other,628001.0,
3973,1132360,1,1,,103164353,3016,Unspecified,,,,,Induction of sedative activity in po dosed ddY mouse assessed as potentiation of thiopental-induced response,Other,628001.0,
3974,1135124,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed rat assessed as impairment of motor performance by forced motor activity test,Other,15111.0,
3975,1135125,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed rat assessed as impairment of motor performance by spontaneous motor activity test,Other,15111.0,
3976,1135126,1,1,,103164353,3016,Unspecified,,,,,Analgesic activity in po dosed mouse assessed as potentiation of ethanol-induced loss of the righting reflex in 50% mouse,Other,15111.0,
3977,1135127,1,1,,103164353,3016,Unspecified,,,,,Analgesic activity in po dosed mouse assessed as potentiation of sodium barbital-induced loss of the righting reflex in 50% mouse,Other,15111.0,
3978,1135128,1,1,,103164353,3016,Unspecified,,,,,Antipsychotic activity in ip dosed rat assessed as reduction in avoidance responding by Sidman avoidance test,Other,15111.0,
3979,1135129,1,1,,103164353,3016,Unspecified,,,,,Antianxiety activity in ip dosed rat assessed as punished responding by conditioned lick suppression behavioral test,Other,15111.0,
3980,1135130,1,1,,103164353,3016,Unspecified,,,,,Antianxiety activity in po dosed rat assessed as punished responding by conditioned lick suppression behavioral test,Other,15111.0,
3981,1135133,1,1,,103164353,3016,Unspecified,,,,,Acute toxicity in mouse measured following single po dose,Other,15111.0,
3982,1135134,1,1,,103164353,3016,Unspecified,,,,,Acute toxicity in mouse measured following single ip dose,Other,15111.0,
3983,1135139,1,1,,103164353,3016,Unspecified,,,,,"Antiaggressive activity in mouse assessed as change in foot shock-induced fighting behavior at 5 mg/kg, po after 30 mins",Other,15111.0,
3984,1135140,1,1,,103164353,3016,Unspecified,,,,,"Antiaggressive activity in mouse assessed as change in foot shock-induced fighting behavior at 5 mg/kg, po after 90 mins",Other,15111.0,
3985,1135144,1,1,,103164353,3016,Inactive,,,,,"Antiaggressive activity in Rhesus monkey assessed as reduction in biting, pushing or attacking the pole responses at 2.5 to 10 mg/mg, po after 0 to 6 hrs",Other,15111.0,
3986,1135312,1,1,,103164353,3016,Unspecified,,,,,Acute toxicity in po dosed mouse,Other,17746.0,
3987,1135313,1,1,,103164353,3016,Unspecified,,,,,Antianxiety activity in po dosed mouse assessed as muscle relaxation by rotarod test,Other,17746.0,
3988,1135314,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed mouse by maximal electroshock test,Other,17746.0,
3989,1135315,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as inhibition of pentylene-tetrazole-induced convulsion,Other,17746.0,
3990,1136110,1,1,,103164353,3016,Unspecified,,,,,Sedative activity in ip dosed CF-1 albino mouse assessed as muscle relaxation by measuring depression of traction,Other,27634.0,
3991,1136112,1,1,,103164353,3016,Unspecified,,,,,Muscle relaxing activity in ip dosed CF-1 albino mouse assessed as depression of dish reflexes,Other,27634.0,
3992,1136113,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed CF-1 albino mouse assessed as antagonism of nicotine-induced tonic extensor convulsions,Other,27634.0,
3993,1136114,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed CF-1 albino mouse assessed as antagonism of nicotine-induced death,Other,27634.0,
3994,1136115,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed CF-1 albino mouse assessed as antagonism of thiosemicarbazide-induced lethality,Other,27634.0,
3995,1136116,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in ip dosed CF-1 albino mouse assessed as antagonism of electric shock-induced effect,Other,27634.0,
3996,1136117,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed CF-1 albino mouse assessed as antagonism of pentylenetetrazole-induced clonic convulsions,Other,27634.0,
3997,1136119,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as antagonism of pentylenetetrazole-induced clonic convulsions,Other,27634.0,
3998,1136286,1,1,,103164353,3016,Unspecified,,,,,Antianxiety activity in ip dosed rat assessed as effect on increase in punished responses administered qd for 5 days measured every day for 5 days,Other,31473.0,
3999,1136287,1,1,,103164353,3016,Unspecified,,,,,Muscle relaxant activity in po dosed mouse assessed as blockade of pentylenetetrazol-induced tonic extensor seizure,Other,31473.0,
4000,1136298,1,1,,103164353,3016,Unspecified,,,,,Muscle relaxant activity in po dosed mouse assessed as increase in strychnine-induced persistant convulsive threshold,Other,31473.0,
4001,1136299,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as blockade of supramaximal electroshock-induced toxic seizure,Other,31473.0,
4002,1136300,1,1,,103164353,3016,Unspecified,,,,,Acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex administered as qd for 4 days measured for 1 min post last dose,Other,31473.0,
4003,1136301,1,1,,103164353,3016,Unspecified,,,,,Acute toxicity in po dosed mouse assessed as mortality administered as qd for 6 days measured on day 7 post last dose,Other,31473.0,
4004,1136302,1,1,,103164353,3016,Unspecified,,,,,Ratio of LD50 for po dosed mouse to PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex,Other,31473.0,
4005,1136303,1,1,,103164353,3016,Unspecified,,,,,"Therapeutic index, ratio of PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex to MED causing antianxiety activity in ip dosed rat assessed as effect on increase in punished responses",Other,31473.0,
4006,1136309,1,1,,103164353,3016,Active,,,,,"Sedative-hypnotic activity in mouse assessed as increase in pentylenetetrazol-induced pseudo/persistent-convulsive threshold at 1 to 5 mg/kg, po",Other,31473.0,
4007,1136310,1,1,,103164353,3016,Unspecified,,,,,"Protection against pentylenetetrazol-induced lethal effect in mouse at 5 mg/kg, po relative to control",Other,31473.0,
4008,1136317,1,1,,103164353,3016,Unspecified,,,,,"Therapeutic index, ratio of PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex to MED20 for muscle relaxant activity in po dosed mouse assessed as blockade of pentylenetetrazol-induced tonic extensor seizure",Other,31473.0,
4009,1136318,1,1,,103164353,3016,Unspecified,,,,,"Therapeutic index, ratio of PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex to MED20 for anticonvulsant activity in po dosed mouse assessed as blockade of supramaximal electroshock-induced toxic seizure",Other,31473.0,
4010,1136319,1,1,,103164353,3016,Unspecified,,,,,"Therapeutic index, ratio of PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex to MED25 for muscle relaxant activity in po dosed mouse assessed as increase in strychnine-induced persistant convulsive threshold",Other,31473.0,
4011,1136339,1,1,,103164353,3016,Unspecified,,,,,Toxicity in rat assessed as depression,Other,31475.0,
4012,1136350,1,1,,103164353,3016,Unspecified,,,,,Neuroleptic activity in ip dosed Long-Evans rat assessed as inhibition of pole-climb avoidance,Other,31478.0,
4013,1136351,1,1,,103164353,3016,Unspecified,,,,,Neuroleptic activity in ip dosed Long-Evans rat assessed as increase in escape failure,Other,31478.0,
4014,1136387,1,1,,103164353,3016,Unspecified,,,,,Effect on motor activity in ip dosed albino CF-1 mouse by traction test,Other,31483.0,
4015,1136388,1,1,,103164353,3016,Unspecified,,,,,Effect on motor activity in ip dosed albino CF-1 mouse by chimney test,Other,31483.0,
4016,1136389,1,1,,103164353,3016,Unspecified,,,,,Effect on motor activity in ip dosed albino CF-1 mouse by dish test,Other,31483.0,
4017,1136390,1,1,,103164353,3016,Unspecified,,,,,Effect on motor activity in ip dosed albino CF-1 mouse by pedestal test,Other,31483.0,
4018,1136391,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of nicotine-induced seizures,Other,31483.0,
4019,1136392,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of pentylenetetrazole-induced seizures,Other,31483.0,
4020,1136393,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of thiosemicarbazide-induced seizures,Other,31483.0,
4021,1136394,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of strychnine-induced seizures,Other,31483.0,
4022,1136395,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of maximal electric shock-induced seizures,Other,31483.0,
4023,1136396,1,1,,103164353,3016,Unspecified,,,,,Antidepressant activity in ip dosed albino CF-1 mouse assessed as inhibition of ethanol-induced response,Other,31483.0,
4024,1136397,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in ip dosed albino CF-1 mouse under hypoxic stress,Other,31483.0,
4025,1137410,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against pentylenetetrazole-induced clonic convulsions,Other,42799.0,
4026,1137411,1,1,,103164353,3016,Unspecified,,,,,Hypothermic activity in ip dosed albino CF1 mouse assessed as effect on body temperature measured after 45 mins,Other,42799.0,
4027,1137412,1,1,,103164353,3016,Unspecified,,,,,Inhibition of apomorphine-induced cage climbing in ip dosed albino CF1 mouse compound administered prior to challenge measured for 5 mins after 5 mins of challenge,Other,42799.0,
4028,1137413,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as inhibition of bicucullin-induced tonic extensor convulsions,Other,42799.0,
4029,1137414,1,1,,103164353,3016,Unspecified,,,,,Antidepressant activity in ip dosed albino CF1 mouse assessed as potentiation of gamma-butyrolactone-induced sleep,Other,42799.0,
4030,1137415,1,1,,103164353,3016,Unspecified,,,,,Reduction of hypoxic stress in ip dosed albino CF1 mouse assessed as prolongation of hypoxic survival time,Other,42799.0,
4031,1137416,1,1,,103164353,3016,Unspecified,,,,,Inhibition of amphetamine aggregation toxicity in ip dosed albino CF1 mouse compound administered 1 hr prior to challenge measured after 2 hrs,Other,42799.0,
4032,1137417,1,1,,103164353,3016,Unspecified,,,,,Potentiation of yohimbine toxicity in ip dosed aggregated albino CF1 mouse,Other,42799.0,
4033,1137418,1,1,,103164353,3016,Unspecified,,,,,Inhibition of oxotremorine-induced hypothermia in ip dosed albino CF1 mouse,Other,42799.0,
4034,1137419,1,1,,103164353,3016,Unspecified,,,,,Potentiation of apomorphine-induced gnawing in ip dosed albino CF1 mouse,Other,42799.0,
4035,1138124,1,1,,103164353,3016,Unspecified,,,,,Washout half life in human,Other,24182233.0,
4036,1141834,1,3,,103164353,3016,Unspecified,20141192.0,23476.0,,,Binding affinity to His-tagged BRD4(1) (unknown origin) expressed in Escherichia coli BL21(DE3) at 50 uM by thermal shift assay,Other,24767840.0,
4037,1141835,2,1,,103164353,3016,Unspecified,20141192.0,23476.0,,,Binding affinity to His-tagged BRD4(1) (unknown origin) expressed in Escherichia coli BL21(DE3) at 100 uM by thermal shift assay,Other,24767840.0,
4038,1141836,1,3,,103164353,3016,Unspecified,20141192.0,23476.0,,,Binding affinity to His-tagged BRD4(1) (unknown origin) expressed in Escherichia coli BL21(DE3) at 200 uM by thermal shift assay,Other,24767840.0,
4039,1141837,1,3,,103164353,3016,Inconclusive,20141192.0,23476.0,,IC50,Displacement of histone peptide from His-tagged BRD4(1) (unknown origin) expressed in Escherichia coli BL21(DE3) by alpha-screen assay,Confirmatory,24767840.0,
4040,1141838,1,3,,103164353,3016,Unspecified,20141192.0,23476.0,,,Displacement of histone peptide from His-tagged BRD4(1) (unknown origin) expressed in Escherichia coli BL21(DE3) at 50 uM by alpha-screen assay,Other,24767840.0,
4041,1146338,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in rat assessed as protection against pentylenetetrazole-induced clonic seizures,Other,22748.0,
4042,1146339,1,1,,103164353,3016,Unspecified,,,,,Antianxiety activity in Holtzman rat assessed as dose required to elicit increase in milk consumption,Other,22748.0,
4043,1146375,1,1,,103164353,3016,Unspecified,,,,,Acute toxicity in ip dosed albino mouse measured within 24 hrs,Other,26804.0,
4044,1146376,1,1,,103164353,3016,Unspecified,,,,,"Neurotoxicity in albino mouse at 10 mg/kg, po up to 5 mins by rotorod test relative to control",Other,26804.0,
4045,1146381,1,2,,103164353,3016,Unspecified,,,,,Antihistamine activity in guinea pig ileum assessed as dose required to decrease 50 to 100% of histamine induced effect treated 5 mins before histamine addition,Other,26804.0,
4046,1146385,1,1,,103164353,3016,Unspecified,,,,,Toxicity in ip dosed mouse assessed as sedative action,Other,26804.0,
4047,1146386,1,1,,103164353,3016,Unspecified,,,,,"Toxicity in albino mouse assessed as translatory movements at 10 mg/kg, ip relative to control",Other,26804.0,
4048,1146387,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed albino mouse assessed as dose causing total prevention of maximal electroshock-induced maximal extensor seizure,Other,26804.0,
4049,1147962,1,1,,103164353,3016,Unspecified,,,,,CNS activity in po dosed mouse assessed as reduction in muscle relaxant activity by inclined screening method,Other,561846.0,
4050,1147963,1,1,,103164353,3016,Unspecified,,,,,CNS activity in po dosed mouse assessed as reduction in fighting behaviour,Other,561846.0,
4051,1147964,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as protection against pentylenetetrazole-induced seizures,Other,561846.0,
4052,1147965,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as protection against maximal electroshock-induced seizures,Other,561846.0,
4053,1147966,1,1,,103164353,3016,Unspecified,,,,,CNS activity in po dosed unanesthesized cat assessed as muscle relaxant activity,Other,561846.0,
4054,1148192,1,1,,103164353,3016,Unspecified,,,,,CNS activity in po dosed mouse by inclined screen test,Other,592339.0,
4055,1148193,1,1,,103164353,3016,Unspecified,,,,,CNS activity in po dosed mouse assessed as antifighting activity by foot shock test,Other,592339.0,
4056,1148194,1,1,,103164353,3016,Unspecified,,,,,CNS activity in po dosed mouse assessed as antagonism against pentylenetetrazole-induced response,Other,592339.0,
4057,1149103,1,1,,103164353,3016,Unspecified,,,,,Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing administered 30 mins prior to acetic acid challenge measured after 5 mins for 20 mins,Other,817021.0,
4058,1149109,1,1,,103164353,3016,Unspecified,,,,,"Analgesic activity in Sprague-Dawley rat assessed as increase in pain threshold at 60 mg/kg, po after 15 to 90 mins by tail flick test",Other,817021.0,
4059,1149116,1,1,,103164353,3016,Unspecified,,,,,"Antianxiety activity in albino BALB/cJ mouse assessed as reduction in footshock-induced fighting behavior at 5 mg/kg, po after 30 to 90 mins",Other,817021.0,
4060,1149118,1,1,,103164353,3016,Unspecified,,,,,"Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 5 mg/kg, po after 2 hrs relative to vehicle-treated control",Other,817021.0,
4061,1149126,1,1,,103164353,3016,Unspecified,,,,,"Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 40 mg/kg, po after 2 hrs relative to vehicle-treated control",Other,817021.0,
4062,1149129,1,1,,103164353,3016,Unspecified,,,,,Antianxiety activity in po dosed rhesus monkey assessed as antiagressive behavior measured every hour post dosing,Other,817021.0,
4063,1149718,1,1,,103164353,3016,Unspecified,,,,,Acute toxicity in ip dosed Wistar rat measured 2 hrs post dose,Other,874970.0,
4064,1149719,1,1,,103164353,3016,Unspecified,,,,,CNS depressant activity in ip dosed mouse assessed as ataxia,Other,874970.0,
4065,1149720,1,1,,103164353,3016,Unspecified,,,,,CNS depressant activity in ip dosed mouse assessed as docility,Other,874970.0,
4066,1149721,1,1,,103164353,3016,Unspecified,,,,,CNS depressant activity in ip dosed mouse assessed as loss of righting reflex,Other,874970.0,
4067,1149722,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed mouse assessed as inhibition of N-sulfamoylhexahydroazepine-induced seizure,Other,874970.0,
4068,1149727,1,1,,103164353,3016,Unspecified,,,,,"CNS depressant activity in mouse assessed as reduction in amphetamine-induced locomotor activity at 50 mg/kg, ip",Other,874970.0,
4069,1149729,1,1,,103164353,3016,Unspecified,,,,,CNS depressant activity in ip dosed mouse assessed as induction of neurologic deficit by rotarod test,Other,874970.0,
4070,1149730,1,1,,103164353,3016,Unspecified,,,,,CNS depressant activity in ip dosed mouse assessed as reinduction of anesthesia measured as loss of righting reflex compound administered immediately post recovery from hexobarbital anesthesia,Other,874970.0,
4071,1150161,1,1,,103164353,3016,Unspecified,,,,,Sedative activity in mouse,Other,926122.0,
4072,1150162,1,1,,103164353,3016,Unspecified,,,,,Muscle relaxant activity in mouse,Other,926122.0,
4073,1150163,1,1,,103164353,3016,Unspecified,,,,,Taming activity in mouse assessed as suppression of electrical current-induced aggressive behavior by foot-shock test,Other,926122.0,
4074,1150164,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsion activity in mouse assessed as protection against pentylenetetrazole-induced convulsion,Other,926122.0,
4075,1150165,1,1,,103164353,3016,Unspecified,,,,,Muscle relaxant activity in cat suspended by scruff of neck assessed as relaxation of body and hind legs,Other,926122.0,
4076,1150961,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as decrease in traction reflex,Other,9511.0,
4077,1150962,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as decrease in dish reflex,Other,9511.0,
4078,1150963,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of nicotine-induced tonic extensor convulsions,Other,9511.0,
4079,1150964,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of nicotine-induced death,Other,9511.0,
4080,1150965,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of thiosemicarbazide -induced lethality,Other,9511.0,
4081,1150966,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of strychnine-induced lethality,Other,9511.0,
4082,1150967,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of pentylenetetrazole-induced clonic convulsions,Other,9511.0,
4083,1150968,1,1,,103164353,3016,Unspecified,,,,,Potentiation of ethanol-induced anxiolytic activity in ip dosed male albino CF-1 mouse,Other,9511.0,
4084,1150969,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of electroshock-induced convulsions,Other,9511.0,
4085,1155746,3,2,,103164353,3016,Unspecified,,,69.0,EC50,Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic rings assessed as inhibition of phenylephrine-induced contraction,Confirmatory,24929291.0,
4086,1155747,3,2,,103164353,3016,Unspecified,,,77.2,EC50,Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic rings assessed as inhibition of phenylephrine-induced contraction,Confirmatory,24929291.0,
4087,1155766,1,1,,103164353,3016,Unspecified,,,,,"Neurotoxicity in albino mouse assessed as alteration of motor activity at 2 mg/kg, po measured after 60 mins for 60 secs by rotarod test",Other,24929294.0,
4088,1159387,1,2,,103164353,3016,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
4089,1159388,1,2,,103164353,3016,Unspecified,,,,,"ASTRAZENECA: Solubility in pH7.4 buffer using solid starting material using the method described in J. Assoc. Lab. Autom. 2011, 16, 276-284. Experimental range 0.10 to 1500 uM",Other,,
4090,1159389,1,2,,103164353,3016,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
4091,1159390,1,2,,103164353,3016,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
4092,1159394,1,2,,103164353,3016,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
4093,1159396,1,2,,103164353,3016,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
4094,1159509,1,1,,144209656,3016,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4095,1159509,1,1,,170464626,3016,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4096,1159515,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4097,1159515,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4098,1159516,1,1,,144209656,3016,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4099,1159516,1,1,,170464626,3016,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4100,1159517,1,1,,144209656,3016,Inconclusive,,,12.4866,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4101,1159517,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4102,1159518,1,1,,144209656,3016,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4103,1159518,1,1,,170464626,3016,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4104,1159519,1,1,,144209656,3016,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4105,1159519,1,1,,170464626,3016,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4106,1159520,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4107,1159520,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4108,1159521,1,1,,144209656,3016,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4109,1159521,1,1,,170464626,3016,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4110,1159523,1,1,,144209656,3016,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4111,1159523,1,1,,170464626,3016,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4112,1159525,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4113,1159525,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4114,1159526,1,1,,144209656,3016,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4115,1159526,1,1,,170464626,3016,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4116,1159527,1,1,,144209656,3016,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4117,1159527,1,1,,170464626,3016,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4118,1159528,1,1,,144209656,3016,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4119,1159528,1,1,,170464626,3016,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4120,1159529,1,1,,144209656,3016,Inconclusive,,,3.9486,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4121,1159529,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4122,1159531,1,1,,144209656,3016,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4123,1159531,1,1,,170464626,3016,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4124,1159551,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4125,1159551,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4126,1159552,1,1,,144209656,3016,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4127,1159552,1,1,,170464626,3016,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4128,1159553,2,1,,144209656,3016,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4129,1159553,2,1,,170464626,3016,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4130,1159555,1,1,,144209656,3016,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4131,1159555,1,1,,170464626,3016,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4132,1159580,2,1,,273003176,3016,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
4133,1159607,2,1,,312310113,3016,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
4134,1159614,1,2,,170464626,3016,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
4135,1159620,1,1,,103164353,3016,Active,,,,,Summary of drug indications.,Other,,
4136,1164680,1,2,,103164353,3016,Inconclusive,120773.0,2562.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4137,1164680,1,2,,103164353,3016,Inconclusive,399519.0,2558.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4138,1164680,1,2,,103164353,3016,Inconclusive,462149.0,2556.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4139,1164680,1,2,,103164353,3016,Inconclusive,6016089.0,2568.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4140,1164680,1,2,,103164353,3016,Inconclusive,13124728.0,2564.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4141,1164680,1,2,,103164353,3016,Inconclusive,13959382.0,55879.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4142,1164680,1,2,,103164353,3016,Inconclusive,13959689.0,2567.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4143,1164680,1,2,,103164353,3016,Inconclusive,23831128.0,2560.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4144,1164680,1,2,,103164353,3016,Inconclusive,27808653.0,2554.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4145,1164680,1,2,,103164353,3016,Inconclusive,59802571.0,2563.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4146,1164680,1,2,,103164353,3016,Inconclusive,116242488.0,2566.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4147,1164680,1,2,,103164353,3016,Inconclusive,126302547.0,2555.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4148,1164680,1,2,,103164353,3016,Inconclusive,126302548.0,2559.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4149,1164680,1,2,,103164353,3016,Inconclusive,206729865.0,2557.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4150,1164680,1,2,,103164353,3016,Inconclusive,209572630.0,2565.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4151,1164680,1,2,,103164353,3016,Inconclusive,292495010.0,2561.0,,,Displacement of [3H]muscimol form GABAA receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 10 mins by liquid scintillation counting method,Other,25226229.0,
4152,1164681,1,1,,103164353,3016,Unspecified,,,,,Displacement of [3H]flunitrazepam form benzodiazepine receptor in rat cerebral cortex assessed as specific radio-ligand binding level at 1 uM incubated for 20 mins by liquid scintillation counting method,Other,25226229.0,
4153,1171131,1,1,,103164353,3016,Unspecified,,,,,"CNS toxicity in Swiss Webster mouse assessed as reduction in motor performance at 10 mg/kg, ip after 40 mins by open field test",Other,25396337.0,
4154,1171132,1,1,,103164353,3016,Unspecified,,,,,"CNS toxicity in Swiss Webster mouse assessed as reduction in motor performance at 10 mg/kg, ip after 40 mins by rotarod test",Other,25396337.0,
4155,1172083,1,1,,103164353,3016,Active,,,,,"Anxiolytic-like activity in mouse assessed as increase in number of punished crossings at 1.25 to 5 mg/kg, ip dosed 60 mins before test by four plate test",Other,25435254.0,
4156,1175008,1,1,,103164353,3016,Unspecified,,,,,"Behavioral activity in Swiss CF1 mouse assessed as activity score at 4 mg/kg, ip measured after 0.5 hrs post dose by actophotometry",Other,25466174.0,
4157,1175009,1,1,,103164353,3016,Unspecified,,,,,"Behavioral activity in Swiss CF1 mouse assessed as activity score at 4 mg/kg, ip measured after 4 hrs post dose by actophotometry",Other,25466174.0,
4158,1175695,1,2,,103164353,3016,Unspecified,,,,,Half life in mouse liver microsomes in presence of NADPH by LC-MS/MS method,Other,25487422.0,
4159,1190362,1,1,,103164353,3016,Active,,,,IC50,Displacement of [3H]-flumazenil from benzodiazepine receptor in Sprague-Dawley rat brain cortical membranes incubated for 35 mins,Confirmatory,25564376.0,
4160,1190363,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed NMRI mouse assessed as reduction in PTZ-induced lethal convulsion dosed 30 mins before PTZ injection and measured 30 mins post PTZ challenge,Other,25564376.0,
4161,1190364,1,1,,103164353,3016,Unspecified,,,,,Anticonvulsant activity in ip dosed NMRI mouse assessed as reduction in MES-induced seizures by measuring occurrence of hind limb tonic extensions dosed 30 mins before MES injection and measured 30 mins post MES challenge,Other,25564376.0,
4162,1190365,1,1,,103164353,3016,Inactive,,,,,Anticonvulsant activity in ip dosed NMRI mouse assessed as reduction in PTZ-induced lethal convulsion dosed 30 mins before PTZ injection and co-treated with BZD antagonist flumazenil and measured 30 mins post PTZ challenge,Other,25564376.0,
4163,1190366,1,1,,103164353,3016,Inactive,,,,,Anticonvulsant activity in ip dosed NMRI mouse assessed as reduction in MES-induced seizures by measuring occurrence of hind limb tonic extensions dosed 30 mins before MES injection and co-treated with 10 mg/kg BZD antagonist flumazenil and measured 30 mins post MES challenge,Other,25564376.0,
4164,1190368,1,1,,103164353,3016,Active,,,,,"Hypnotic effect in NMRI albino mouse assessed as potentiation of pentobarbital sleeping time by measuring duration of loss of righting reflex at 1 mg/kg, ip dosed 30 mins before pentobarbital challenge",Other,25564376.0,
4165,1192730,1,1,,103164353,3016,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25614117.0,
4166,1192731,1,1,,103164353,3016,Unspecified,,,,,Permeability of the compound in PBS/EtOH buffer at 100 ug/ml by PAMPA,Other,25614117.0,
4167,1196609,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity in po dosed male Sprague-Dawley rat assessed as increase in drinking time after 1 hr by Vogel conflict test,Other,25565255.0,
4168,1196645,1,1,,103164353,3016,Unspecified,,,,,Anxiolytic activity po dosed in male NMRI mouse assessed as reduction of stress-induced hyperthermia measured after 1 hr,Other,25565255.0,
4169,1196646,1,1,,103164353,3016,Active,,,,,Anxiolytic activity po dosed in male Sprague-Dawley rat assessed as lever press within conditioning period measured after 1 hr by conditioned emotional response assay,Other,25565255.0,
4170,1196647,1,1,,103164353,3016,Active,,,,,Anxiolytic activity po dosed in male Sprague-Dawley rat assessed as fear-potentiated startle response measured after 1 hr on third day before test session by fear-potentiated startle response assay,Other,25565255.0,
4171,1204326,1,1,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in Swiss mouse assessed as increase in number of punished crossings measured during 60 seconds period at 5 mg/kg, ip by four-plate test",Other,25965777.0,
4172,1204327,1,1,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in Swiss mouse assessed as increase in number of punished crossings measured during 60 seconds period at 2.5 mg/kg, ip by four-plate test",Other,25965777.0,
4173,1204348,1,1,,103164353,3016,Unspecified,,,,,"Anxiolytic-like activity in Swiss mouse assessed as increase in number of punished crossings measured during 60 seconds period at 1.25 mg/kg, ip by four-plate test",Other,25965777.0,
4174,1207735,1,1,,103164353,3016,Active,,,30.5,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
4175,1209581,1,2,,103164353,3016,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
4176,1209582,1,1,,103164353,3016,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
4177,1209583,1,1,,103164353,3016,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
4178,1209593,1,1,,103164353,3016,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
4179,1211293,1,2,,103164353,3016,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
4180,1211294,1,1,,103164353,3016,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
4181,1211295,1,1,,103164353,3016,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
4182,1211296,1,2,,103164353,3016,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
4183,1211297,1,1,,103164353,3016,Unspecified,,,,,Drug recovery in plasma (unknown origin),Other,21098647.0,
4184,1211298,1,1,,103164353,3016,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21098647.0,
4185,1215120,1,1,,103164353,3016,Active,,,3.24,Kd,Binding affinity to Wistar rat brain lipid by TRANSIL assay,Confirmatory,21071520.0,
4186,1215121,1,2,,103164353,3016,Unspecified,,,,,Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method,Other,21071520.0,
4187,1215122,1,1,,103164353,3016,Unspecified,,,,,Fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay,Other,21071520.0,
4188,1215123,1,2,,103164353,3016,Active,124028612.0,24186.0,15.1,Kd,Binding affinity to Wistar rat serum albumin,Confirmatory,21071520.0,
4189,1215124,1,1,,103164353,3016,Unspecified,,,,,Binding affinity to Wistar rat brain lipid assessed as fraction unbound by TRANSIL assay,Other,21071520.0,
4190,1215127,1,2,,103164353,3016,Unspecified,,,,,Ratio of fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay to fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method,Other,21071520.0,
4191,1223488,1,1,,103164353,3016,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4",Other,22096083.0,
4192,1223490,1,1,,103164353,3016,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells,Other,22096083.0,
4193,1224834,3,1,,144209656,3016,Inconclusive,,,62.0642,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
4194,1224834,3,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
4195,1224835,1,1,,144209656,3016,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
4196,1224835,1,1,,170464626,3016,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
4197,1224836,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4198,1224836,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4199,1224837,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4200,1224837,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4201,1224838,1,1,,144209656,3016,Inactive,66775687.0,9970.0,62.0642,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4202,1224838,1,1,,170464626,3016,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4203,1224839,1,1,,144209656,3016,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4204,1224839,1,1,,170464626,3016,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4205,1224840,3,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
4206,1224840,3,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
4207,1224841,3,1,,144209656,3016,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4208,1224841,3,1,,170464626,3016,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4209,1224842,3,1,,144209656,3016,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4210,1224842,3,1,,170464626,3016,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4211,1224843,1,1,,144209656,3016,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4212,1224843,1,1,,170464626,3016,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4213,1224844,1,1,,144209656,3016,Inconclusive,,,55.7756,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
4214,1224844,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
4215,1224845,1,1,,144209656,3016,Inconclusive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
4216,1224845,1,1,,170464626,3016,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
4217,1224846,1,1,,144209656,3016,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
4218,1224846,1,1,,170464626,3016,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
4219,1224847,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
4220,1224847,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
4221,1224848,3,1,,144209656,3016,Inconclusive,325495545.0,2101.0,0.3111,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4222,1224848,3,1,,170464626,3016,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4223,1224849,3,1,,144209656,3016,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4224,1224849,3,1,,170464626,3016,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4225,1224857,2,1,,170464626,3016,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
4226,1224859,2,1,,170464626,3016,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
4227,1224867,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
4228,1224867,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
4229,1224868,1,1,,144209656,3016,Inconclusive,,,44.3041,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
4230,1224868,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
4231,1224869,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
4232,1224869,1,1,,170464626,3016,Inconclusive,,,13.4481,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
4233,1224870,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
4234,1224870,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
4235,1224871,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
4236,1224871,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
4237,1224872,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
4238,1224872,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
4239,1224873,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
4240,1224873,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
4241,1224874,1,1,,144209656,3016,Inconclusive,,,24.914,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
4242,1224874,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
4243,1224875,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
4244,1224875,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
4245,1224876,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
4246,1224876,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
4247,1224877,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
4248,1224877,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
4249,1224878,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
4250,1224878,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
4251,1224879,1,1,,144209656,3016,Inconclusive,,,55.7756,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
4252,1224879,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
4253,1224880,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
4254,1224880,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
4255,1224881,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
4256,1224881,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
4257,1224882,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
4258,1224882,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
4259,1224883,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
4260,1224883,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
4261,1224884,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
4262,1224884,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
4263,1224885,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
4264,1224885,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
4265,1224886,1,1,,144209656,3016,Inconclusive,,,39.4861,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
4266,1224886,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
4267,1224887,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
4268,1224887,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
4269,1224888,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
4270,1224888,1,1,,170464626,3016,Inconclusive,,,13.4481,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
4271,1224889,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
4272,1224889,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
4273,1224890,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
4274,1224890,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
4275,1224892,1,1,,144209656,3016,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4276,1224892,1,1,,170464626,3016,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4277,1224893,1,1,,144209656,3016,Inconclusive,66775687.0,9970.0,62.0642,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4278,1224893,1,1,,170464626,3016,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4279,1224894,1,1,,144209656,3016,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
4280,1224894,1,1,,170464626,3016,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
4281,1224895,1,1,,144209656,3016,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4282,1224895,1,1,,170464626,3016,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4283,1224896,1,1,,144209656,3016,Inconclusive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
4284,1224896,1,1,,170464626,3016,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
4285,1230943,1,1,,103164353,3016,Unspecified,,,,,Apparent permeability from apical to basolateral side in MDCK2 cells expressing MDR1 at 200 ug/ml by UV-visible spectroscopy,Other,26107513.0,
4286,1230946,1,1,,103164353,3016,Unspecified,,,,,Apparent permeability from basolateral to apical side in MDCK2 cells expressing MDR1 at 200 ug/ml by UV-visible spectroscopy,Other,26107513.0,
4287,1230947,1,1,,103164353,3016,Unspecified,,,,,Efflux ratio of apparent permeability from basolateral to apical side to apical to basolateral side in MDCK2 cells expressing MDR1 at 200 ug/ml by UV-visible spectroscopy,Other,26107513.0,
4288,1231637,1,1,,103164353,3016,Unspecified,,,,,"Toxicity in mouse assessed as sedative effect by measuring reduction of total distance traveled at 10 mg/kg, po measured over 60 mins by open-field test",Other,25936260.0,
4289,1231638,1,1,,103164353,3016,Unspecified,,,,,"Toxicity in mouse assessed as sedative effect by measuring prolongation of immobility time at 10 mg/kg, po measured over 60 mins by open-field test",Other,25936260.0,
4290,1232164,1,1,,103164353,3016,Unspecified,,,,,Fraction unbound in human plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
4291,1232166,1,1,,103164353,3016,Unspecified,,,,,Fraction unbound in rat plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
4292,1232307,1,1,,103164353,3016,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,25799158.0,
4293,1232308,1,1,,103164353,3016,Unspecified,,,,,"Distribution coefficient, log D of the compound",Other,25799158.0,
4294,1232309,1,1,,103164353,3016,Unspecified,,,,,Unbound fraction in human plasma,Other,25799158.0,
4295,1232310,1,1,,103164353,3016,Unspecified,,,,,Volume of distribution at steady state in human,Other,25799158.0,
4296,1232311,1,1,,103164353,3016,Unspecified,,,,,Unbound volume of distribution at steady state in human,Other,25799158.0,
4297,1254852,1,1,,103164353,3016,Unspecified,130253.0,24230.0,,,Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane at 10 uM by radiometric competitive assay,Other,26355532.0,
4298,1254853,1,1,,103164353,3016,Unspecified,130253.0,24230.0,,,Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane at 1 uM by radiometric competitive assay,Other,26355532.0,
4299,1254854,1,1,,103164353,3016,Unspecified,130253.0,24230.0,,,Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane at 100 nM by radiometric competitive assay,Other,26355532.0,
4300,1254855,1,1,,103164353,3016,Unspecified,130253.0,24230.0,,,Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane at 10 nM by radiometric competitive assay,Other,26355532.0,
4301,1254856,1,1,,103164353,3016,Unspecified,130253.0,24230.0,,,Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane at 1 nM by radiometric competitive assay,Other,26355532.0,
4302,1254857,1,1,,103164353,3016,Active,130253.0,24230.0,0.19399999999999998,IC50,Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane by radiometric competitive assay,Confirmatory,26355532.0,
4303,1259241,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
4304,1259241,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
4305,1259242,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
4306,1259242,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
4307,1259243,1,1,,144209656,3016,Active,124375976.0,367.0,27.7231,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
4308,1259243,1,1,,170464626,3016,Inconclusive,124375976.0,367.0,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
4309,1259244,1,1,,144209656,3016,Active,348019627.0,2099.0,24.7082,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
4310,1259244,1,1,,170464626,3016,Inconclusive,348019627.0,2099.0,16.7855,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
4311,1259247,1,1,,144209656,3016,Active,124375976.0,367.0,32.9489,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
4312,1259247,1,1,,170464626,3016,Active,124375976.0,367.0,23.7101,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
4313,1259248,1,1,,144209656,3016,Active,348019627.0,2099.0,24.7082,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
4314,1259248,1,1,,170464626,3016,Active,348019627.0,2099.0,9.43918,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
4315,1259251,1,1,,46386554,3016,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of Unc-51 Like Autophagy Activating Kinase 1 (ULK1).,Screening,,
4316,1259310,1,1,,46386554,3016,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4317,1259325,1,2,,336954783,3016,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
4318,1259344,1,1,,144206622,3016,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
4319,1259364,1,1,,144209656,3016,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
4320,1259364,1,1,,170464626,3016,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
4321,1259365,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
4322,1259365,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
4323,1259366,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4324,1259366,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4325,1259367,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4326,1259367,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4327,1259368,1,1,,144209656,3016,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4328,1259368,1,1,,170464626,3016,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4329,1259369,1,1,,144209656,3016,Active,109731339.0,2737.0,4.3938,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4330,1259369,1,1,,170464626,3016,Inconclusive,109731339.0,2737.0,5.9557,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4331,1259377,1,1,,144209656,3016,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4332,1259377,1,1,,170464626,3016,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4333,1259378,1,1,,144209656,3016,Inconclusive,54288833.0,2100.0,34.9013,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4334,1259378,1,1,,170464626,3016,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4335,1259379,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4336,1259379,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4337,1259380,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4338,1259380,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4339,1259381,1,1,,144209656,3016,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
4340,1259381,1,1,,170464626,3016,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
4341,1259382,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4342,1259382,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4343,1259383,1,1,,144209656,3016,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
4344,1259383,1,1,,170464626,3016,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
4345,1259384,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
4346,1259384,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
4347,1259385,1,1,,144209656,3016,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4348,1259385,1,1,,170464626,3016,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4349,1259386,1,1,,144209656,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4350,1259386,1,1,,170464626,3016,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4351,1259387,1,1,,144209656,3016,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
4352,1259387,1,1,,170464626,3016,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
4353,1259388,1,1,,144209656,3016,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
4354,1259388,1,1,,170464626,3016,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
4355,1259389,1,1,,124658985,3016,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
4356,1259390,1,1,,144209656,3016,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4357,1259390,1,1,,170464626,3016,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4358,1259391,1,1,,144209656,3016,Inconclusive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
4359,1259391,1,1,,170464626,3016,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
4360,1259392,1,1,,144209656,3016,Active,109731339.0,2737.0,5.53148,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4361,1259392,1,1,,170464626,3016,Inconclusive,109731339.0,2737.0,5.30804,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4362,1259393,1,1,,144209656,3016,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
4363,1259393,1,1,,170464626,3016,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
4364,1259394,1,1,,144209656,3016,Inconclusive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4365,1259394,1,1,,170464626,3016,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4366,1259395,1,1,,144209656,3016,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4367,1259395,1,1,,170464626,3016,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4368,1259396,1,1,,144209656,3016,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4369,1259396,1,1,,170464626,3016,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4370,1259400,1,1,,170464626,3016,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
4371,1259401,1,1,,144209656,3016,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4372,1259401,1,1,,170464626,3016,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4373,1259402,1,1,,144209656,3016,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4374,1259402,1,1,,170464626,3016,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4375,1259403,1,1,,144209656,3016,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4376,1259403,1,1,,170464626,3016,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4377,1259404,1,1,,144209656,3016,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4378,1259404,1,1,,170464626,3016,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4379,1259406,1,1,,363920136,3016,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
4380,1259406,1,1,1.0,363920136,3016,Inactive,26638650.0,3778.0,0.00226544,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
4381,1259406,1,1,2.0,363920136,3016,Inactive,4758626.0,3779.0,-0.026397000000000004,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
4382,1259406,1,1,3.0,363920136,3016,Inactive,5031823.0,10242.0,0.020353,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
4383,1259406,1,1,4.0,363920136,3016,Inactive,26051275.0,27345.0,0.0208541,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
4384,1259406,1,1,5.0,363920136,3016,Inactive,160410009.0,389816.0,-0.043745599999999996,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
4385,1259406,1,1,6.0,363920136,3016,Inactive,26638650.0,3778.0,-0.0486625,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
4386,1259406,1,1,7.0,363920136,3016,Inactive,4758626.0,3779.0,-0.0700255,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
4387,1259406,1,1,8.0,363920136,3016,Inactive,5031823.0,10242.0,-0.00580211,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
4388,1259406,1,1,9.0,363920136,3016,Inactive,26051275.0,27345.0,0.0195109,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
4389,1259406,1,1,10.0,363920136,3016,Inactive,5031823.0,10242.0,0.017575900000000002,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
4390,1259407,1,1,,363903959,3016,Inactive,,,,,CCRIS mutagenicity studies,Other,,
4391,1259408,1,1,,363895612,3016,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
4392,1259413,1,2,,46386554,3016,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
4393,1259416,1,2,,340079797,3016,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4394,1259421,1,1,,340079797,3016,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
4395,1259423,1,2,,355026457,3016,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
